Evaluation of novel dual-hit models of 'schizophrenia-like' symptoms in the rat by Gaskin, Philip Laurence Roy
Gaskin, Philip Laurence Roy (2014) Evaluation of novel 
dual-hit models of 'schizophrenia-like' symptoms in the 
rat. PhD thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/14242/1/GaskinP-ThesisCorrections2.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
   
EVALUATION OF NOVEL DUAL-HIT 
MODELS OF µ6CHIZOPHRENIA-L,.(¶
SYMPTOMS IN THE RAT 
 
 
PHILIP LAURENCE ROY GASKIN, MPharmacol. 
 
 
 
 
Thesis submitted to the University of Nottingham 
 for the degree of Doctor of Philosophy  
 
 
JULY 2014
 i 
 
Abstract 
 
Schizophrenia is a debilitating disorder comprising positive, negative and 
cognitive deficits with a poorly-defined neurobiological basis. Animal models 
with greater translational reliability and validity are essential to develop 
improved therapies and aid understanding of disease aetiology. This thesis 
utilised the well-established isolation rearing developmental disruption model 
RI VFKL]RSKUHQLD LQ WKH UDW DV WKH EDVH IRU SURGXFLQJ QRYHO µGXDO-KLW¶
combination models of the disease, with the aim of improving disease validity 
and model robustness. Pharmacological insults were added to the isolation 
rearing model, first in the form of prenatal administration of the antimitotic 
agent methylazoxymethanol (MAM), and subsequently perinatal treatment 
with the N-methyl-D-aspartate receptor antagonist phencyclidine (PCP). The 
UHVXOWLQJµGXDO-KLW¶Podels were assessed for behavioural and neurobiological 
validity to schizophrenia, and the incurred deficits challenged with the atypical 
antipsychotic risperidone and the putative adjunct therapy lamotrigine. 
Combination of isolation rearing and prenatal MAM on gestational day 17 did 
not produce more robust behavioural deficits than isolation rearing alone, but 
did cause marked reductions in hippocampal volume, akin to those observed in 
the clinic. Addition of perinatal PCP treatment on post-natal days seven, nine 
and eleven to the isolation rearing protocol produced more robust behavioural 
deficits, with limitations.  Baseline hyperlocomotion in a novel arena in three 
cohorts was accompanied by an elevated locomotor response to acute PCP 
treatment, highlighting sensitization. Visual and spatial learning deficits were 
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observed in the novel object discrimination task, whilst fear-motivated 
conditioning was impaired in a conditioned emotional response paradigm. 
Preattentional processing was also somewhat deficient in combination-treated 
animals in the prepulse inhibition of acoustic startle paradigm. Inconsistent 
deficits in visuo-spatial learning and cognitive flexibility were observed in a 
Morris water maze task. 
Acute treatment with the atypical antipsychotic compound risperidone at 
0.5mg/kg caused marked sedation. At lower doses, pretreatment 30 mins prior 
to behavioural testing elevated prepulse inhibition and reversed emotional 
conditioning deficits, and returned baseline locomotor activity to levels similar 
to control. There was no effect on visual reference memory deficits. 
Conversely, pretreatment with the sodium-channel blocker lamotrigine 
reversed a deficit in visual reference memory, but had no effect on 
sensorimotor gating or fear-motivated conditioning. 
These data suggest that the combination of isolation rearing and perinatal PCP 
treatment to rats produces a model of schizophrenia-like symptoms that 
possesses some validity to the human condition, but lacks the desired 
robustness of a preclinical model. Further validation and improvement may 
allow this model to become a useful tool in on-going preclinical research. 
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1.1 Schizophrenia 
1.1.1 Background 
Schizophrenia is a major neuropsychiatric disorder with a lifetime incidence of 
1% worldwide, rising to 10% of those with a family history of the condition. It 
most commonly presents to patients post-puberty, and can progress from a 
range of mild and non-specific symptoms at an early stage to a severe, 
persistent and unremitting disease in later progression (NICE 2009; Wood et 
al. 2011). Due to continuing debate over the exact aetiology of the disease, it is 
characterised by a core of psychological symptoms divided into three key 
domains: positive, negative, and cognitive, that may alter perception, thoughts 
and behavioural traits in a way neither specific, nor exclusive to the condition 
(NICE 2009). 7KHSRVLWLYHGRPDLQHQFRPSDVVHV³JDLQ-of-IXQFWLRQ´V\PSWRPV
such as visual/auditory hallucinations and delusions. Negative symptoms are 
associated with a loss of sociality, volition, or pleasure, and are hence 
FDWHJRULVHG DV ³ORVV-of-IXQFWLRQ´ &RJQLWLYH symptoms have been subdivided 
into seven key domains (attention and vigilance, working memory, reasoning 
and problem solving, processing speed, visual learning and memory, verbal 
learning and memory, and social cognition (Marder and Fenton 2004; Young 
et al. 2009)) and represent the poorest addressed symptoms in the clinic.  
 
1.1.2 Schizophrenia aetiology 
1.1.2.1 Genetics 
It has long been concluded that schizophrenia development carries a genetic 
link, particularly considering the 10-fold increase in risk of developing the 
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condition if one parent suffers, and some have concluded that up to 80% of 
risk for schizophrenia is due to heritable/genetic factors (McGuffin and 
Gottesman 1999)+RZHYHUQR³0HQGHOLDQ´IRUPVRIVFKL]RSKUHQLDKDYHEHHQ
found, i.e. deterministically caused by rare mutations (Need et al. 2012), 
despite suggestions that DISC-1 (disrupted in schizophrenia-1) may follow this 
profile (St Clair et al. 1990; Sullivan 2013). Up to eight rare copy number 
variations (CNVs) have been consistently associated with psychiatric disorders 
including schizophrenia (Levinson et al. 2011; Malhotra and Sebat 2012). 
These changes in the number of expected DNA copies can result in a change in 
³GRVDJH´ RI JHQHV LQ WKHDIIHFWHG UHJLRQ DQG H[HUW D ODUJH HIIHFW RQ GLVHDVH
development risk (Giusti-Rodriguez and Sullivan 2013). These CNVs often 
involve many genes, such as the 16p11.2 CNV which encompasses 29 genes, 
and are not specific to schizophrenia, so offer only limited understanding to the 
genetic basis of schizophrenia (McCarthy et al. 2009). 
Genome-wide association studies (GWAS) have enabled better identification 
of specific loci that may be determinant of schizophrenia by massively 
increasing sample sizes through large collaborative projects. These large 
samples, with appropriate statistical power, can identify links between 
common genetic variations or single-nucleotide polymorphisms (SNPs) and 
disease not possible with smaller studies, highlighted by a recent GWAS which 
estimated that 8300 independent SNPs at 22 loci contribute to risk of 
schizophrenia (Ripke et al. 2013). This study noted that calcium signalling 
may be key in schizophrenia, with SNPs in the Į1C and ȕ2 subunits of voltage-
gated L-type calcium channel reaching genome-wide significance. This is a 
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particularly intULJXLQJILQGLQJGXHWRFDOFLXP¶VORQJDVVRFLDWLRQZLWKOHDUQLQJ
memory and neuronal plasticity, and a disruption in calcium signalling may 
impact on multiple functions due to prevalence of calcium signalling cascades. 
Further genetic involvement has been suggested in a neurodevelopmental 
hypothesis of schizophrenia (Murray et al. 1991). After identification that 
schizophrenia patients commonly exhibit enlarged cerebral ventricles and 
decreased hippocampal and temporal lobe volume, it was noted that patients 
commonly experienced obstetric complications and were born in late winter, 
suggesting a foetal origin for the disease (Murray et al. 1991). Genetic defects 
in processes of cell proliferation, migration, differentiation and death during 
neurodevelopment may lead to the structural abnormalities seen in patients, 
and may indeed be detectable earlier than the outwards symptoms of psychosis 
(Jones and Murray 1991). It is also plausible that obstetric complications could 
be important for these genetic susceptibilities to be unveiled. Furthermore, two 
key susceptibility genes for schizophrenia, DISC1 and neuregulin-1, have 
emerged as having potentially prominent roles in neurodevelopment. Several 
studies have linked polymorphisms in these genes to schizophrenia, and rodent 
mutation models display abnormalities in neuroanatomy and behaviour akin to 
those seen in patients (Pletnikov et al. 2008; Wolpowitz et al. 2000). 
 
1.1.2.2 Environment 
Environmental aspects that may induce schizophrenia can be broadly 
subdivided into three categories: prenatal complications; social 
stress/adversity, particularly in early life; and pharmacological. Gestational 
problems and schizophrenia have long been associated, with two theories 
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producing a relatively consistent clinical linkage to schizophrenia: pre and 
perinatal foetal hypoxia (Clarke et al. 2006; Handford 1975), and maternal 
infection (Brown 2006; Brown and Derkits 2010). Hypoxia, starvation of 
oxygen to the brain, produces toxic effects on a cellular level mediated through 
changes in intracellular calcium leading to the creation of reactive oxygen 
species (ROS), mitochondrial dysfunction, and subsequent apoptosis 
(Thornton et al. 2012). The cellular damage caused has been shown through 
numerous clinical and preclinical studies (Golan and Huleihel 2006; Van Erp 
et al. 2002), and the epidemiological links to later development of 
schizophrenia in adulthood are strong (Joyce 2005; Schmidt-Kastner et al. 
2006). Initial links between epidemic infections and later schizophrenia 
development in populations suggested a relationship between maternal 
infection and schizophrenia aetiology. Candidate infections including 
toxoplasmosis gondii (Brown et al. 2005) and herpes simplex virus type-2 
(Buka et al. 2008), leading to elevated maternal serum immunoglobulin G 
(IgG) and pro-inflammatory cytokines such as interleukin-8 (IL-8) and tumour 
necrosis factor-alpha (TNFĮ), have been associated with significant increases 
in risk of schizophrenia. Evidence suggests that foetal exposure to elevated 
levels of pro-inflammatory cytokines may lead to disrupted maturation of 
oligodendrocytes through nitric oxide and excitatory amino acid production, 
and hence abnormalities in white matter, as seen in schizophrenia (Brown and 
Derkits 2010; Davis et al. 2003). Subsequently, activation of the immune 
system of gestating rodent dams has become a commonly studied preclinical 
model of schizophrenia. Offspring from dams treated with the synthetic viral 
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product polyinosinic-polycytidilic acid (Poly(I:C)) display a variety of 
behavioural deficits, including in cognitive and social domains (Meyer 2014; 
Pacheco-Lopez et al. 2013; Wolff and Bilkey 2010), associated with elevated 
maternal inflammatory cytokines, including TNFĮ (Cunningham et al. 2007). 
A social aetiology for schizophrenia is also a popular evidence-based concept, 
with particular salience placed on early-life adversity such as maternal 
separation and childhood abuse (MacMillan et al. 2001; Schenkel et al. 2005; 
Wicks et al. 2005). Mechanistically, it has been suggested that these 
experiences may only lead to specific psychosis development in the presence 
of particular genetic predispositions, and that activation of the hypothalamic-
pituitary-adrenal axis related to stress or altered dopaminergic transmission and 
sensitization may be viable links between environmental and genetic risk 
factors (Collip et al. 2008). Social stressors are a popular method for inducing 
schizophrenia-like deficits in animal models of the disease, with maternal 
separation, chronic social defeat, and rearing in social isolation all inducing 
behavioural and neurobiological abnormalities with salience to the disease 
(Fone and Porkess 2008; Millstein et al. 2006; Selten and Cantor-Graae 2007). 
There have been continuing links between substance abuse and schizophrenia 
development, particularly based on the observation that N-methyl-D-aspartate 
(NMDA) receptor antagonists (such as phencyclidine (PCP)) taken for illicit 
recreational use can exacerbate psychotic symptoms in schizophrenia sufferers, 
and can induce auditory and visual hallucinations in healthy individuals (Javitt 
and Zukin 1991; Krystal et al. 1994; Luby et al. 1959). There is also some 
evidence that the symptoms induced by NMDA receptor antagonism endure 
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even after cessation of drug administration (Rainey and Crowder 1975), which 
has led to the development of an NMDA receptor hypofunction theory of 
schizophrenia (Olney et al. 1999). The co-morbidity between substance abuse 
disorders and schizophrenia is also notably high (Brown et al. 2012; Jones et 
al. 2011c; Koola et al. 2012), with particular focus paid to the potential 
causative links between adolescent cannabis use and schizophrenia 
(Andreasson et al. 1987). However until recently few studies highlighted 
whether cannabis use is causal or as a consequence of the disease (Arseneault 
et al. 2004). More recent work has indicated it may be associated with aberrant 
development of the prefrontal cortex (PFC) (Bossong and Niesink 2010), could 
cause significant alterations in dopamine transmission in the brain (Muller-
Vahl and Emrich 2008), and may be associated with working-memory deficits 
and altered globus pallidus, striatum and thalamus structure by MRI (Smith et 
al. 2014). However, some inconsistencies still exist in the link between 
cannabis and schizophrenia, with recent evidence showing that cannabis use 
does not increase the risk of schizophrenia morbidity in people either with, or 
without, a familial history of the disease (Proal et al. 2014). Indeed, this study 
found that risk of schizophrenia was only significantly increased by familial 
history, lending yet more support to the genetic aetiology of the disease. 
 
1.1.2.3 Gene x Environment Interactions 
The most likely answer is that genes and environment interact to increase the 
risk of developing schizophrenia. A genetic predisposition to the disease may 
be subsequently precipitated by environmental factors. One example include 
the presence of polymorphisms which, when combined with prenatal immune 
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activation in rodents, may lead to aberrant neurodevelopment (Ibi et al. 2010; 
Lipina et al. 2013). The influence of post-natal environment on genetic 
predisposition is difficult to study clinically, but a number of rodent models 
examining the interplay between individual genes and early-life stress have 
emerged (Chesworth et al. 2012; Desbonnet et al. 2012; Haque et al. 2012; 
Ishihama et al. 2010; Jiang et al. 2013). Results of these studies have added to 
the suggestion that an underlying genetic susceptibility to neuropsychiatric 
disorders may be precipitated when environmental stressors are presented. 
 
1.1.3 Neurobiological Basis of Schizophrenia 
1.1.3.1 The Dopamine Hypothesis 
The involvement of dopamine signalling in schizophrenia has long been 
established, since the discovery that primary drugs with efficacy against 
psychoses were dopaminergic in nature (Carlsson and Lindqvist 1963; 
Carlsson et al. 1957). Advanced imaging studies using PET and SPECT 
technology have demonstrated a modest increase in D2/3 receptor density in the 
striatum of schizophrenia sufferers (Kestler et al. 2001), and striatal dopamine 
release significantly increases following amphetamine treatment to patients, 
coinciding with an exacerbation of positive symptoms (Abi-Dargham et al. 
2000; Laruelle et al. 1996). Recent advances have also shown that elevated 
dopamine is limited to the precommissural dorsal caudate, and not the limbic 
or sensorimotor regions, of the associative striatum (Kegeles et al. 2010). This 
region is involved in associative information processing, and also accepts input 
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from the dorsolateral PFC, hence hyperdopaminergic activity may influence a 
range of disease symptoms (Kegeles et al. 2010; Lodge and Grace 2011). 
Reduced dopaminergic activity in frontal regions (for example through lesion 
studies in rodents) seemingly mirrors negative symptoms of the disease (Davis 
et al. 1991; Howes and Kapur 2009). Prominent recent papers have shown 
increased frontal D1 receptor density, reflecting an up-regulation in gene 
expression in response to hypodopaminergic activity that may be involved in 
the working memory deficits seen in schizophrenia (Abi-Dargham et al. 2002; 
Abi-Dargham et al. 2012). However, reproducible changes in frontal dopamine 
levels have not been observed (Akil et al. 1999). 
A large meta-analysis covering all available neuroimaging data recently 
concluded that the largest abnormality in dopamine function is presynaptic, 
rather than in post-synaptic receptor density (Howes et al. 2012). The authors 
suggested that dopamine synthesis capacity, baseline dopamine levels and 
dopamine release may all be strongly implicated, and that future therapeutics 
should address this pathology. 
 
1.1.3.2 The Glutamate Hypothesis 
The NMDA receptor hypofunction model has been proposed to link the natural 
GHYHORSPHQWRI VFKL]RSKUHQLD DQG WKH µVFKL]RSKUHQLD-OLNH¶ HIIHFWVRI10'$
receptor antagonists (Cohen et al. 1962; Javitt and Zukin 1991; Krystal et al. 
1994; Lahti et al. 1995; Luby et al. 1959; Olney et al. 1999). The model 
suggests that dysfunction of NMDA receptors may cause excess synaptic 
glutamate release to overcome the loss of signalling. This release of excitatory 
neurotransmitter may overstimulate post-synaptic cells by overcoming the 
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blockade or stimulating Į-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors. Excessive activation could lead to post-synaptic 
excitotoxicity, and subsequently cause neuronal cell death (Deutsch et al. 
2001). This could explain the neuropathology identified in schizophrenia 
patients (Kreczmanski et al. 2007; Shenton et al. 2001).  
7KHKLSSRFDPSXV¶ pivotal role in long-term memory implicates it strongly in 
the cognitive disease domain (Tamminga et al. 2010). Pathology of the 
hippocampus has long been observed in post-mortem tissue from patients 
(Bogerts et al. 1985), supported by imaging studies suggesting an inability to 
recruit the hippocampus when required for memory-based tasks (Heckers and 
Konradi 2002; Nelson et al. 1998). Basal activity of the hippocampus is 
increased in schizophrenia (Medoff et al. 2001) and atrophy of the 
hippocampus is seen in patients after psychosis onset (Schobel et al. 2013). 
Ketamine treatment to mice mirrors these effects, with pathology occurring in 
parvalbumin-expressing hippocampal interneurons, confirming the 
involvement of glutamate and NMDA receptors in hippocampal atrophy. 
Hippocampal glutamate hyperfunction and excess striatal dopamine activity, 
both linked to the positive symptom domain, can be linked through a 
polysynaptic pathway from the ventral hippocampus (vHipp) to the ventral 
tegmental area (VTA) (Figure 1.1) (Blaha et al. 1997; Floresco et al. 1997; 
Floresco et al. 2001; Floresco et al. 2003). Top-down inputs are received from 
the prefrontal cortex (PFC) during cognitive tasks, further implicating frontal 
pathology in schizophrenia (Floresco et al. 1997; Jones and Wilson 2005). 
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Figure 1.1 ± Elevated activity in the ventral hippocampus (vHipp) and medial 
prefrontal cortex (mPFC) in schizophrenia leads to increased excitatory input to the 
nucleus accumbens (NAc). Hyperactive GABAergic projections from the NAc to 
ventral tegmental area (VTA) via the ventral pallidum (VP) lead to disinhibition of 
dopaminergic neurons, and hence excessive dopamine is released from the VTA into 
the limbic system. Adapted from (Lodge and Grace 2009). 
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Particular attention has been focused on GABAergic interneuron pathology in 
the hippocampus and PFC in schizophrenia (Beasley and Reynolds 1997; 
Beasley et al. 2002; Benes et al. 2007; Hashimoto et al. 2003; Konradi et al. 
2011; Lewis et al. 2005; Lodge et al. 2009; Zhang and Reynolds 2002). Post-
mortem studies reveal a significant loss of interneurons in hippocampal sub-
regions (Benes et al. 1998), and further analysis shows that the density of 
interneurons expressing the calcium-binding protein parvalbumin (PV) 
(Konradi et al. 2011; Zhang and Reynolds 2002) and the peptide hormone 
somatostatin (Konradi et al. 2011) is decreased. These findings have been 
replicated in a number of animal models of schizophrenia (Braun et al. 2007; 
Lodge et al. 2009; McKibben et al. 2010; Nakatani-Pawlak et al. 2009; 
Schobel et al. 2013), suggesting that loss of GABAergic inhibition could cause 
aberrant glutamatergic activity. By acting as a negative feedback loop to 
glutamatergic neurons, or as a route for glutamatergic regulation of inhibitory 
tone, hypofunction of NMDA receptors on these GABAergic interneurons may 
lead to excitotoxic cell death via excessive glutamate release as described 
above (Figure 1.2). The reported positive effects of benzodiazepines (positive 
GABAergic allosteric modulators) in alleviating psychotic symptoms in subset 
of schizophrenia patients further supports GABAergic involvement, however 
the varied side-effects including sedation and cognitive impairments limit 
EHQ]RGLD]HSLQHV¶ XWLOLW\  (Wolkowitz and Pickar 1991). Targeting specific 
GABA receptor subtypes may provide a new therapeutic approach to the 
treatment of schizophrenia in the future (Lodge and Grace 2011). 
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Figure 1.2 ± Diagrammatic representation of a negative feedback loop within the 
ventral hippocampus through which glutamatergic output is regulated by GABAergic 
interneurons. (A) In a normal system, glutamatergic neurons (GLU) project onto 
GABAergic interneurons (GABA) within the ventral hippocampus (vHipp), and cause 
excitation through NMDA receptors on GABAergic cell bodies. Through a negative 
feedback loop, GABAergic projections onto GLU axons regulate GLU output. (B) 
Following loss of GABAergic interneuron function (via NMDA receptor dysfunction, 
apoptotic cell death etc.) this negative feedback loop is lost, and GLU output is 
disinhibited. Diagram adapted from (Del Arco et al. 2011). 
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1.1.4 Treatment of Schizophrenia 
Broadly, available treatments for schizophrenia fall into two categories: typical 
and atypical antipsychotics. However, these groups have many characteristics 
in common, and are divided as much by their time of discovery as their 
differing pharmacology. 
Typical antipsychotics, the first treatments to be discovered, are mostly defined 
as dopamine antagonists or inverse agonists. Drugs of this class, such as 
chlorpromazine and haloperidol, have relatively high affinities for the 
dopamine D2 receptor, where binding levels correlate with successful treatment 
of positive symptoms (Nordstrom et al. 1993; Nyberg et al. 1995). However, 
dopamine antagonism produces significant side-effects along with benefits. 
Extrapyramidal side-effects due to dopamine antagonism in the basal ganglia 
produce ataxia, dystonia and Parkinsonism-like movement disorders. Further, 
typical antipsychotics produce a number of off-target side-effects, whilst 
having little benefit on the negative or cognitive disease symptoms. 
&KORUSURPD]LQH LV D SDUWLFXODUO\ ³GLUW\´ FRPSRXQG ZLWK KLJK DIILQLW\ DW
dopamine receptors D1-4, as well as at 5-HT1/2 serotonin receptors, H1 
KLVWDPLQH UHFHSWRUV Į1 adrenergic receptors and muscarinic acetylcholine 
receptors M1/2 (Savelyeva et al. 1988) $QWDJRQLVP RI KLVWDPLQH DQG Į-
adrenergic receptors leads to strong sedation, which although may help to 
alleviate psychoses, does not aid a pDWLHQWV UHWXUQ WR ³QRUPDOLW\´ 7KH
anticholinergic effect of chlorpromazine leads to both common side-effects 
associated with this pharmacology (constipation, dry mouth etc.) and 
potentially to further cognitive impairment. Serotonin antagonism may aid the 
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activity of chlorpromazine, by reducing aggression and anxiety, and is also 
hypothesised to reduce extrapyramidal side-effects by reducing serotonin 
control of the basal ganglia (Kapur and Remington 1996; Kapur et al. 1999). 
But antagonism at serotonin receptors is also believed to lead to significant 
weight gain, a common side effect of antipsychotic treatment.  Alternatively, 
haloperidol has a much cleaner binding profile, with highly selective dopamine 
receptor affinity. However, this specificity is accompanied by elevated 
extrapyramidal side-effects, overshadowing the positive symptom control. 
The main pharmacological difference between the typical and atypical 
antipsychotics is 5-HT activity. The new class of compounds, whilst 
maintaining dopamine receptor affinity, also have greatly increased serotonin 
antagonism, particularly at 5-HT2A receptors. Clozapine, the first atypical 
antipsychotic developed, in fact has a relatively low D2 affinity compared to 5-
HT2A, and instead has greater D4 affinity. Due to low D4 expression in the 
basal ganglia, as well as the influence of serotonin antagonism, clozapine 
displays relatively few extrapyramidal side-effects. However, clozapine carries 
a black box warning for drug-induced agranulocytosis, which can cause death; 
hence use is limited to patients with symptoms resistant to other antipsychotic 
medication. Other compounds in this class, such as olanzapine and risperidone, 
are safer than clozapine but less efficacious. Both express high affinity at 5-
HT2A receptors compared to D2, believed to aid with their antipsychotic action, 
but this is accompanied by the weight gain side-effects due to serotonin 
antagonism. Both are also potent H1 antagonists, which like chlorpromazine 
leads to sedation. Again, drugs of this class are relatively successful in the 
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treatment of positive symptoms, but generally offer little in the way of 
negative or cognitive symptoms, although some potentially beneficial effects 
of particularly risperidone have been noted in clinical trials (Bilder et al. 2002; 
Houthoofd et al. 2008). There is also a subset of patients who do not respond 
to any antipsychotic medication, even the last line of treatment clozapine. 
7KHVH³FOR]DSLQH-UHVLVWDQWSDWLHQWV´UHSUHVHQWDIXUWKHUVHULRXVXQPHWPHGLFDO
need for novel antipsychotic drugs. 
 
1.2 Preclinical Research in Schizophrenia 
 
The lack of efficacy of current antipsychotic medication towards the cognitive 
symptoms of schizophrenia means the availability of preclinical animal models 
that accurately replicate this domain in the laboratory are vital. The utility of 
animal models is two-fold. Firstly, models can be used to determine the 
underlying mechanisms associated with the aetiology and risk-factors for 
disease development, including an assessment of potential interactions 
between different genetic and environmental factors. A greater disease 
understanding may reveal new avenues for drug development. Secondly, 
models are essential for evaluating novel treatments for their potential use in 
patients. This, however, relies on the validity of the model used, assessed in 
three domains: construct, predictive and face (Willner 1984). Face validity 
describes how similar an animal model looks to the human condition, in terms 
of behaviour in relevant paradigms and similar biological changes or markers. 
Construct validity examines similarities in the way deficits are created; if the 
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model and disease are induced in a similar manner. Predictive validity is 
gained by demonstrating similar responses to pharmacological challenge as 
seen in patients. This domain is therefore key when selecting a model to test 
putative new compounds.  
With the development of the MATRICS (Measurement and Treatment 
Research to Improve Cognition in Schizophrenia) and TURNS (Treatment 
Units for Research on Neurocognition and Schizophrenia) initiatives to 
develop reliable, valid and consensus-derived methods of assessing cognition, 
there is a clear framework established for preclinical models of schizophrenia-
like symptoms to be judged against. With seven key cognitive domains 
identified as deficient in schizophrenia patients, a wide-ranging battery of 
behavioural techniques is available against which to assess the face and 
construct validity of animal models (Jones et al. 2011b; Young et al. 2009). 
 
1.2.1 Locomotor Activity 
Locomotor activity (LMA) in an open field is a long established behavioural 
paradigm that has a wide variety of uses, from assessing motor co-ordination 
WRVHGDWLRQ7KH³SRVLWLYH´V\PSWRPVRIVFKL]RSKUHQLDDUHGLIILFXOWWRPRGHOLQ
rodents, as symptoms of hallucinations are highly subjective; however 
neophobia is seen as a suitable correlate for positive human symptoms based 
on its reasonable predictive and construct validity (Fone and Porkess 2008; 
Levine et al. 2007; McIntosh et al. 2013). Rats placed in a novel environment 
show elevated exploratory activity decreasing with time as they habituate to 
the novelty. However, rodents of a schizophrenia-like phenotype exhibit 
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elevated horizontal exploration and vertical rearing and habituate at a slower 
rate than control counterparts (Fone and Porkess 2008; Gentsch et al. 1988; Le 
Pen et al. 2011; Zhang et al. 2012b). This hyperlocomotion has been 
interpreted as an elevated propensity to escape from the novel arena, and hence 
reflects fear of novelty (Fone et al. 1996). This hyperlocomotion is robust 
across groups, cohorts and methods of interference (Fone and Porkess 2008; 
Jones et al. 2011b), and also displays predictive validity as it is consistently 
reversed by standard antipsychotic compounds notably strong at reversing 
positive symptoms in the clinic (Fabricius et al. 2011; Le Pen et al. 2011; 
McIntosh et al. 2013). Elevations in locomotor activity have been correlated 
with increased striatal dopamine release in rodents (Flagstad et al. 2004; 
Paulson and Robinson 1995), similar to the correlation between striatal 
dopamine and the onset of psychosis in schizophrenia patients (Abi-Dargham 
et al. 1998; Abi-Dargham et al. 2000; Laruelle et al. 1996). The PFC is also 
implicated, with a strong correlation between hyperlocomotion in rodent 
models and differential expression of genes involved in cell differentiation and 
apoptosis (Kaiser et al. 2004; Levine et al. 2007; Liu et al. 2010; Turnock-
Jones et al. 2009).  
 
1.2.2 Locomotor Response to Acute NMDA receptor antagonist 
An additional arm of locomotor activity analysis involves an altered response 
to acute NMDA receptor antagonist administration. As discussed previously, 
NMDA receptor antagonists produce symptoms similar to the positive domain 
of schizophrenia in healthy individuals, and exacerbate positive symptoms in 
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patients (Javitt and Zukin 1991; Krystal et al. 1994; Lahti et al. 1995). 
Preclinically, acute NMDA receptor antagonists cause hyperlocomotion in 
many animal models of schizophrenia, particularly those using NMDA 
receptor antagonist pre-WUHDWPHQWWRLQGXFHWKHµVFKL]RSKUHQLD-OLNH¶V\QGURPH
providing good face validity (Boctor and Ferguson 2010; Le Pen et al. 2011; 
Nakatani-Pawlak et al. 2009; Wang et al. 2001).  
 
1.2.3 Novel Object Discrimination 
Novel object discrimination (NOD) is a common task often utilized for 
cognition research, particularly relative to schizophrenia (Akkerman et al. 
2012; Dere et al. 2007; Ennaceur and Delacour 1988; Grayson et al. 2007; 
McIntosh et al. 2013; McLean et al. 2010a). NOD relies on an innate tendency 
to explore novelty, tending to previously unseen objects placed into an arena 
with vibrissae, nose and forepaws (Dere et al. 2007), and has been identified as 
a key correlate for visual learning and memory impairment by MATRICS 
(Young et al. 2009). After exposure to two identical objects, rodents will 
preferentially explore a novel object over one of those they have been pre-
exposed to following a delay away from the context. However, animals that 
have impairments in visual learning and memory may be unable to encode the 
necessary information during the first trial, or not able to retain/retrieve the 
information when required in the second trial, and hence explore novel and 
familiar objects to a similar extent, showing a measurable behavioural deficit 
(Ennaceur and Delacour 1988). 
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Evidence suggests that NOD performance relies heavily on the entorhinal and 
SHULUKLQDO FRUWH[ RYHU WKH PRUH WUDGLWLRQDO ³PHPRU\ FHQWUH´ RI WKH
hippocampus, with perirhinal lesions able to impair NOD in a study where 
hippocampal lesions did not (Winters et al. 2004). However, some 
hippocampal involvement is likely, particularly with longer intervals between 
trials (Clark et al. 2000). Alterations in the perirhinal cortex of schizophrenia 
patients have been noted through MRI studies (Turetsky et al. 2003), and 
deficits in visual memory tasks in patients with schizophrenia are directly 
comparable to those with temporal lobe epilepsy that have a clear hippocampal 
lesion impairing performance (Yoo et al. 2006). Hence, NOD displays a level 
of face validity and etiological relevance. However, the predictive validity of 
this model is highly questionable. The effects of current antipsychotic 
medication on NOD performance varies greatly between studies, but both 
acute (Grayson et al. 2007) and subchronic clozapine (Hashimoto et al. 2005), 
acute risperidone (Grayson et al. 2007; McIntosh et al. 2013) and repeated 
aripiprazole (Nagai et al. 2009) have all been shown to reverse NOD deficits. 
Considering the very limited efficacy of current antipsychotic compounds on 
cognition in schizophrenia, these reversals of NOD deficits represent a 
weakness of this paradigm (Keefe 2007; Young et al. 2009) 
 
1.2.4 Prepulse Inhibition of the Acoustic Startle Response 
Considered as a paradigm with high translational relevance to schizophrenia, 
despite a lack of consistency in preclinical studies (Fone and Porkess 2008), 
prepulse inhibition (PPI) of the acoustic startle response is thought to evaluate 
Chapter 1 Ȃ General Introduction 
- 21 - 
 
preattentional processing, identified as a key domain in the MATRICS battery 
(Young et al. 2009). In PPI, a low amplitude, non-startle eliciting sound 
presented immediately before a startle eliciting tone causes a decreased startle 
response than elicited with the tone alone. Thus, PPI is considered to require 
sensorimotor gating, the ability of the brain to filter out unnecessary sensory 
inputs. Deficits in this behaviour have been observed schizophrenia patients 
(Braff et al. 2001; Swerdlow et al. 2006a), although the link between PPI and 
cognitive deficits is unclear as they do not necessarily co-exist in the same 
patients (Swerdlow et al. 2006a). Regardless, this test has face validity in a 
preclinical model as it is highly conserved across species and can be directly 
measured in humans (Swerdlow et al. 2006a). 
The networks involved in PPI are highly complicated, and their modulation of 
the primary auditory startle network from the cochlear to the caudal pontine 
reticular nucleus (PnC) and spinal motor neurons has been extensively 
reviewed (Campbell et al. 2007; Fendt et al. 2001; Swerdlow et al. 2001) 
(Figure 1.3). Key to the link between PPI and schizophrenia are the inputs of 
the NAc, hippocampus and frontal regions feeding into the primary networks 
controlling auditory startle response. With previously described pathology in 
these regions, the impairment of PPI in schizophrenia is unsurprising.  
Atypical antipsychotic treatments can normalise PPI responses in patients or 
³ORZ-33,´SKHQRW\SHLQGLYLGXDOV(Swerdlow et al. 2006b; Vollenweider et al. 
2006; Wynn et al. 2007), and similar results have been reported in rodent 
models of schizophrenia (Bakshi et al. 1994; Geyer et al. 2001). Hence, the 
predictive validity and relevance of this paradigm is strong. 
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Figure 1.3 ± Neural circuitry involved in acoustic startle and prepulse inhibition. The 
DFRXVWLFVWLPXOXV³6´VWLPXODWHVDVLPSOHFLUFXLWWKURXJKWKHFRFKOHD&RFKDQGWKH
caudal pontine reticular nucleus (PnC) to eliFLWDVWDUWOHUHVSRQVH³5´$VHFRQGDU\
circuit, via the inferior (IC) and superior colliculus (SC) to the pendunculopontine 
tegmentum (PPTg) can also influence startle response, and is regulated by a network 
of descending projections from the forebrain, importantly via the ventral pallidum 
(VP) and nucleus accumbens (NAC), and implicating the hippocampal formation 
(HPC), medial prefrontal cortex (MPFC), and ventral tegmental area (VTA). Also 
included in the diagram are the mediodorsal thalamus (MD), the medial septal nucleus 
(MS), the basolateral amygdala (BLA) and the auditory cortex (Aud). Diagram 
adapted from Swerdlow, 2001. 
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1.2.5 Conditioned Emotional Response 
Although not considered a core part of the MATRICS test battery, there is 
significant evidence that associative learning is impaired in schizophrenia 
(Herbener 2009; Rushe et al. 1999). The conditioned emotional response 
(CER) paradigm involves associating a non-aversive conditioned stimulus 
(CS), e.g. a light and sound tone, with an aversive unconditioned stimulus 
(US), like a mildly-aversive foot-shock. Successful association of the stimuli 
results in a reaction to the conditioned stimulus that would normally be 
observed upon presentation of just the US.  
The CER protocol has been well validated in rodents (Woods et al. 2012), and 
the neurobiological basis of conditioning has been mapped (Figure 1.4) (Maren 
2001). The amygdala is the centre for integration of physiological responses to 
sensory inputs and is a likely centre for association between aversive and non-
aversive inputs (Maren 2001). Hippocampal involvement in contextual 
conditioning circuitry is also evident from indirect projections to the CE via 
the mPFC, where pre-limbic projections to the BLA enhance fear renewal 
while infra-limbic projections to intercalated cells have an inhibitory effect on 
the CE to reduce fear-responses (Maren et al. 2013). Post-mortem studies have 
highlighted a reduced volume and neuron number in the lateral nucleus of the 
amygdala of patients (Kreczmanski et al. 2007), suggesting pathology may be 
responsible for observed associative learning deficits (Herbener 2009; Rushe et 
al. 1999). 
  
Chapter 1 Ȃ General Introduction 
- 24 - 
 
 
Figure 1.4 ± Neural circuits governing fear conditioning. The basolateral amygdala 
complex (the lateral (LA), basolateral (BL) and basomedial (BM) muclei) and the 
central nucleus (CE) combine to form the amygdaloid nuceli. Sensory information 
from the thalamus (medial and ventral thalamic medial geniculate, MGm and MGv; 
posterior intralaminar nucleus, PIN), neocortex (insular cortex, INS; piriform cortex, 
PIR; primary auditory cortex, TE; perirhinal cortex, PRh), and hippocampus (CA1 
area; ventral subiculum, vSUB; entorhinal cortex, ENT) is received by the basolateral 
complex, and is conveyed to the CE by intra-amygdaloid circuitry, suggested as a 
location for conditioned-unconditioned stimuli to be integrated. From the CE, 
divergent projections mediate physiological responses such as freezing, potentiated 
startle, and altered cardiac rhythm via the midbrain (periacqueductal grey, PAG; 
parabrachial nucleus, PB; caudal pontine reticular nucleus, RPC), medulla (dorsal 
motor nucleus of the vagus, DMN), hypothalamus (ventromedial hypothalamus, VPN; 
lateral hypothalamus), and bed nucleus of the stria terminalis (BNST) in the extended 
amygdala. Diagram adapted from Maren, 2001.  
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Numerous groups have shown that deficits in contextual and cue-based 
conditioning can be readily reproduced in animal models of cognitive 
dysfunction, and that these can be ameliorated by pharmacological treatments 
including antipsychotics (Csernansky et al. 2005; Martin et al. 2005; Woods et 
al. 2012), providing some predictive validity to the paradigm. However, the 
exclusion of any kind of conditioning-based paradigm from the MATRICS 
initiative does indicate that the translational relevance of CER is somewhat 
limited compared to others described here (Young et al. 2009). 
1.2.6 Morris Water Maze 
In contrast to CER, the Morris Water Maze (MWM) (Morris 1984) is highly 
translatable to the MATRICS battery, and has a protocol that can include 
working memory, visual learning and memory, and reasoning and problem 
solving (Young et al. 2009). The MWM task involves a repetitive training 
regime that requires rodents to locate a hidden, fixed-location platform below 
the surface of a water-filled pool using visual extra-maze clues. Over repeated 
trials, rodents can successfully locate the platform with decreasing latency, and 
can be tested for their level of task acquisition by removing the platform and 
assessing the search profile. This simple protocol requires inputs from the 
dorsal hippocampus particularly, based on the strong spatial aspect of the task 
(Moser et al. 1993), but the habenula has also been implicated. Lesions of this 
nucleus in rat impairs water maze performance (Lecourtier et al. 2004; 
Lecourtier et al. 2005; Wang et al. 2013) and calcification of the habenula and 
neighbouring pineal gland has been seen in schizophrenia patients (Sandyk 
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1992), although the correlation between calcification and cognitive 
performance has not been examined. 
In addition, a more complicated reversal task can be performed. The fixed 
location of the platform can be changed, requiring extinction of a previously 
learnt rule and re-acquisition of a new location. Alternatively, a new search 
strategy can be implemented by altering the position of the platform between 
each trial, or each day, following a consistent rule, requiring working memory 
and problem solving to successfully complete (Young et al. 2009). 
Schizophrenia patients display cognitive deficits in multi-modal 3D virtual 
maze tasks that require continual working memory to complete, adding face 
validity (Sorkin et al. 2005; Sorkin et al. 2006). Although not analogous to the 
MWM task, the use of altered visual and spatial clues to update a maze-escape 
procedure does provide considerable cross comparison between the human and 
rodent tasks. Some difficulty in construct validity occurs when considering the 
neural aspects of working memory that may be involved in a MWM reversal 
task, as the hippocampus, key in rodent studies (Dong et al. 2013; Duffy et al. 
2008), contrasts with findings that the frontal cortex is integral to working 
memory performance in humans (Bor et al. 2006; Bor et al. 2001). 
Many antipsychotics cause impairments in the MWM, including clozapine 
(Didriksen et al. 2006), olanzapine (Didriksen et al. 2006; Terry et al. 2002), 
and haloperidol (Terry et al. 2002; Terry et al. 2003). Short term risperidone 
causes a slight improvement in performance (Terry et al. 2003), but longer-
term treatment causes impairment (Terry et al. 2007). This data is partially 
comparable to the clinic, where most antipsychotics have little beneficial effect 
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on cognition (Keefe 2007), whilst some potentially positive effects of 
risperidone have been noted (Bilder et al. 2002; Houthoofd et al. 2008). 
 
The MATRICS battery includes further tests to assess social cognition through 
interactions, and attentional processing through tasks like the five choice serial 
reaction time task (5CSRTT), however as these have not been utilised in this 
thesis they have not been further discussed. 
 
1.3 Preclinical Models of Schizophrenia 
 
With continuing uncertainty over the aetiology of schizophrenia, it is 
XQVXUSULVLQJ WKDW D QXPEHU RI PHWKRGV IRU SURGXFLQJ µVFKL]RSKUHQLD-OLNH¶
symptoms in rodents also exist. Broadly, these fit into four categories: 
developmental, pharmacological, lesion, and genetic, each with strengths in 
terms of validity to schizophrenia (Jones et al. 2011b).  
Developmental models of schizophrenia, including those based on prenatal 
immune challenge or neurodevelopmental disruption, social stress and early-
life adversity, hold a high level of construct validity to the disease. Each is 
closely linked to a specific risk factor for schizophrenia development, 
identified through clinical risk studies: maternal immune activation to the co-
incidence of maternal viral infection and subsequent psychoses in offspring; 
isolation rearing to the social stress theory of schizophrenia aetiology; and 
prenatal MAM treatment to the neurodevelopmental disruption hypothesis 
(Jones et al. 2011b). Each also has considerable face and some predictive 
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validity, with behaviours relating to positive, negative and cognitive symptoms 
known to be deficient and reversible by some current antipsychotic agents. The 
weakness of these models, however, is that they do not address the clear 
genetic linkage of schizophrenia. 
Specific genetic models of schizophrenia hold a high level of construct validity 
by addressing this issue. DISC-1, neuregulin-1, and other genetic mutation/ 
knockout lines in rodents hold deficits in potentially key susceptibility genes 
that may underlie the development of schizophrenia. Dual-hit models where 
these genetic predispositions are exacerbated by subsequent developmental 
challenges have been developed to further increase the validity (discussed 
below). However, as no Mendelian forms of schizophrenia have been 
discovered, the relevance of these single knockout/point-mutation models is 
difficult to conclude. 
Pharmacological models, particularly those based around NMDA receptor 
antagonists also hold some construct validity, inducing NMDA receptor 
hypofunction and impeding glutamate signalling. Dopamine-elevating 
compounds such as amphetamine can also be used to model particularly the 
positive symptoms of the disease, but these are less successful in inducing 
either negative or cognitive deficits, so have limited face validity. One 
considerable issue with NMDA receptor antagonist models of schizophrenia 
are the false-positive effects of current and putative antipsychotics on the 
behavioural deficits of these models. This is considered in greater depth below. 
Lesion models, such as the ventral hippocampal lesioning approach, hold 
limited construct validity. However, their face validity in terms of behavioural 
Chapter 1 Ȃ General Introduction 
- 29 - 
 
responses and changes in neurotransmitter systems are equal to those produced 
by pharmacological challenge, and are potentially much longer-lasting (Jones 
et al. 2011b). 
In this investigation, research focused on models with a strong developmental/ 
perinatal insult, following the early-life adversity theory of aetiology. 
 
1.3.1 Isolation Rearing  
Rearing rats in social isolation following weaning (postnatal day (PND) 20-
25), maintaining auditory, olfactory and visual, but not physical contact with 
conspecifics, prevents establishment of a hierarchy in a litter which is key in 
neurodevelopment. Alterations in behaviour and neurobiology are produced 
that persist into adulthood (Fone and Porkess 2008; Lapiz et al. 2003; Schubert 
et al. 2009). This developmental disruption protocol mimics the early-life 
adversity hypothesis of schizophrenia aetiology, and the model phenotype is 
termed µLVRODWLRQV\QGURPH¶(Fone and Porkess 2008; Jones et al. 2011b). 
Neophobia, fear of novelty, can be examined in LMA tasks as described 
previously (see Chapter 1.2.1), and this is one of the most robust changes 
induced in isolation-reared rats. Multiple groups have shown elevated 
horizontal locomotor activity and vertical rears following two to six weeks of 
single housing (Del Arco et al. 2004; Fone and Porkess 2008; Powell et al. 
2002; Robbins et al. 1996). The early onset of this behaviour and the simple 
testing procedure make LMA a useful marker for assessing the establishment 
of isolation syndrome. As discussed previously (see Chapter 1.2.1), one theory 
of the underlying basis of this hyperlocomotion is alteration in PFC function. 
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Structural deficits in the PFC of isolation reared animals have been noted 
(Day-Wilson et al. 2006; Schubert et al. 2009), which replicates results seen in 
schizophrenia patients (Hirayasu et al. 2001; Wible et al. 2001). Predictive 
validity is also provided with evidence that clinically relevant antipsychotics 
such as risperidone (McIntosh et al. 2013), haloperidol and olanzapine 
(Fabricius et al. 2011) are able to reverse the hyperactivity seen.  
The impairment of PPI of acoustic startle in isolation syndrome (Cilia et al. 
2001; Geyer et al. 1993; Powell et al. 2002; Schubert et al. 2009; Varty and 
Higgins 1995; Wilkinson et al. 1994) is analogous to commonly observed 
deficits in schizophrenia patients (Braff and Geyer 1990; Braff et al. 2001; 
Swerdlow et al. 2006a), but an increasing number of negative studies have 
called the robustness of the deficit into question (Cilia et al. 2005; Fone and 
Porkess 2008; Jones et al. 2011a; McIntosh et al. 2013). The isolation rearing-
induced deficit in PPI can be reversed by infusion of 6-hydroxydopamine into 
the NAc to deplete dopamine levels, which does not occur in socially housed 
animals (Powell et al. 2003). This suggests that excess dopamine in the NAc 
may be a key neuropathology in isolation-reared animals, providing construct 
validity linking the model to dopaminergic theories of schizophrenia. Isolation 
rearing deficits in PPI are also susceptible to reversal with antipsychotics 
including quetiapine, olanzapine, clozapine, haloperidol and risperidone (Cilia 
et al. 2001; Varty and Higgins 1995).  
In paradigms with strong cognitive substrates such as NOD, isolation causes 
impairment (Bianchi et al. 2006; King et al. 2004; McIntosh et al. 2013; 
McLean et al. 2010a; Watson et al. 2012a). There is also evidence that this can 
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be reversed by current and putative antipsychotics, including risperidone 
(McIntosh et al. 2013) and 5-HT6 receptor antagonists (King et al. 2004), 
providing some predictive validity. Whilst there is some face validity to the 
model as it mirrors the visual recognition deficits seen in schizophrenia 
(McClure et al. 2007), there is no published evidence on the effect of isolation 
rearing on the perirhinal cortex in rats thought crucial for NOD performance 
(see Chapter 1.2.3). In the Morris Water Maze and T-Maze, involving spatial 
cognition, isolation rearing fails to induce impairment in acquisition of a fixed 
rule (Quan et al. 2010; Schrijver et al. 2002), but reduces retention of a learned 
task (Quan et al. 2010), and causes deficits in reversal protocols that require 
cognitive flexibility (Schrijver et al. 2004). Adding validity to the model, these 
deficits are accompanied by reduced long-term potentiation in the 
hippocampus (Ibi et al. 2008) and PFC (Quan et al. 2010). Although not 
considered a core cognitive symptom of schizophrenia, rats reared in isolation 
are impaired in their retention of both context and cue in the rodent CER 
paradigm, deficits that were not reversed by risperidone (McIntosh et al. 2013). 
In correlation with schizophrenia and cognitive symptoms (Goldman-Rakic et 
al. 2004), isolates have a reduced D1 dopamine receptor density in the PFC 
(Toua et al. 2010) and increased density in the striatum (Gill et al. 2013). There 
is some evidence that isolation rearing does not affect basal dopamine levels in 
the NAc (Fulford and Marsden 1998; Howes et al. 2000; Jones et al. 1992), but 
may cause higher levels and altered asymmetry in the mPFC (Jones et al. 
1992) and decreased overall turnover in this region (Heidbreder et al. 2000). 
Treatment with clozapine and olanzapine, but not haloperidol, causes elevated 
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dopamine in the mPFC of isolates, which may underlie some of their clinical 
efficacy against positive symptoms (Heidbreder et al. 2001).   
Much less focus has been on the glutamatergic system in isolates, perhaps due 
to clinically relevant dopamine receptor antagonists being readily available for 
study. A variety of NMDA receptor subunits and metabotropic glutamate 
receptors have been shown to be differentially regulated in the PFC (Melendez 
et al. 2004; Turnock-Jones et al. 2009) and hippocampus (Zhao et al. 2009) of 
isolation reared animals, suggesting an important role for glutamate function in 
the isolation phenotype. 
Following 11 weeks of isolation rearing, female Sprague-Dawley rats have 
decreased levels of parvalbumin and calbindin in the hippocampus ex vivo, 
correlated with deficits in PPI performance (Harte et al. 2007). A reduced 
expression of the GABA-transporter 1 (GAT-1) in the ventral prelimbic cortex, 
a marker of alterations in prefrontal GABAergic chandelier cartridges, has also 
been noted in (Bloomfield et al. 2008), with GAT-1 reductions at a level 
comparable to those seen in schizophrenia patients (Woo et al. 1998). These 
results suggest a decrease in GABAergic control throughout the brain of 
isolation reared animals may be a common origin of a number of the 
behavioural deficits observed. 
The isolation rearing model does have some limitations. As discussed 
previously, the model is highly susceptible to alterations in protocol, with even 
minimal repeated handling post-weaning preventing the induction of some 
behavioural changes, including hyperlocomotion to novelty (Holson et al. 
1991) and PPI deficits (Krebs-Thomson et al. 2001; Rosa et al. 2005). 
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Furthermore, some behaviours such as PPI lack robustness (Cilia et al. 2005; 
Cilia et al. 2001; Fone and Porkess 2008; Jones et al. 2011a; McIntosh et al. 
2013). Additional understanding of the molecular basis underlying the 
behavioural deficits observed would also increase the strength of this model. 
Work presented in this thesis attempts to address some of these issues by 
comparing and combining the isolation rearing model with pharmacological 
protocols to produce a dual-hit treatment with increased robustness and 
validity to schizophrenia. 
 
1.3.2 Methylazoxymethanol (MAM)  
Administration of the anti-mitotic and anti-proliferative agent 
methylazoxymethanol (MAM) (Matsumoto and Higa 1966) to pregnant rat 
dams on gestational day 17 (GD17) can also be considered a developmental 
disruption model of schizophrenia (Lodge and Grace 2009). By methylating 
DNA, selectively targeting developing neuronal cells without causing 
teratogenic effects elsewhere (Cattabeni and Di Luca 1997), gestational MAM 
impairs the development of brain structures in the foetus undergoing rapid 
mitosis, with construct validity to the neurodevelopmental theory of 
schizophrenia aetiology (Jones and Murray 1991; Murray et al. 1991). When 
administered on GD15, a time of peak neurogenesis in developing rat pups 
(Bayer 1995), MAM treatment induces gross neuronal histopathology and 
microencephaly (Banfi et al. 1984), reducing total cortical mass and brain 
weight (Moore et al. 2006). This pathology does not mimic the subtle changes 
in tissue morphology throughout the prefrontal cortical and temporal lobe in 
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schizophrenia (Shenton et al. 2001). By contrast, MAM treatment on GD17, 
when neuronal proliferation has peaked in cortical and subcortical regions 
(Bayer 1995), produces subtle reductions in cortical thickness throughout the 
mPFC, parahippocampal cortices, mediodorsal thalamus and the hippocampus 
(Chin et al. 2011; Flagstad et al. 2004; Le Pen et al. 2006; Matricon et al. 2010; 
Moore et al. 2006), increased neuronal packing in the mPFC (Moore et al. 
2006), disorganisation and sporadic density of hippocampal pyramidal neurons 
(Le Pen et al. 2006; Moore et al. 2006), and enlargements of the lateral and 
third cerebral ventricles (Chin et al. 2011), all noted clinically in schizophrenia 
(Harrison 1999; Kovelman and Scheibel 1986; Shenton et al. 2001). This 
similarity in pathology lends considerable validity to the model. 
GD17 MAM produces a number of neurochemical and activity-related changes 
with further similarities with schizophrenia, particularly in dopaminergic 
function. Elevated dopamine release in the NAc of MAM-treated animals in 
response to amphetamine treatment, akin to hyperdopaminergia in 
schizophrenia (Breier et al. 1997; Howes and Kapur 2009), correlates with 
spontaneous hyperactivity of dopaminergic neurons in the VTA (Flagstad et al. 
2004; Lodge and Grace 2007). This is proposed to be through hippocampal 
pathology (Matricon et al. 2010; Moore et al. 2006), with modulatory activity 
on the VTA and NAc dopaminergic neurons via glutamatergic projections 
elevated in MAM rats (Floresco et al. 2001; Floresco et al. 2003; Lodge and 
Grace 2007), replicating pathology in schizophrenia patients (Heckers and 
Konradi 2002; Shenton et al. 2001). A decrease in hippocampal PV-positive 
interneuron number has also been identified (Lodge et al. 2009; Penschuck et 
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al. 2006), providing the GD17 MAM model with further construct validity 
(Beasley et al. 2002; Benes et al. 2007; Konradi et al. 2011; Lewis et al. 2005).  
The behavioural phenotypes created by MAM treatment are dependent on the 
time of drug administration. Deficits in PPI are evident following GD17, but 
not GD15, treatment to rats (Moore et al. 2006) and display a post-pubertal 
onset profile (Hazane et al. 2009; Le Pen et al. 2006), akin to the emergence of 
schizophrenia.  Basal locomotion has been shown to be elevated post-puberty 
in some studies of GD17 MAM treatment (Hazane et al. 2009; Le Pen et al. 
2006),  and is reproducible following stimulant treatment (Flagstad et al. 2004; 
Le Pen et al. 2006; Lodge and Grace 2007; Moore et al. 2006; Penschuck et al. 
2006); correlated with increased NAc dopamine release (Flagstad et al. 2004). 
There is some limited data examining the effect of prenatal MAM on 
cognition, but it is spread across multiple time points, making direct 
comparisons difficult. Of the GD17-based studies, a reproducible impairment 
in hippocampus-dependent spatial learning and memory emerges, with deficits 
in the radial arm maze (Featherstone et al. 2009), Y-maze (Hazane et al. 2009; 
Le Pen et al. 2006), and Morris Water Maze (Hazane et al. 2009; Snyder et al. 
2013). Few studies have examined the effect of MAM treatment in the novel 
object discrimination task. GD17 treatment caused a deficit in NOD (Flagstad 
et al. 2005), whilst GD11/12 treatment produced no impairment (Fiore et al. 
1999). Deficits in reversal learning and cognitive flexibility have also been 
identified with GD17 MAM (Gastambide et al. 2012; Moore et al. 2006), as 
have impairments in social interaction paradigms (Hazane et al. 2009; Le Pen 
et al. 2006); the latter representing an important correlate to the negative 
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symptoms of human schizophrenia. Earlier MAM administration does not 
necessarily translate to a more severe behavioural phenotype, despite severe 
neuropathology, with GD9-15 MAM producing severe reductions in total brain 
mass and entorhinal, prefrontal and striatal volumes, but no accompanying 
deficit in PPI, latent inhibition, or a conditioned freezing paradigm (Jongen-
Relo et al. 2004), and only minor reversal learning deficits (Leng et al. 2005). 
Comparatively few studies examining the predictive validity of the MAM 
model with standard or putative antipsychotic agents have been published. 
Whilst a single treatment with risperidone is able to selectively reverse basal 
hyperlocomotion induced by GD17 MAM treatment in rats, haloperidol and 
clozapine are non-selective in causing reductions in locomotor activity across 
MAM- and saline-treated animals (Le Pen et al. 2011).  
The lack of available drug-reversal data limits the predictive validity of the 
MAM model. Combined with the apparent disparity between the degree of 
neuropathology and behavioural deficits induced by treatment on different 
gestational days, many questions still remain over this model. However, with 
very clear and reproducible neuroanatomical deficits that closely mirror those 
seen in schizophrenia, the GD17 MAM model has some value. Thus, work in 
this thesis attempts to combine the MAM and isolation rearing models to 
establish whether the two might have synergistic effects on behaviours in the 
adult rat, with greater translational relevance to schizophrenia. 
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1.3.3 Phencyclidine (PCP)  
By reversibly binding within the channel of ionotropic NMDA receptors, 
antagonists such as PCP block calcium ion influx following voltage- and 
ligand-activated channel pore opening, preventing the activation of calcium-
triggered signalling cascades. The ability of NMDA receptor antagonists to 
artificially induce NMDA receptor hypofunction makes these compounds an 
attractive option for use in a variety of preclinical models, and provides 
construct validity (Anastasio and Johnson 2008b; Csernansky et al. 2005; 
Keilhoff et al. 2004; Li et al. 2011a; Neill et al. 2010; Sabbagh et al. 2012; 
Wang et al. 2001).  
Whilst acute administration of PCP in adulthood has been used to cause 
alterations in behaviours with salience to all symptom domains of 
schizophrenia including hyperlocomotion (Kalinichev et al. 2008), impaired 
social interaction (Sams-Dodd 1995), decreased PPI response (Bakshi et al. 
1994; Li et al. 2011a; Takahashi et al. 2006) and cognitive impairment (Idris et 
al. 2009; Thomson et al. 2010), a number of these deficits are short-lived. A 
stable, longer-lasting profile of changes more valid to schizophrenia is 
achieved with repeated PCP administration. This protocol was hypothesised to 
recapitulate effects observed in the clinic where schizophrenia-like symptoms 
persist in recreational PCP users following cessation of their abuse (Rainey 
and Crowder 1975), and structural deficits in the frontal and temporal lobes 
can be observed using PET scanning (Hertzmann et al. 1990). 
One of the most reproducible effects of repeated PCP administration in rodents 
is sensitization to subsequent PCP challenge. Acute treatment causes an 
Chapter 1 Ȃ General Introduction 
- 38 - 
 
elevation in locomotor activity in controls, but the degree of hyperlocomotion 
is markedly increased by previous drug exposure (Abekawa et al. 2002; 
Fletcher et al. 2005; Xu and Domino 1994), mirroring the clinical exacerbation 
of positive symptoms (Lahti et al. 1995; Malhotra et al. 1997), providing face 
validity. Both acute (Bakshi et al. 1994; Li et al. 2011a) and 
repeated/subchronic PCP treatment (Li et al. 2011a; Martinez et al. 1999; 
Takahashi et al. 2006; Tunstall et al. 2009) induce PPI deficits in rodents, 
however this deficit is transient, even after repeated exposure, and the ability to 
recover from PCP-induced deficits may be partially responsible for the 
variability in reported outcomes. 
There is also face validity to the negative and cognitive symptoms of 
schizophrenia, with deficits in social interaction (Sams-Dodd 1998a; b; 
Snigdha and Neill 2008a; b), visual and spatial cognition (Beninger et al. 2010; 
McKibben et al. 2010; Nagai et al. 2009; Roseman et al. 2012), and reasoning 
and problem solving (Idris et al. 2009; Large et al. 2011) observed in PCP-
based models. Some of these deficits are also susceptible to challenge with 
antipsychotic compounds (Grayson et al. 2007; Hashimoto et al. 2005; 
McLean et al. 2010b), potentially providing predictive validity. However, as 
the evidence for efficacy of these compounds against cognitive deficits in the 
clinic is limited at best, these results are suggestive of false-positive effects in 
PCP-based models rather than true predictive validity. 
A number of relevant neuropathological changes are readily produced by PCP 
treatment. As well as amphetamine-induced hyperlocomotion (Beninger et al. 
2010) and elevated mesolimbic dopamine activity (Jentsch et al. 1998), basal 
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levels of dopamine in the PFC are reduced by chronic PCP treatment to rats 
(Jentsch et al. 1997). Changes in receptor expression levels are also common, 
with striatal D1 receptor expression decreased (Choi et al. 2009), and GABA 
subunit levels altered throughout the frontal cortex, hippocampus and striatum 
(Beninger et al. 2010). Furthermore, alterations in NMDA receptor binding in 
the hippocampus, NAc, striatum and cortex occur following chronic PCP 
treatment (Newell et al. 2007). A reduction in PV-positive GABAergic 
interneuron immunoreactivity in the hippocampus and frontal cortex is noted 
after subchronic PCP treatment (Abdul-Monim et al. 2007; Jenkins et al. 
2010b; McKibben et al. 2010), along with reductions in GAT-1 and the GABA 
synthesising enzyme glutamate decarboxylase 1, 67kDa-isoform (GAD67) 
mRNA levels in the cerebellum (Bullock et al. 2009). Both protein and mRNA 
levels of GAD67 and GAT-1 are decreased throughout the brain of 
schizophrenia patients (Akbarian et al. 1995; Bullock et al. 2008; Guidotti et 
al. 2000; Hashimoto et al. 2003; Lewis et al. 2005) and may be linked to 
disease development (Curley et al. 2013; Zhao et al. 2007). 
In order to add a neurodevelopmental aspect to the PCP model, repeated 
administration of high dose PCP in early life was examined (Wang et al. 
2001). Administration of PCP at 10mg/kg on PND 7, 9 and 11 produced PPI 
impairments, a delay in acquisition of the spatial learning task, and hyper 
responsiveness to an acute PCP dose (2mg/kg) in a locomotor task post-
adolescence (Wang et al. 2001). Subsequently, perinatal PCP administration to 
rats has been shown to induce lasting deficits in spatial working memory and 
reversal learning in the Morris Water Maze (Andersen and Pouzet 2004; Sircar 
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2003), impaired delayed and continuous spatial alternation performance 
(Boctor and Ferguson 2010; Wiley et al. 2003), impaired novel object 
recognition performance (Redrobe et al. 2012), deficits in PPI which are more 
enduring than caused by acute adult PCP treatment (Anastasio and Johnson 
2008a; Takahashi et al. 2006), deficient social novelty discrimination (Harich 
et al. 2007) and a robust sensitization to subsequent PCP administration 
(Anastasio and Johnson 2008a; Boctor and Ferguson 2010). Similar treatment 
in mice revealed impaired spatial working memory, produced hyperlocomotion 
in response to a subsequent PCP challenge, and significantly reduced social 
interaction behaviours (Nakatani-Pawlak et al. 2009).  
Apoptotic cell death induced by neurotoxicity in the frontal cortex may be 
partly responsible for the behavioural alterations seen (Wang et al. 2001; Wang 
and Johnson 2005), with four pro-apoptotic genes up-regulated and four anti-
apoptotic genes down-regulated at PND12 by perinatal PCP treatment (Liu et 
al. 2010). This is accompanied by altered NMDA receptor expression in the 
frontal cortex (Anastasio and Johnson 2008b; Wang et al. 2001). A highly 
reproducible and enduring deficit in PV-positive GABAergic interneurons has 
also been observed in the cortex of rats following perinatal PCP treatment 
(Kaalund et al. 2013; Redrobe et al. 2012; Wang et al. 2008). 
Whilst administration of PCP in early-life rather than adulthood maintains the 
vast majority of schizophrenia-like behaviours and neuropathology obtained by 
adult treatment, and adds a neurodevelopmental aspect to the model, it still 
produces false positive effects in drug reversal studies. Clozapine reverses 
impairments in social novelty (Harich et al. 2007) and social interaction tasks 
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(Nakatani-Pawlak et al. 2009), whilst it has little beneficial effect clinically on 
the cognitive or negative symptoms of schizophrenia (Keefe 2007).  
Alternative approaches to using PCP to model schizophrenia utilise ketamine 
or MK-801. Whilst these compounds have similar modes of action to PCP and 
can produce deficits in spatial working memory, cognitive flexibility and 
attentional set-shifting (Stefani and Moghaddam 2005a; b), as well as impaired 
PPI performance (Cilia et al. 2007; Harris et al. 2003; Sabbagh et al. 2012; 
Uehara et al. 2009) they have some weaknesses. Acute ketamine treatment 
produces only small impairments in conditioned emotional response (Bolton et 
al. 2012)DQGUHSHDWHGSHULQDWDONHWDPLQHGRHVQ¶WSURGXFH the impairment in 
spatial alternation caused by perinatal PCP (Boctor and Ferguson 2010). The 
potential for false positive effects of antipsychotics is also maintained, with 
clozapine able to reverse MK-801-induced NOD deficits in mice (Mutlu et al. 
2011) and social memory deficits in rats (Shimazaki et al. 2010). Although 
hippocampal PV-positive interneurons are reduced in both ketamine (Keilhoff 
et al. 2004) and MK-801 (Braun et al. 2007) treated rats, MK-801 does not 
produce the same result in the PFC (Braun et al. 2007), a relative strength of 
PCP. These results support the use of PCP-based models of schizophrenia over 
other NMDA receptor antagonist models. The current thesis therefore also 
examines the combined effect of perinatal PCP and isolation rearing in the rat 
to attempt to produce more robust and relevant deficits than either treatment 
alone. 
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Table 1.1 ± Table comparing the behavioural and neuropathological 
characteristics of the isolation rearing, GD17 MAM and perinatal PCP 
WUHDWPHQWPRGHOVRIµVFKL]RSKUHQLD-OLNH¶V\PSWRPVLQUDWV 
 
Isolation Rearing GD17 MAM Perinatal PCP Treatment 
³3RVLWLYH´
Symptoms 
Hyperlocomotion in a 
novel arena
1,2
 
Increased amphetamine-
induced locomotion18,19 
Increased amphetamine-
induced locomotion24 
³1HJDWLYH´
Symptoms 
Increased social 
aggression
3
 
Decreased social 
interactions19 
No effect on social 
interaction25 
Visual 
Learning 
and Memory 
Novel Object 
Discrimination 
impairments
4,5
 
Novel object 
discrimination 
impairments20 
Novel Object 
Discrimination 
impairment26 
Sensorimotor 
Gating 
Prepulse Inhibition 
Impairments
6,7
 
Prepulse Inhibition 
Impairments18 
Prepulse Inhibition 
impairments24 
Spatial 
Working 
Memory 
Morris Water Maze 
Improvements
8
 and 
Impairments
9
 
Impaired Morris Water20 
and Y-maze18 performance 
Decreased acquisition of 
spatial alternation task24 
Problem 
Solving 
Impaired reversal 
learning
10
 
Impaired reversal 
learning18,20 
Impaired reversal 
learning27 
Additional 
Behaviours 
Impaired emotional 
conditioning
11
 
- 
Sensitization to NMDA 
receptor antagonists28 
Neuro-
pathology 
Increased dopamine 
release in NAc after 
amphetamine
12
  
Altered dopamine receptor 
distribution13,14 
Loss of PV+ interneurons 
in hippocampus15 
Structural PFC deficits16 
Loss of PV+ interneurons 
in hippocampus21,22 
Structural deficits in PFC18 
Elevated glutamate output 
from vHipp23 
Altered NMDA receptor 
subunit expression29 
Loss of PV+ interneurons 
in cortex26,30,31 
Increased oxidative 
stress32 
Relative 
Strengths 
No confounding drug 
treatment 
Wide-ranging deficits 
Strong neuropathology Strong glutamate involvement 
Relative 
Weaknesses 
Susceptible to procedural 
differences 
Un-robust deficits17 
Less complete symptom 
profile 
Limited reversal data 
False-positive drug 
reversal 
  References: (Gentsch et al. 1988)1, (Varty et al. 2000)2, (Wongwitdecha and Marsden 1996b)3, (Bianchi et al. 
2006)4, (Watson et al. 2012b)5, (Cilia et al. 2001)6, (Cilia et al. 2005)7, (Wongwitdecha and Marsden 1996a)8, 
(Hellemans et al. 2004)9, (Jones et al. 1991)10, (McIntosh et al. 2013)11, (Jones et al. 1992)12, (Hall et al. 
1998)13, (Gill et al. 2013)14, (Harte et al. 2007)15, (Schubert et al. 2009)16, (Fone and Porkess 2008)17, (Moore 
et al. 2006)18, (Flagstad et al. 2004)19, (Flagstad et al. 2005)20, (Lodge et al. 2009)21, (Penschuck et al. 2006)22, 
(Lodge and Grace 2007)23, (Wang et al. 2001)24, (du Bois et al. 2008)25, (Redrobe et al. 2012)26, (Andersen 
and Pouzet 2004)27, (Anastasio and Johnson 2008a)28, (Anastasio and Johnson 2008b)29, (Kaalund et al. 
2013)30, (Wang et al. 2008)31, (Radonjic et al. 2010)32 
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1.3.4 Dual-Hit Models 
In an attempt to overcome the weaknesses of preclinical models, emerging 
research focuses on combining two protocols to FUHDWH µGXDO-KLW¶PRGHOs that 
may have improved robustness and face, construct and predictive validity. 
In rats, much work has focused on the isolation rearing model, with its broad 
variety of reproducible behavioural deficits and relatively strong construct 
validity to the early-life adversity aetiology theory, combining it with 
pharmacological challenges. In almost all studies where the behaviour was 
assessed, isolation rearing induced baseline hyperlocomotion in a novel arena 
(Ashby et al. 2010; Gill et al. 2013; Hickey et al. 2012), but only twice was 
this effect enhanced by a second hit, subchronic or neonatal MK-801 (Lim et 
al. 2012; Simpson et al. 2010). Methylphenidate treatment did not affect 
anxiety caused by isolation rearing (Gill et al. 2013), and subchronic MK-801 
did not affect isolation-induced polydipsia (Hawken et al. 2013) or emotional 
processing (Simpson et al. 2010). Subchronic methamphetamine produced 
similar deficits to isolation in PPI and social interaction studies, but when 
combined no additive effects were seen (Strauss et al. 2014). In contrast, 
combination of MK-801 treatment on PNDs 7-10 with isolation rearing 
produced consistent PPI and NOD deficits in Sprague-Dawley rats, where 
single treatments did not (Lim et al. 2012). These models, particularly those 
utilising NMDA receptor antagonists, could be considered to have greater 
construct validity due to the addition of glutamatergic hypofunction to the 
model, which isolation rearing alone lacks (Fone and Porkess 2008). Increased 
behavioural face validity is somewhat lacking in this approach, aside from the 
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work by Lim and colleagues, but some neurobiological effects of dual-hit 
treatment in rats have been observed. Subchronic MK-801 elevated GABAA 
receptor expression in the hippocampus of adult rats, coinciding with isolation-
induced elevations in the frontal cortex, and increased GAT-1 expression in the 
frontal cortex and hippocampus (Hickey et al. 2012). Thus, combining 
perinatal NMDA receptor antagonists with isolation rearing appears a viable 
option for dual-hit treatment; but as discussed, PCP represents a potentially 
better pharmacological agent than MK-801. For this reason, work in this thesis 
will combine isolation rearing and perinatal PCP treatment. 
Another approach used as one of two dual-hits in rodents is maternal immune 
activation through prenatal Poly(I:C) administration (Dalton et al. 2012; 
Deslauriers et al. 2013; Giovanoli et al. 2013; Richtand et al. 2012; Yee et al. 
2011). This treatment has been successfully combined in mice with 
unpredictable mild stress (Giovanoli et al. 2013) or restraint stress (Deslauriers 
et al. 2013) to produce improved deficits in PPI paradigms, as well as 
increased sensitivity to acute MK-801 and amphetamine challenge. In rats, 
however, results have been mixed, with combined Poly(I:C) and adolescent 
stress only able to produce additional alterations in drug place-preference 
behaviour (Richtand et al. 2012), and not PPI or anxiety-related behaviour or 
physiology (Yee et al. 2011). The benefit of Poly(I:C)-based models is their 
very strong construct validity, given the available clinical odds ratio data 
(Sullivan 2005). Combining this model with stressor protocols may provide 
even greater validity, if more convincing behavioural data is forthcoming. 
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Additionally, Poly(I:C)-based models can be performed in mouse lines 
carrying a schizophrenia-relevant genetic alteration, including DISC-1 and 
Nurr-1 (Abazyan et al. 2010; Lipina et al. 2013; Vuillermot et al. 2012). These 
dual-hits have considerable construct validity, combining an underlying 
genetic predisposition with an obstetric complication, but as yet the face 
validity of these models is little better than single-hit treatments. Combining 
DISC-1 mutations with Poly(I:C) treatment has little additive effect on 
behaviours relating to the cognitive or positive symptoms of schizophrenia 
(Lipina et al. 2013), but there is some indication that negative symptom-like 
traits, such as social interaction and anxiety may be additionally impaired in 
dual-hit animals (Abazyan et al. 2010). Conversely, Nurr-1 mutants treated 
prenatally with Poly(I:C) show some potential additive deficits in cognition in 
latent inhibition and visual operant tasks (Vuillermot et al. 2012). A similar 
approach is to combine genetic knock-out models with stress protocols. DISC-
1 mutations combined with isolation stress produced marked deficits in PPI 
and in a forced swim test (Niwa et al. 2013), whilst a combination with chronic 
social defeat produced little additional benefit (Haque et al. 2012). Similarly, 
neuregulin-1 knockouts did not present additional behavioural deficits having 
undergone stressor protocols (Chesworth et al. 2012; Desbonnet et al. 2012).  
 
No publications have examined the role of prenatal MAM administration in a 
dual-hit model of schizophrenia. This thesis will therefore examine GD17 
MAM in combination with post-weaning social isolation.  
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2.1 Introduction 
 
Despite the wealth of preclinical models of schizophrenia available, the 
limitations are notable. The rodent paradigms of rearing rat pups in social 
isolation after weaning (Fone and Porkess 2008; Jones et al. 2011b) and 
prenatal treatment with the anti-mitotic agent methylazoxymethanol 
(Hradetzky et al. 2012; Lodge and Grace 2009; Moore et al. 2006), produce a 
variety of behavioural alterations including hyperactivity in a novel arena or 
increased amphetamine-induced activity, ERWKWKRXJKWWRUHIOHFWµSRVLWLYH-OLNH¶
symptoms of schizophrenia (Table 1.1). However, any accompanying loss of 
working memory and negative symptoms may be more sensitive to procedural 
differences, such as the length of isolation rearing (Fone and Porkess 2008), or 
the gestational time of MAM administration (Jongen-Relo et al. 2004; Leng et 
al. 2005; Moore et al. 2006). Combining multiple interventions to attempt to 
produce more extensive and relevant abnormalities is a logical and worthy 
development, an approach not attempted until recently (Ashby et al. 2010; 
Hawken et al. 2013; Hickey et al. 2012; Simpson et al. 2010). Previous work 
combining isolation rearing and subchronic administration of the NMDA 
receptor antagonist MK-801 found only mild behavioural changes induced, 
with little or no evidence of additive or synergistic effects of combined 
administration (Hickey et al. 2012). However, a study utilising neonatal 
pharmacological challenge of the NMDA receptor with MK-801 in 
combination with isolation rearing did produce marked and robust deficits in 
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relevant behavioural paradigms (Lim et al. 2012), and so further investigation 
of combination models is warranted.  
Based on their strength as pre-existing preclinical models of schizophrenia-like 
symptoms (see Table 1.1), and expertise in our lab, the combination of prenatal 
MAM treatment and subsequent rearing in social isolation post-weaning was 
examined in a variety of paradigms to mimic the deficits seen in schizophrenia. 
6HFRQGO\ WKH QHXURELRORJLFDO RXWFRPH RI WKLV µGXDO-KLW¶ ZDV H[DPLQHG ZLWK
specific attention paid to the hippocampus, a key brain region in theories of 
schizophrenia aetiology. To ensure that this dual-hit did not produce severe 
deficits such as stereotypy in the home cage, a pilot study with six pregnant 
dams was undertaken, before an expanded twelve dam protocol. As this was 
the first time MAM administration had been used in our laboratory, the pilot 
study also allowed for refinement of the experimental techniques used. To best 
ensure a successful outcome, the well-characterised isolation rearing protocol 
previously utilised, and behavioural tests already validated in our laboratory, 
were used in the study. Furthermore, the two challenges used were presented 
both alone and in combination, giving four treatment groups (control, isolation, 
MAM, and isolation-MAM), to allow evaluation of the effectiveness of each 
individual treatment and any additive or synergistic effect of the combination. 
In keeping with previous isolation rearing studies, Lister-Hooded rats were 
selected since the behavioural and neurochemical changes evoked have been 
very well described in our laboratory (Bianchi et al. 2006; Jones et al. 2011a; 
McIntosh et al. 2013; Schubert et al. 2009), showing their relevance to 
µVFKL]RSKUHQLD-OLNH¶ V\PSWRPV )XUWKHUPRUH WKH /LVWHU-Hooded rat has good 
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visual acuity, making it ideal for visual attention tasks compared to albino 
strains (Broersen and Uylings 1999). However, no literature could be found on 
previous work assessing the effect of MAM in Lister-Hooded rats at any 
gestational day. Previous work with gestational MAM has been documented in 
Fischer 344 (Moore et al. 2006), Sprague-Dawley (Hradetzky et al. 2012; 
Lodge and Grace 2007), and Wistar (Flagstad et al. 2005) strains, and also in 
studies involving cognitive tasks like those reported herein. As there is a lack 
of consensus on the most suitable rat strain to utilise in prenatal MAM studies, 
the current study bases a new protocol on addition of prenatal MAM 
administration with isolation rearing in Lister-Hooded rats.  
2.1.1 Hypothesis 
Based on the previous literature detailing the extensive cognitive deficits 
observed in both isolation-reared and prenatal MAM-treated rats, combination 
treatment was hypothesised to produce a phenotype in adolescent rats that 
exhibited deficits in all cognitive paradigms investigated, and with greater 
robustness/reliability than previously reported in either preclinical model used 
DORQH )XUWKHUPRUH WKH µGXDO-KLW¶ SURWRFRO ZRXOG SURGXFH VLJQLILFDQW
neurobiological changes in the hippocampus of rats with some relevance to 
schizophrenia in patients.  
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2.2 Materials and Methods 
2.2.1 Animals 
Pregnant female Lister-Hooded rats (BMSU, University of Nottingham, Pilot 
study n=6, Charles River UK, Margate, Main Study n=12), were injected with 
methylazoxymethanol (MAM, 24mg/kg base weight, adjusted from 28mg/kg 
salt weight, i.p.; obtained from the National Cancer Institute Chemical 
Carcinogen Reference Standard Repository, Midwest Research Institute, 
Kansas City, MO, USA) or saline vehicle (1ml/kg) as control, on gestational 
day 17 (Table 2.1). From the resulting litters, male pups (Pilot study n=30, 
Main Study n=63) were weaned on PND23 so that approximately equal 
numbers of each litter were housed in groups of 3-4 (32x51cm polycarbonate 
cages with metal grid lids), or placed into social isolation (25x42cm cages), 
giving four conditions; group-housed control (GH-Con), group-housed MAM-
treated (GH-MAM), isolate control (Iso-Con) and isolate MAM-treated (Iso-
MAM) (Table 2.1). 
Rats were reared for 40 days post-weaning prior to beginning behavioural tests 
(Figure 2.1), housed on a 12h light-dark cycle (06:00-18:00 light), with food 
and water provided ad libitum, and the ambient temperature and humidity 
maintained (21±2°C and 45±15% respectively). All subsequent behavioural 
studies were performed such that the observer was unaware of rearing 
condition and all apparatus was cleaned with 20% w/v ethanol to remove 
odour cues between tests. All experiments complied with the UK Home Office 
Animals (Scientific Procedures) Act 1986, and were approved by the local 
ethical review committee and conform to the ARRIVE guidelines. 
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Male Female Group Isolation
1 MAM on GD17 (24mg/kg i.p.) 310 23 7 9 3 3
2 Saline on GD17 (1ml/kg, i.p.) 289 22 2 3 0 2 All animals Total brain mass measured, 
3 Saline on GD17 (1ml/kg, i.p.) 302 22 3 4 3 0 performed hippocampus extracted,
4 Saline on GD17 (1ml/kg, i.p.) 297 22 3 5 0 3 LMA, NOD, sectioned and volume
5 MAM on GD17 (24mg/kg i.p.) 354 22 10 7 5 5 PPI and CER estimated in all animals
6 Saline on GD17 (1ml/kg, i.p.) 311 23 6 9 3 3
Male Female Group Isolation
1 Saline on GD17 (1ml/kg, i.p.) 306 23 5 7 3 2 LMA, NOD, PPI, MWM
2 Saline on GD17 (1ml/kg, i.p.) 329 23 7 6 3 4 LMA, NOD, PPI, MWM
3 Saline on GD17 (1ml/kg, i.p.) 283 22 8 5 4 4 LMA, NOD, PPI, CER
4 MAM on GD17 (24mg/kg i.p.) 297 22 5 8 3 2 LMA, NOD, PPI, CER Hippocampus, striatum,  
5 MAM on GD17 (24mg/kg i.p.) 287 22 7 5 3 4 LMA, NOD, PPI, MWM frontal cortex and 
6 MAM on GD17 (24mg/kg i.p.) 340 23 3 8 0 3 LMA, NOD, PPI, CER (x2), MWM (x1) hypothalamus dissected
7 MAM on GD17 (24mg/kg i.p.) 303 22 7 3 4 3 LMA, NOD, PPI, CER  and weighed. Tissue used
8 MAM on GD17 (24mg/kg i.p.) 295 23 1 3 0 1 LMA, NOD, PPI, CER, MWM    for HPLC analysis of 
9 MAM on GD17 (24mg/kg i.p.) 307 23 5 6 4 1 LMA, NOD, PPI, CER, MWM monoamine concentration.
10 Saline on GD17 (1ml/kg, i.p.) 311 23 5 6 0 5 LMA, NOD, PPI, CER (x4), MWM (x1)
11 Saline on GD17 (1ml/kg, i.p.) 296 22 5 4 3 2 LMA, NOD, PPI, CER, MWM
12 Saline on GD17 (1ml/kg, i.p.) 283 23 5 3 3 2 LMA, NOD, PPI, CER
Post-Mortem
Dam Treatment received Dam Mass (g) Gestation Length (days) Behaviours Post-Mortem
Dam Treatment received Dam Mass (g) Gestation Length (days) Behaviours
Litter Male Assignments
Litter Male Assignments
Table 2.1 Table to show the prenatal drug treatment and post-weaning housing condition of each pup in (A) the pilot study, and 
(B) the main study. Also shown, the behavioural tests undertaken, and the post-mortem analysis that was performed on tissue 
from each litter. 
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Figure 2.1 ± Timestick representations of the protocols used in (A) the pilot and 
(B) main study. Protocols were identical until PND 78. In the pilot study, all rats 
performed the CER task, whereas in the main study, half were excluded from 
CER and performed the Morris Water Maze task from PND 85 onwards instead. 
A
 
B 
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2.2.2 Locomotor Activity 
To examine a motor response thought to be related to the positive aspects of 
schizophrenia, open field locomotor activity (LMA) testing occurred in twelve 
activity chambers, consisting of clear Perspex boxes (39 x 23.5 x 24.5cm), 
screened from their neighbours by white opaque sheeting. Rats were assigned 
to a chamber in a pseudo-random manner. Activity boxes were crossed by 
infrared beams 2cm above the floor (Photobeam Activity System, San Diego 
Instruments, USA) to measure ambulatory movements. The number of beams 
broken was counted in 5 min time bins for 1 h to measure horizontal 
ambulatory activity (a movement breaking two beams in a consecutive 
sequence (Bianchi et al. 2006; Hewitt et al. 2005; Jones et al. 2011b)) 
presented as locomotor counts distinct from stereotyped behaviour (repetitive 
breaking of one beam), which was not analysed. 
 
2.2.3 Novel Object Discrimination 
In order to assess visual learning and memory in a simple discrimination/ 
recognition task, novel object discrimination (NOD) was tested 24 h after the 
completion of locomotor activity, with rats assigned to the same chamber as 
during locomotor activity testing. The task was performed as described 
previously (Bianchi et al. 2006; King et al. 2004), but with some minor 
modifications. Briefly, rats were placed in a chamber for a 3 min 
acclimatisation period, before being returned to their home cage for 1 min, 
during which two identical objects (8cm high plastic bottles, 5cm diameter, 
filled with water and secured to the floor by blue-tac) were introduced to the 
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chamber. Rats were then returned to chamber, and exploration of each object 
recorded for 3 min (familiarisation, Trial 1). During a 2 h inter-trial interval the 
rats were returned to their home cage, and one object selected in a pseudo-
UDQGRPPDQQHUZDV VZLWFKHG IRU DYLVXDOO\GLVWLQFW ³QRYHO´REMHFW (identical 
bottle covered in three rings of black 2cm wide tape) in each chamber. A 
second 3 min trial (choice, Trial 2) was performed, and object exploration 
(GLUHFWLRQDODWWHQWLRQ WRHDFKREMHFWZLWKWKHQRVHFPDZD\VQLIILQJZLWK
active vibrissae)) recorded using stop watches. Climbing on or chewing the 
object was not recorded as active exploration. Any rats that failed to explore 
both objects in trial 1 (minimum 5s per object), or failed to spend a total of 5s 
exploring both objects in trial 2 were judged to have not completed the task, 
and so excluded from analysis. Rats were also excluded where biting/chewing 
led to damage to the objects in the second, choice trial leading to sustained 
directed attention to the damage caused (loose tape, water leak etc.).  
 
To analyse the results, a direct comparison between the time spent exploring 
WKH ³QRYHO´ DQG ³IDPLOLDU´ REMHFWV LQ WKH VHFRQG FKRLFH WULDO ZDV PDGH $
discrimination ratio (D1) was calculated by dividing the time spent exploring 
the novel object by the total (novel + familiar) object exploration time in the 
second choice trial, providing an index of preferential object exploration 
independent of total exploration. These D1 discrimination ratios were 
compared between treatment groups. 
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2.2.4 Prepulse Inhibition of Acoustic Startle 
Rats were examined in a prepulse inhibition of acoustic startle test (PPI) to 
evaluate any change in sensorimotor gating, which is thought to map to the 
preattentional processing cognitive domain in man. Altered PPI is recognised 
to share a similar neurobiological basis to sensorimotor gating deficits seen in 
schizophrenia (Geyer et al. 2001). Prepulse inhibition of acoustic startle testing 
was performed in four computerized startle boxes (San Diego Instruments, San 
Diego, CA, USA) consisting of a clear Perspex tube attached to an 
accelerometer in a sound-proofed chamber containing a loudspeaker to 
administer the acoustic stimuli, as described previously (Jones et al. 2011a; 
Schubert et al. 2009). After acclimatisation to white background noise (65dB, 
5mins), a series of 66 x 120dB tones (40ms in duration) were delivered, either 
alone, or preceded by a 20ms prepulse of 72, 76, 80 or 84dB, with an 
unpredictable inter-trial interval (10-20 seconds). The amplitude of the startle 
response to 120dB tone alone was compared to the final 120dB responses to 
calculate habituation, and compared to that produced by prepulse-pulse 
combinations to assess PPI, expressed as a percentage of the average pulse-
alone startle amplitude. Previous studies by our group have shown that startle 
responses to 72dB trials fail to elicit attenuation of PPI, but exclusion of these 
trials leads to greater variation in response to other prepulse intensities, so the 
data from 72dB prepulse trials were collected, but excluded from analysis. 
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2.2.5 Conditioned Emotional Response 
Rats were tested for their conditioned emotional response (CER) in a 
hippocampus- and amygdala-dependent contextual and cue-conditioned fear 
learning protocol (Anagnostaras et al. 1999; Fanselow 2000; Sigurdsson et al. 
2007; Woods et al. 2012). Rats were placed in the light section of the 
partitioned CER chamber (510 (W) x 250 (D) x 240 (H) mm internal; 580 x 
360 x 305 mm external, PanLab, LE 916)  for 30 seconds, after which a centre 
door automatically opened and allowed the subject access to the dark part of 
the chamber. The latency for the rat to enter the dark chamber was recorded 
and the centre door closed. Following 30 seconds habituation, the rat was 
presented with a conditioned stimulus - a light and sound tone (5 sec, 40 Lux, 
89 dB, 3 KHz, CS), and an unconditioned stimulus - an unavoidable foot shock 
(1 sec, 0.4 mA, US). This was followed by a 55 second consolidation period, 
after which the light/tone/shock sequence was presented once more. A further 
consolidation-CS+US-consolidation cycle was completed and the rat then 
returned to its home cage. Twenty-four hours later, the rats were returned 
directly to the dark side of the CER chamber with the centre door permanently 
closed. On this occasion, no stimuli were presented, but freezing, defined as a 
lack of movement for more than 1s (excluding respiration) was scored for 5 
minutes. A further 24 hours later (48h after initial exposure) the rats were 
again returned to the dark side of the chamber. For 5 minutes, no stimuli were 
presented and freezing was scored. Following this, the CS was re-presented in 
absence of the US. Freezing was again scored for 5 minutes after the CS 
presentation and the rats then returned to their home cage. 
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2.2.6 Morris Water Maze 
In order to assess spatial learning and memory, including a reversal learning 
aspect to examine cognitive flexibility, an in-house Morris Water Maze 
protocol was designed, based on concepts described previously (Morris 1984). 
Briefly, rats were taught to locate a hidden, submerged platform in a pool 
using visual cues positioned around the experimental arena by repeated 
exposure to the context.  
Prior to the initiation of training, rats were exposed to the water maze (2m 
diameter, water depth of 80cm, made opaque with liquid latex added to the 
water) without the presence of the platform for a 60s habituation period. On 
experimental day one, rats were exposed to the water maze three consecutive 
times (trials) with the circular platform (10cm diameter, Atlantis Platform, Ugo 
Basile, Comerio, VA, Italy) always located in one of four fixed position: 
North, South, East, West (Figure 2.2). For each of the three trials, rats were 
placed at the edge of the maze, facing the wall, in one of the three other 
North/South/East/West locations, so that across the day, each location was 
represented. Upon placing in the maze, a trial lasted 90 s of free exploration or 
until the platform was located. If successful, the rat remained on the platform 
for 15 s to reinforce its location, before being removed from the arena and 
hand-dried prior to the next trial 1 min later. If unsuccessful after 90 s, the rat 
was removed from the water and immediately placed on the platform, where it 
was then left for the 15 s reinforcement period. If, during the reinforcement, 
the rat left the platform and did not immediately return, the rat was manually 
placed back on the platform to continue the reinforcement period. 
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Figure 2.2 ± Diagrammatic representation of the Morris Water Maze apparatus, split into 4 
quadrants (North, South, East, West). The left panel shows the 4 positions rats were taught 
to locate a fixed-position hidden platform (P), as well as the four starting points which each 
trial began from in a pseudo-random order. The right panel shows the new locations of the 
SODWIRUPIRUWKHUHYHUVDOOHDUQLQJDVSHFWRIWKHSURWRFRODVZHOODVWKH³3ODWIRUP5LQJ´DUHD
used during Probe 3 to assess exploration of the maze. 
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After the completion of three trials with reinforcement periods, rats were 
returned to their home cage. For 5 consecutive days, each rat was trained for 3 
trials per day, with the platform in a fixed location, and the start point of each 
trial in a new pseudo random order. Following completion of trials 13, 14 and 
15 on day five, a probe trial was performed. The platform was completely 
submerged and fixed and the bottom of the pool by electromagnet, making it 
undiscoverable by the rat. Rats were placed in the maze in one of the four start 
points (randomly assigned) and their exploration of the maze recorded for 60 s, 
after which the platform was released, allowing it to rise to the surface in its 
previously fixed position. The rat was then directed to the platform for a 15s 
reinforcement period, such that the probe trial did not cause extinction of the 
previously learned platform location. 
Sixty hours (2.5 days) after probe 1, a second probe trial was performed, to 
DVVHVV WKH UDWV¶ UHWHQWLRQ RI WKH WDVN DQG SODWIRUP ORFDWLRQ DIWHU DQ H[WHQGHG 
period away from the experimental context. This trial was identical to probe 1 
and termed probe 2. Immediately after completion of probe 2, a reversal 
learning period was initiated with a rule change included, to assess cognitive 
flexibility. For this period, the platform was no longer in a fixed position, but 
located in one of four different positions around the maze at 60 cm from the 
arena wall, alternating for each individual trial, and never in the initially 
³FRUUHFW´ TXDGUDQW (Figure 2.2). This new rule forced the rats to adopt a 
different search strategy and abandon their previously learnt rule that the 
platform location was fixed. As before, each rat performed three trials per day, 
with the trial start points assigned randomly, never in the same maze quadrant 
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as the platform. In this study, rats were trained for three experimental days 
(nine trials), before being assessed in a final probe trial (probe 3), identical to 
those performed previously. 
Throughout the experiment, all trials were recorded via a video camera fixed 
above the centre of the arena, with the rats¶ movements tracked and analysed 
by Ethovision software, at four images per second. For each training trial, the 
software recorded the latency for the rat to locate the platform, and during 
probe trials assessed what percentage of the 60s trial was spent in each area of 
the maze, indicating whether there was a preference for exploration in the 
³FRUUHFW´TXDGUDQWLQSUREHVDQGDVZHOODVWKHWLPHVSHQWH[SORULQJLQWKH
³SODWIRUP ULQJ´ LQ Srobe 3 ± the circular zone around the maze at 
approximately 60cm from the walls where the four different platform locations 
were found. 
 
2.2.7 Neuroanatomical Analysis 
One week post-behaviour, rats were killed by concussion followed by 
immediate decapitation, and brains removed on a cold plate (4ºC). In the pilot 
study, whole brains were weighed and preserved in cooled OCT embedding 
matrix (VWR International Ltd, UK). OCT-coated brains were sliced using a 
Leica CM 100 CryoStat (Leica Microsystems, UK) into 75µm coronal sections 
in the region containing the hippocampus (approximately -1.8mm to -6.8mm 
from the bregma (Paxinos 1997)), mounted on 3-amino-propylmethoxysaline 
(APES)-coated slides and stained with cresyl violet to visualise internal 
structures. Cortical slices containing hippocampal cross-sections were imaged 
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electronically (AcquisBio, Synoptics Ltd., Cambridge, UK) and analysed for 
cross-sectional area (Scion Image, Scion Corp., Frederick, MD, USA). Using 
&DYDOLHUL¶V SULQFLSOH 9ROXPH RI ' VWUXFWXUH    FURss-sectional areas x 
distance between cross-sectional surfaces (Gundersen and Jensen 1987)), and 
systematic-random sampling of cross-sectional areas, an estimate of the total 
hippocampal volume was calculated. In the main study, the right hippocampus 
and frontal cortex (FC) were removed by blunt dissection and weighed before 
freezing in liquid nitrogen for future use (see below). The striatum and 
hypothalamus were also blunt dissected and weighed before being discarded. 
 
2.2.8 HPLC Analysis 
To each hippocampal and FC sample dissected, a perchloric acid (PCA) 
homogenisation solution was added (0.1M PCA, 0.02% w/v sodium 
metabisulfite, 0.01% w/v EDTA) at 1500µL per 100mg of tissue. Using a 
sonic probe (Soniprobe 150, Dawe Instruments Ltd, London, Output 20kHz), 
tissue was homogenised in the PCA solution and the resulting homogenate 
centrifuged at 17500g, 4ºC, for 20mins and the supernatant removed and stored 
at -80ºC. Before analysis, the samples were filtered through a 0.45µm PVDF 
4mm syringe filter. 
For HPLC analysis, a phenomenex sphereclone column (4.6x150mm, 5uM 
Octadecyl Saline (ODS(2))) was used with an initial mobile phase composition 
of 0.05M KH2PO4, 0.1mM EDTA, 0.16mM Octane Sulfonic Acid, 21% 
Methanol, adjusted to pH3 with orthophosphoric acid and a 0.8ml/min flow 
rate. A linearity check was performed to ensure the detector was responding in 
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a linear way across the concentrations of interest. Mixed standards of stock 
solutions of the monoamines of interest (dopamine (DA), 3,4-
dihydroxyphenylacetic acid (DOPAC), serotonin/5-hydroxytryptamine (5-HT), 
5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA)) at a 
range of 5x10-9 to 1x10-6M were prepared and analysed in triplicate. The peaks 
elicited were plotted against concentration to assess linearity, with r2>0.99 
required for continuation. Following a standard manual, full loop injection 
SURWRFRO SHU PDQXIDFWXUHU¶V LQVWUXFWLRQV µL of sample was loaded and 
manually injected to the column. Using the mobile phase and column outlined 
above, the expected run time of the five monoamines was from 4mins for the 
earliest detectable peak (DA) to 21mins for the last peak (HVA). Sample peak 
heights were measured manually with a ruler, and compared to the peak 
heights of the known concentration reference samples to calculate the 
monoamine concentration within each sample (Equation 2.1).  
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moles/mg tissue = pk ht samp (mm)  X  std conc.(moles/L)  X   homog. Vol (L) x  ATTsamp 
         pk ht std (mm)                    sample wt (mg)     ATT std 
 
Where  pk ht = peak height in mm of std/sample 
ATT = integrator attenuation setting 
Std conc. = concentration of standard in moles/L 
 Equation 2.1 ± Equation for the calculation of monoamine concentration in brain tissue samples via 
HPLC analysis 
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2.2.9 Statistical Analyses 
Microsoft Excel 2010, GraphPad Prism v6 (GraphPad Software Inc., La Jolla, 
CA, USA), SPPS (IBM SPSS Statistics for Windows, Version 19.0. Armonk, 
NY: IBM Corp) and InVivoStat (InVivoStat, Cambridge, UK) were used for 
statistical analyses. Three-way repeated-measures ANOVA (RM ANOVA), 
with isolation rearing and drug treatment as between subject factors, and time 
as the repeated measure, was used to analyse the LMA timecourse, whilst two-
way ANOVA was used to compare total cumulative locomotor activity. Two-
way ANOVA was further used to compare EHWZHHQH[SORUDWLRQRIWKH³QRYHO´
DQG³IDPLOLDU´REMHFWVDQG'GLVFULPLQDWLRQUDWLRVEHWZHHQWUHDWPent groups, 
in the NOD protocol, while three way ANOVA was used to assess the total 
object exploration time (novel+familiar) over the two NOD trials. Three-way 
RM ANOVA was used to analyse the effect of housing, drug treatment 
(between subject), and prepulse intensity (within subject) in PPI, with two-way 
ANOVA used to examine habituation and initial startle intensity to the 120dB 
tone. Two-way ANOVA assessed the effects of isolation and drug treatment on 
freezing at each consecutive time point in CER, as well as changes in latency 
to enter the CER chamber. Three-way RM ANOVA was used to analyse both 
acquisition phases of the MWM protocol, and two-way ANOVA to examine 
the exploration times in each probe trial. Finally, two-way ANOVA was used 
to compare hippocampal volume, frontal cortical wet weight, and monoamine 
concentrations calculated from HPLC analysis. For all experiments, multiple 
FRPSDULVRQ WHVWV DQG %RQIHUURQL¶V SRVW-hoc analysis were used following 
statistically significant (p<0.05) effects or interactions by ANOVA.  
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2.3 Results 
2.3.1 Effect of isolation rearing and MAM treatment on locomotor activity 
Pilot study: All rats showed the expected horizontal ambulations and 
progressively decreased locomotor activity, reflecting habituation to the 
initially novel arena (Figure 2.3), supported by a significant main effect of time 
by RM ANOVA [F(11,286)=69.307, p<0.001] over the 60 min timecourse. There 
was, however, no significant main effect of housing [F(1,26)=1.415, p=0.245] or 
of MAM treatment [F(1,26)=0.018, p=0.893] by RM ANOVA, and there were 
no significant interactions between any of the factors. 
 
Main study: Whilst all rats successfully habituated to the novel arena through 
the 60 minute protocol (significant effect of time, repeated-measures ANOVA 
[F(11,649)=89.549, p<0.001], Figure 2.4), there was no significant effect of 
isolation [F(1,59)=0.447, p=0.507], MAM [F(1,59)=0.245, p=0.622], and no 
interaction between any of the factors by RM ANOVA. Of note the activity 
counts obtained from one of the 12 experimental chambers were significantly 
lower than those from the other chambers, regardless of treatment group. 
However removing these data points from the analysis did not affect the 
statistical outcome (data not shown). 
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Figure 2.3 ±A progressive decrease in locomotor activity during a 60 min 
exposure to a novel arena. (A) No significant main effect of isolation rearing (Iso) or 
prenatal MAM (MAM) treatment, compared with group-housed (GH) and vehicle-
treated (Con) controls respectively, on horizontal beam breaks (mean ±SEM, n=6-8) 
per 5 min time bin reflecting habituation, supported by RM ANOVA [significant main 
effect of time, F(11,286)=69.307, p<0.001]. (B) Total cumulative activity counts (mean 
±SEM, n=6-8) over the 1h trial. Two-way ANOVA showed no significant effect of 
MAM, or isolation, and no interaction between the two treatments. 
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Figure 2.4 - A progressive decrease in locomotor activity during a 60 min 
exposure to a novel arena. (A) No significant main effect of isolation rearing (Iso) or 
prenatal MAM (MAM) treatment, compared with group-housed (GH) and vehicle-
treated (Con) controls respectively, on horizontal beam breaks (mean ±SEM, n=14-
19) per 5 min time bin. Overall reduction over time, reflecting habituation, supported 
by RM ANOVA [significant main effect of time, F(11,649)=89.549, p<0.001]. (B) Total 
cumulative activity counts (mean ±SEM, n=14-19) over the 1h trial. Two-way 
ANOVA showed no significant effect of MAM, or isolation, and no interaction 
between the two treatments. 
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2.3.2 Effect of isolation rearing and MAM treatment on novel object 
discrimination 
Pilot Study: During the second choice trial of the NOD test, rats explored the 
novel object significantly more than the familiar (Figure 2.5A, two-way 
ANOVA [F(1,26)=29.62, p<0.0001]), with no main effect of treatment, nor an 
interaction. Bonferroni post-hoc analysis revealed that only GH-Con and GH-
MAM groups explored the novel object significantly more (p<0.01) than 
familiar. Further analysis showed that the discrimination ratio for exploration 
of the novel and familiar objects was significantly affected by housing [two-
way ANOVA, F(1,26)=6.248, p=0.0191], but not by MAM-treatment 
[F(1,26)=2.141, p=0.1554] and there was no housing x MAM interaction 
[F(1,26)=0.1124, p=0.7401] (Figure 2.5B). There was no significant main effect 
of isolation rearing, prenatal MAM treatment, or of NOD trial on total object 
exploration (object 1 + object 2) by three way ANOVA (Figure 2.5C). 
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Figure 2.5 ± Isolation rearing (Iso) caused impairment in novel object discrimination 
compared to group-housed (GH) controls, irrespective of prenatal MAM or vehicle 
control (Con) treatment. (A). Group-housed rats spent significantly more time 
exploring the novel object (s, mean±SEM, n=6-8), while isolation reared rats did not 
during the second choice trial of a two-trial novel object discrimination task  
[F(1,26)=29.62, p<0.0001]  **p<0.01 vs. Novel object by Bonferroni post-hoc test 
following ANOVA. (B) The discrimination ratio (novel/novel+familiar object 
exploration, mean±SEM, n=6-8) during the second choice trial. Note a significant 
main effect of isolation rearing [ANOVA F(1,26)=6.248, p=0.0191], but not MAM, and 
no interaction. (C) No significant main effects of isolation rearing, prenatal MAM 
treatment or of NOD trial were observed on total object exploration (object 1+ object 
2) by three-way ANOVA.  
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Main Study: Rats preferentially explored the novel over the familiar object in 
the second choice trial of the NOD paradigm [two-way ANOVA, F(1,56)=48, 
p<0.0001], indicative of object recognition memory, but there was no 
significant effect of treatment, and no treatment x object interaction (Figure 
2.6). However, Bonferroni post-hoc analysis revealed that this significance was 
present in the GH-Con (p<0.01), GH-MAM (p<0.001) and Iso-MAM (p<0.05) 
groups, but not in the Iso-Con group (p>0.05). Analysis of the derived D1 
discrimination ratio revealed that the effects of isolation rearing [F(1,59)=3.040, 
p=0.0865], MAM treatment [F(1,59)=3.649, p=0.0610], and the isolation x 
MAM interaction [F(1,59)=0.1088, p=0.7427] all failed to reach significance by 
two-way ANOVA. There was no significant main effect of isolation rearing, 
prenatal MAM treatment, or of NOD trial on total object exploration (object 1 
+ object 2) by three way ANOVA, despite a trend towards a decrease in 
exploration time in the Iso-Con group (Figure 2.6C). 
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Figure 2.6 ± Preferential exploration of the novel over familiar object in the second, 
choice trial of a two-trial NOD paradigm. (A) Significantly higher exploration (s, 
mean±SEM, n=14-19) of the novel vs. the familiar object regardless of treatment 
[F(1,56)=48.00, p<0.0001]. Post-hoc significance observed in group-housed vehicle-
treated (GH-Con), group-housed MAM-treated (GH-MAM) and isolation-reared 
MAM-treated (Iso- MAM), but not isolation-reared vehicle-treated (Iso-Con), 
indicating a loss of discrimination in this group alone. *p<0.05, **p<0.01, 
***p<0.001 vs. Novel object by Bonferroni post-hoc test following ANOVA (B) The 
discrimination ratio (novel/novel+familiar object exploration, mean±SEM, n=14-19) 
during the second choice trial was unaffected by isolation rearing or MAM treatment, 
and there was no between-factor interaction. (C) No significant main effects of 
isolation rearing, prenatal MAM treatment, or of NOD trial were observed on total 
object exploration (object 1+ object 2) by three way ANOVA, despite a trend towards 
decreased exploration in trial 2 in the Iso-Con group.  
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2.3.3 Effect of isolation rearing and MAM treatment on prepulse inhibition of 
acoustic startle 
Pilot Study: Exposure to a sub-threshold acoustic pulse produced a significant 
attenuation of the acoustic startle response increasing with prepulse intensity 
(Figure 2.7).  RM ANOVA revealed significant main effects of prepulse 
[F(2,50)=51.084, p<0.001], and a MAM x isolation interaction [F(1,25)=9.097, 
p=0.006], but there was no main effect of isolation rearing or prenatal MAM 
treatment alone. Post-hoc analysis showed the route of this interaction was a 
significant PPI decrease in Iso-MAM rats compared to the single hit treatment 
groups at the 80dB pulse level. Two-way ANOVA showed there was no effect 
of isolation rearing or prenatal MAM on initial startle intensity or habituation 
to the 120dB tone, nor an interaction in either measure (data not shown).  
 
Main study: Isolation rearing had a significant effect on PPI such that RM 
ANOVA revealed significant main effects of housing [F(1,59)=6.737, p=0.012] 
and prepulse level [F(2,118)=117.593, p<0.001], but no main effect of MAM 
[F(1,59)=0.385, p=0.537], and no interaction between any of the factors (Figure 
2.8A). Post-hoc significance was seen due to isolation rearing at the 76dB 
prepulse level only. Two-way ANOVA revealed that there was a significant 
main effect of isolation rearing on initial startle intensity [F(1,59)=14.615, 
p<0.001], but there was no effect of MAM [F(1,59)=0.1052, p=0.747] and no 
isolation x MAM interaction [F(1,59)=0.04980, p=0.8242] (Figure 2.8B). There 
was no significant effect on habituation to the 120dB tone by isolation or 
MAM, nor was there an interaction (data not shown).   
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Figure 2.7 ± A significant attenuation of the acoustic startle response by a 
combination of isolation rearing and prenatal MAM treatment. Despite a 
significant main effect of prepulse on percentage prepulse inhibition (mean±SEM, 
n=6-8) [F(2,50)=51.084, p<0.001, RM ANOVA], no main effect of MAM treatment 
(MAM) or of isolation (Iso), either alone or combined, compared to vehicle-treated 
(Con) and group-housed (GH) rats was observed. There was a significant isolation x 
MAM interaction [F(1,25)=9.097, p=0.006], with post hoc significance showing a 
decrease in PPI performance at the 80dB prepulse level. **p<0.01 isolation vs. MAM-
matched group-housed controls, p<0.001 MAM-treatment vs. rearing-matched 
saline-treated control by Bonferroni post-hoc analysis following ANOVA. 
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Figure 2.8 ± A significant effect of isolation rearing on prepulse inhibition of 
acoustic startle. (A) The percentage PPI response (mean±SEM, n=14-19)  was 
significantly altered by isolation rearing (Iso) [F(1,59)=6.737, p=0.012] and prepulse 
intensity [F(2,118)=117.593, p<0.001], but not prenatal MAM compared to group-
housed (GH) and vehicle treated (Con) controls. There were no interactions between 
factors. *p<0.05 isolation vs. MAM-matched group-housed controls by Bonferroni 
post-hoc analysis following ANOVA. (B) The initial startle amplitude (mean±SEM, 
n=14-19) elicited by 120dB tone was significantly altered by isolation rearing 
[ANOVA, F(1,59)=14.615, p<0.001], but not MAM, with no interaction. *p<0.05 
isolation vs. MAM-matched group-housed controls, #p<0.05 isolation+MAM 
treatment vs. GH-Con absolute control by Bonferroni post-hoc following ANOVA.  
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2.3.4 Effect of isolation rearing and MAM treatment on a conditioned 
emotional response 
Pilot Study: To examine contextual and conditioned emotional memory, 
processes involving input from the hippocampus and amygdala, behaviour was 
examined in an associative learning conditioned emotional response paradigm. 
There was a significant main effect of isolation rearing at 24h [F(1,25)=16.58, 
p=0.0004] and 48h post-conditioning [F(1,25)=21.15, p=0.0001] and following 
re-presentation of the CS alone [F(1,25)=9.701, p=0.0046] by two-way ANOVA, 
with post hoc tests showing isolation significantly decreased freezing duration 
at all time points. Despite no effect of MAM at 24 or 48 h post-conditioning, a 
significant main effect occurred following presentation of the CS alone 
[F(1,25)=7.322, p=0.0121]. There was a tendency for MAM-treatment to 
increase freezing response, but this failed to reach significance by post-hoc 
analysis. At none of the three time points was a significant isolation x MAM 
interaction observed (Figure 2.9).  
 
Main Study: Half of the main study cohort was advanced into the CER 
paradigm (n=31 in total, n=7-10 per group). Freezing responses were 
decreased in isolates such that at all time points two-way ANOVA revealed a 
significant main effect of isolation rearing (24h: [F(1,27)=9.852, p=0.0041], 48h: 
[F(1,27)=13.64, p=0.001], Post-CS [F(1,27)=15.72, p=0.0005]), with post hoc 
significance observed at the 24h and Post-CS time points. No alterations in 
freezing were observed due to MAM treatment, with no isolation x MAM 
interactions, and any stage of the protocol (Figure 2.10).   
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Figure 2.9 ± Significant reduction in freezing time due to isolation rearing (Iso) 
compared to group-housed (GH) rats in a conditioned emotional response paradigm, 
irrespective of prenatal treatment with MAM (MAM) or saline control (Con). Two-
way ANOVA revealed significant main effects of isolation rearing on freezing time (s, 
mean±SEM, n=6-8) at 24h [F(1,25)=16.58, p=0.0004] and 48h [F(1,25)=21.15, p=0.0001] 
post-conditioning to an aversive footshock (US) and a paired light-sound tone (CS), 
and following re-presentation of the CS alone (Post-CS) [F(1,25)=9.701, p=0.0046]. 
ANOVA showed a main effect of prenatal MAM-treatment (24mg/kg, i.p.) on CS 
alone induced freezing [F(1,25)=7.322, p=0.0121], but there was no isolation x MAM 
interaction. **p<0.01 *p<0.05 isolation vs. group-housing, ##p<0.01 #p<0.05 
isolation+MAM vs. group-housed control treated by Bonferroni post-hoc analysis 
following ANOVA. Note that isolation rearing reduced freezing at all time points, 
but whilst there was a tendency for MAM to increase freezing on presentation of 
the CS, this did not reach post-hoc significance. 
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Figure 2.10 ± Significant reduction in freezing time due to isolation rearing (Iso) 
compared to group-housed (GH) rats in a conditioned emotional response paradigm. 
Two-way ANOVA revealed a significant main effect of isolation rearing on freezing 
time (s, mean±SEM, n=7-10) at 24h [F(1,27)=9.852, p=0.0041] and 48h [F(1,27)=13.64, 
p=0.001] post-conditioning of an aversive footshock (US) and a paired light-sound 
tone (CS), and following re-presentation of the CS alone (Post-CS) [F(1,27)=15.72, 
p=0.0005]. No significant main effect of prenatal MAM treatment (MAM, 24mg/kg, 
i.p.) compared to vehicle control (Con), nor was there an isolation x MAM interaction 
by ANOVA. **p<0.01 *p<0.05 isolation vs. group-housing by Bonferroni post-hoc 
following ANOVA. Note that freezing decreases due to isolation rearing reached 
post-hoc significance at the 24h and Post-CS time points. 
 
.  
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2.3.5 Effect of isolation rearing and MAM treatment on Morris Water Maze 
performance 
Main study: Rats which did not perform the CER paradigm advanced into the 
Water Maze task (total n=32). RM ANOVA revealed a highly significant main 
effect of trial on latency to platform [F(14,392)=17.042, p<0.001], indicating that 
rats were able to successfully learn the position of the hidden platform and 
progressively find it more quickly (Figure 2.11A). Despite a trend, there was 
no significant main effect of isolation rearing or MAM, and no interaction. 
Two-way ANOVA showed a significant rearing x MAM interaction on the 
time spent in the correct maze quadrant in probe 1 [F(1,28)=4.962, p=0.0341], 
but no main effect of MAM or isolation alone. In Probe 2 there was a 
significant main effect of MAM on time in the correct quadrant [F(1,28)=8.424, 
p=0.0071, two-way ANOVA], but no main effect of isolation and no 
interaction observed (Figure 2.12A and B). 
During reversal learning training there was no significant effect of trial number 
on platform location latency by RM ANOVA [F(8,224)=1.826, p=0.073], 
indicating that overall performance did not improve with training. There was 
no significant main effect of housing or MAM treatment, nor an interaction 
between the two (Figure 2.11B). 
Two-way ANOVA indicated a significant MAM x isolation interaction 
[F(1,28)=4.709, p=0.0386] on the time spent in the previous ³FRUUHFW´TXDGUDQW 
during Probe 3, but no main effect of housing or MAM treatment alone. There 
was no significant effect of any factor on the time spent swimming in the 
platform ring area in probe 3 (two-way ANOVA, Figure 2.12C and D). 
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Figure 2.11 - Comparison of the effect of isolation rearing (Iso) and prenatal MAM 
treatment (MAM), both alone and in combination, with that of group-housed (GH) and 
vehicle treated (Con) controls, on the latency (s, mean±SEM, n=7-9) to find a hidden 
platform in the Morris Water Maze during (A) 15 consecutive learning trials, and (B) 
following a rule change, 9 further trials during a reversal learning period. Repeated-
measures ANOVA showed a significant main effect of trial during the learning phase 
[F(14,392)=17.042, p<0.001], but no main effect of isolation rearing or MAM treatment, 
and no interaction. There were no significant main effects of isolation rearing, MAM 
treatment, or trial by repeated-measures ANOVA during the reversal learning phase, 
and no interaction between any of the factors. 
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Figure 2.12 ± Comparison of the effect of isolation rearing (Iso) and prenatal MAM 
treatment (MAM), both alone and in combination, compared with group-housed (GH) 
DQG YHKLFOH WUHDWHG &RQ FRQWUROV RQ WKH SHUFHQWDJH WLPH VSHQW LQ WKH ³FRUUHFW´
quadrant (mean ±SEM, n=7-9) in (A) Probe 1, (B) Probe 2, and (C) Probe 3 and in (D) 
WKH ³3ODWIRUP 5LQJ´ DUHD LQ 3UREH . (A) A significant isolation x MAM interaction 
occurred by two-way ANOVA in Probe 1 [F(1,28)=4.962, p=0.0341], but there was no 
effect of isolation or MAM alone. (B) In Probe 2 a significant effect of MAM treatment 
was seen by two-way ANOVA [F(1,28)=8.424, p=0.0071], but no effect of isolation and 
no interaction. (C) A significant interaction occurred between isolation rearing and 
MAM treatment by two-way ANOVA in Probe 3 [F(1,28)=4.709, p=0.0386], but no 
effect of isolation or MAM alone. (D) There was no effect on the percentage time spent 
LQ WKH ³SODWIRUP ULQJ´ DUHD due to isolation rearing or MAM treatment, and no 
interaction occurred. No post-hoc significance was observed between any treatment 
groups in any measure examined. 
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2.3.6 Effect of isolation rearing and MAM treatment on hippocampal size 
Pilot Study8VLQJ&DYDOLHUL¶VSULQFLSOHKLSSRFDPSDOYROXPHVZHUHHVWLPDWHG
to a mean of 30.48mm3 across all treatment groups. Two-way ANOVA 
analysis revealed a significant main effect of MAM treatment [F(1,25)=23.72, 
p<0.0001] which reduced the mean volume from 39.12 ±2.73 mm3 in the GH-
Con group, to 25.66 ±1.88 mm3 in the Iso-MAM group, approximately 34% 
reduction, supported by Bonferroni post-hoc analysis revealing a significant 
reduction (p<0.01) in hippocampal volume in GH-MAM compared to GH-
Con, and Iso-Con compared to Iso-MAM. There was no effect of rearing 
[F(1,25)=1.387, p=0.25], and no rearing x MAM interaction [F(1,25)=0.07599, 
p=0.7851] (Figure 2.13A). A significant main effect of MAM treatment was 
also seen on total brain mass [ANOVA, F(1,25)=105.6, p<0.001], but again no 
effect of housing condition, and no between-factor interaction was observed 
(Figure 2.13B). The hippocampal volume to total brain mass ratio was also 
significantly affected MAM such that two-way ANOVA revealed a significant 
main effect of MAM [F(1,25)=7.731, p=0.0102], but no effect of housing 
condition [F(1,25)=0.9327, p=0.3434], nor any MAM x housing interaction 
[F(1,25)=0.05366, p=0.8187]. Despite a trend towards reduced hippocampal 
volume:total brain mass ratio, post-hoc analysis revealed no significance 
between groups (Figure 2.13C). 
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Figure 2.13 ± Prenatal MAM treatment caused a significant reduction in brain 
mass and hippocampal volume. (A) Significant main effect of prenatal MAM 
treatment (MAM, 24mg/kg i.p.) compared to vehicle control (Con) on hippocampal 
volume (mm3, bars = mean±SEM, n=6-8) by Cavalieri Principle, regardless of rearing 
in social groups (GH) or isolation (Iso) [two-way ANOVA, F(1,25)=23.72, p<0.0001]. 
No main effect of isolation rearing, nor an isolation x MAM interaction. **p<0.01 
*p<0.05 MAM-treatment vs. rearing-matched vehicle-treated controls, ##p<0.01 
isolation+MAM treatment vs. GH-Con absolute control by Bonferroni post-hoc test 
following ANOVA. (B) Significant main effect of prenatal MAM treatment on total 
brain mass (bars = mean±SEM) compared to vehicle controls [ANOVA, F(1,25)=105.6, 
p<0.001]. No main effect of isolation rearing, and no rearing x MAM interaction. (C) 
Significant main effect of prenatal MAM treatment on hippocampal volume:total 
brain mass ratio (bars = mean±SEM) compared to vehicle controls [ANOVA, 
F(1,25)=7.731, p=0.0102]. No main effect of isolation rearing, and no rearing x MAM 
interaction. Note a trend towards decreased ratio of hippocampal volume to total brain 
mass that failed to achieve post-hoc significance.  
Chapter 2 Ȃ Isolation and Prenatal MAM 
- 83 - 
 
Main Study: Hippocampal wet mass was significantly altered by MAM-
treatment [two-way ANOVA, F(1,46)=12.49, p=0.0009] irrespective of whether 
rats were isolated or group-housed, such that the mass (mean±SEM) in the 
GH-MAM group (43.8 ± 2.5 mg) was reduced by 16% of control (52.1 ± 2.8 
mg) (Figure 2.14A). The striatal wet mass was also significantly affected by 
MAM treatment by two-way ANOVA [F(1,47)=4.688, p=0.0355], but 
unaffected by isolation rearing, and no interaction occurred (Figure 2.14B). 
Despite trends towards reduced volume in both regions, no post-hoc 
significance was observed in either region following ANOVA. There was no 
effect of MAM treatment or isolation rearing on frontal cortex or 
hypothalamus wet weight by two-way ANOVA, nor any interaction between 
factors. 
Chapter 2 Ȃ Isolation and Prenatal MAM 
- 84 - 
 
H ip p o c a m p u s
G H -C o n G H -M A M Is o -C o n Is o -M A M
0
2 0
4 0
6 0
8 0
M
a
s
s
 
(m
g
)
S tr ia tu m
M
a
s
s
 
(m
g
)
G H -C o n G H -M A M Is o -C o n Is o -M A M
0
2 0
4 0
6 0
8 0
A
B
 
Figure 2.14 ± Prenatal MAM treatment caused a significant change in 
hippocampal and striatal wet weights. There was a significant main effect of 
prenatal MAM treatment (MAM, 24mg/kg i.p.) on the wet weight (mg,  mean±SEM, 
n=14-19) of (A) hippocampus [two-way ANOVA, F(1,46)=12.49, p=0.0009] and (B) 
striatum [F(1,47)=4.688, p=0.0355] compared to vehicle treated controls (Con), 
regardless of subsequent rearing in social groups (GH) or isolation (Iso). No main 
effect of isolation rearing or a rearing x MAM interaction in either region, with no 
post-hoc significance observed between any treatment group, despite a trend towards 
reduced hippocampal and striatal wet weights due to MAM.  
Chapter 2 Ȃ Isolation and Prenatal MAM 
- 85 - 
 
2.3.7 Effect of isolation rearing and MAM treatment on neurochemistry 
Main Study: HPLC analysis of the monoamine concentration in the frontal 
cortex and hippocampus revealed a significant main effect of MAM on 
dopamine concentration in the FC [F(1,45)=6.031, p=0.0180], however *UXEE¶V
test for outliers (Į = 0.0500) identified two data points as anomalous (one in 
each of the GH-MAM and Iso-MAM groups),  and removal of these points 
removed this significance. There was no main effect of isolation rearing, nor a 
rearing x MAM interaction (two-way ANOVA, Figure 2.15A). A significant 
change in 5-HIAA concentration due to MAM was observed in the 
hippocampus [F(1,44)=8.131, p=0.0066] by two-way ANOVA (Figure 2.15B), 
but no change in the 5-HT:5-HIAA ratio was seen, nor was there an effect of 
isolation rearing or a rearing x MAM interaction here also (Table 2.2). There 
was no effect of treatment or rearing, nor an interaction, on any other 
monoamine level tested in either structure (Table 2.2).  
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Figure 2.15 - Comparison of the effect of isolation rearing (Iso) and prenatal MAM 
treatment (MAM), both alone and in combination, with group-housed (GH) and 
vehicle treated (Con) controls, on (A) dopamine concentration in the post-mortem 
frontal cortex tissue via HPLC and (B) 5-HIAA concentration in post-mortem 
hippocampal tissue via HPLC (n=11-16, pmol/mg, bars: mean±SEM). (A) A 
significant main effect of MAM on dopamine levels [two-way ANOVA, F(1,45)=6.031, 
p=0.0180], however removal of the highlighted anomalous data points removed this 
significance. There was no effect of isolation, nor an interaction between the two 
factors. (B) A significant effect of MAM on 5-HIAA levels [two-way ANOVA, 
F(1,44)=8.131, p=0.0066] was observed, with no effect of isolation rearing, and no 
interaction observed. Despite a trend towards elevated 5-HIAA by prenatal MAM 
treatment, this effect failed to reach post-hoc significance. 
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Table 2.2 ± Table to show the metabolite levels (pmol/mg) in post-mortem 
tissue of the the frontal cortex and hippocampus of vehicle and MAM treated 
rats, reared either in isolation or social groups, measured by HPLC analysis. 
 
 
  
Frontal Cortex
Monoamine Mean SEM Mean SEM Mean SEM Mean SEM
DA 0.282 ±0.020 0.668 ±0.246 0.294 ±0.029 0.599 ±0.205
DOPAC 0.310 ±0.048 0.349 0±.062 0.344 ±0.049 0.323 ±0.070
5HIAA 2.571 ±0.356 3.354 ±0.421 2.567 ±0.334 2.907 ±0.396
5-HT 2.818 ±0.399 3.300 ±0.231 3.563 ±0.404 3.405 ±0.327
HVA 0.233 ±0.022 0.311 ±0.077 0.205 ±0.024 0.244 ±0.063
Turnover Ratio
5-HT:5HIAA 1.344 ±0.271 1.200 ±0.200 1.680 ±0.284 1.332 ±0.188
DA:DOPAC+HVA 0.643 ±0.087 0.979 ±0.309 1.088 ±0.427 1.010 ±0.290
Hippocampus
Monoamine Mean SEM Mean SEM Mean SEM Mean SEM
DA 0.164 ±0.053 0.128 ±0.042 0.196 ±0.040 0.175 ±0.047
DOPAC 0.113 ±0.017 0.111 ±0.012 0.138 ±0.051 0.141 ±0.026
5HIAA 2.749 ±0.138 3.272 ±0.216 2.674 ±0.115 3.214 ±0.271
5-HT 1.913 ±0.226 1.736 ±0.173 2.211 ±0.356 1.904 ±0.186
HVA
Turnover Ratio
5-HT:5HIAA 0.747 ±0.128 0.571 ±0.082 0.861 ±0.149 0.655 ±0.094
DA:DOPAC 1.456 ±0.042 1.156 ±0.027 1.420 ±0.046 1.241 ±0.036
GH Con GH MAM Iso Con Iso MAM
GH Con GH MAM Iso Con Iso MAM
Could not be detected in any sample
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Figure 2.16 ± Representative results from HPLC analysis of the hippocampus and 
frontal cortex in rats treated with prenatal MAM or vehicle control and subsequently 
reared in group or isolation. (A) A 1x10-7M mixed monoamine standard with peaks 
representing, from top to bottom, DA, DOPAC, 5-HT, 5-HIAA, HVA (B) Sample of 
frontal cortex with peaks for all 5 monoamines of interest identified, with peak run 
time (printed number, mins) and height measurements (mm) shown.  
A 
B 
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2.4 Discussion 
 
The results obtained in these studies provide little support for the hypothesis 
that an isolation-MAM combination model may provide an improved model of 
µVFKL]RSKUHQLD-OLNH¶ V\PSWRPV FRPSDUHG WR HLWKHU HDUO\-life perturbation 
alone, due to the lack of robust and reproducible behavioural deficits observed. 
Although in many of the behavioural paradigms assessed a significant effect 
was seen due to at least one of the treatments given, and reductions in 
hippocampal size were observed, these deficits were inconsistent and not 
reliably in line with previous publications. 
 
Whilst the locomotor response of rats in both the pilot and main study 
displayed the expected habituation and reduced activity in consecutive epochs, 
no significant effects were observed due to isolation rearing or MAM treatment 
in either study. Elevations in locomotor activity in a novel environment, 
interpreted as an increased propensity to escape (neophobia) and/or attenuation 
of the ability to habituate to mildly aversive novelty (Fone and Porkess 2008; 
Jones et al. 2011b), have been reported in in up to 88% of cohorts where rats 
have been isolated for 5 weeks (Fone and Porkess 2008), and by multiple 
groups using both longer and shorter isolation periods than this study, as well 
as in various strains of rat (Bakshi and Geyer 1999; Fabricius et al. 2011; 
Schubert et al. 2009). An absence of this hyperlocomotion is therefore 
somewhat unexpected, and has only been previously reported as a result of 
changes in environmental enrichment (Schrijver et al. 2002). It was anticipated 
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that this behavioural deficit would be highly reproducible here, and was 
intended as a marker of model efficacy; however the lack of isolation-induced 
hyperactivity instead calls in to question whether the isolation procedure was 
successful at all. Previous publications have reported that MAM can enhance 
the locomotor stimulant effect of amphetamine or NMDA receptor antagonists 
such as PCP, and on occasion may enhance baseline locomotor activity (Le 
Pen et al. 2011). However, a number of studies have shown that GD17 MAM 
has no effect on baseline locomotor activity in a novel arena (Featherstone et 
al. 2009; Flagstad et al. 2004; Moore et al. 2006; Penschuck et al. 2006). 
Consistent with this, no main effect of MAM was seen in either cohort of this 
study.  
 
Conversely, significance was observed due to one of the two treatments used 
in each cohort in each remaining behavioural paradigm. The ability for rats to 
discriminate between a novel and familiar object in the second choice trial of 
the NOD protocol was impaired by isolation rearing in the pilot study, where 
group-housed rats explored the novel object significantly more than the 
familiar, and those reared in isolation did not. This suggests that group-housed 
rats were more able to use working memory to remember previous attention to 
the object, and hence explore it significantly less on re-exposure. Furthermore, 
the D1 discrimination ratio of isolated rats was shown to be significantly lower 
than their group-housed counterparts, irrespective of prenatal treatment with 
MAM. As this test was performed just 24h after the LMA protocol and shows 
an isolation-induced deficit, it is difficult to conclude that the lack of 
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hyperactivity in the previous paradigm was due to a failure in producing 
isolation syndrome. The impairment of NOD in isolation-reared rats in the 
pilot study was as previously shown in the literature (Bianchi et al. 2006; 
McLean et al. 2010a; Neill et al. 2010). However, there is also a body of 
evidence to suggest that discrimination deficits similar to those observed here 
are produced in adolescent offspring from dams treated during gestation with 
MAM (Fiore et al. 1999; Lodge and Grace 2009), a finding not replicated 
herein. One potential explanation for the lack of effect of MAM is the use of 
Lister-Hooded rats in this study. As noted, there is no published data on the use 
of this strain of rats in studies where prenatal MAM is administered on GD17, 
and it is possible that strain sensitivity to MAM may account for the different 
results seen herein. In the main study, unlike the pilot, no significant effect was 
observed on the D1 discrimination ratio due to isolation rearing, and although 
rats in the Iso-Con group were identified as not exploring the novel 
significantly more than the familiar object, rats in the Iso-MAM group 
exhibited a preference for the novel object, indicating intact visual learning and 
memory at this time point. However, ANOVA of D1 data showed that there 
was no main effect of isolation or MAM alone, and there was no isolation x 
MAM interaction, which prevents the conclusion that the MAM treatment may 
have reversed a deficit induced by isolation. With inconsistent deficits 
produced by isolation rearing, and no MAM-induced deficits observed 
(whether due to a strain effect or not), results of the NOD protocol also 
undermine the reliability and viability of this dual-hit approach. 
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It is important to note that an additive or synergistic effect of combining 
isolation rearing and MAM treatment may be difficult to observe in this 
protocol due to a ceiling effect. Whilst an effect due to one treatment alone can 
be observed in one of the single treatment groups, as was seen in the Iso-Con 
group of both these cohorts, an inability to perform the task cannot be 
subsequently worsened by the addition of a second perturbation in the dual-hit 
group. This means any additive or synergistic effects of the dual-hit approach 
will be masked. Procedurally, the protocol could be made easier (shortening 
the inter-trial interval), so that rats in a single treatment group are still able to 
perform the task (potentially to a lesser extent), but a synergistic/additive effect 
of dual-hit treatment could produce an impairment in visual learning and 
memory. 
 
A similar result to the NOD protocol was observed in the CER paradigm, 
where isolation rearing significantly reduced contextual and cue-mediated 
freezing responses following fear-motivated associative learning in both the 
pilot and main studies. MAM treatment alone had a significant main effect on 
freezing at the Post-CS time point of the pilot study, but no post-hoc 
significance was observed and the finding was not replicated in the main study. 
This paradigm may have particular relevance to psychiatric disorders, 
including schizophrenia, as previous reports indicate significant deficits in 
conditioned associative learning (Rushe et al. 1999) as well as the ability to 
maintain stimulus-reward relationships in memory over long delay periods in 
individuals with schizophrenia (Herbener 2009). The results observed due to 
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isolation rearing agree with previous literature including that of our laboratory. 
The CER protocol was extensively validated by the group and has been used in 
a number of studies relevant to cognition and schizophrenia, including a recent 
publication with the protocol showing sensitivity to serotonin mediation and 
NMDA receptor antagonism in rats exposed to the experimental conditions 
described here (Woods et al. 2012). The significant reduction in freezing 
response caused by isolation rearing in both cohorts here supports the findings 
of a number of other publications that observed decreased fear-induced 
freezing in a contextual fear conditioning paradigm (Weiss et al. 2004) and 
shorter retention latencies in a passive avoidance test (Del Arco et al. 2004) in 
isolation-reared Sprague-Dawley rats,  as well as impaired context-induced 
freezing in mice reared in social isolation (Gresack et al. 2010).  
The effect of prenatal MAM treatment on contextual fear-conditioning is less 
well characterised, but would be expected to be similar to that of isolation 
rearing since it also produces morphological deficits in the hippocampus. 
However, there is some evidence to suggest that despite marked reductions in 
entorhinal, prefrontal cortical and striatal volumes, MAM administration on 
GD12-15 produces no deficit in active avoidance or freezing paradigms (Leng 
et al. 2005). Whilst the neuroanatomical profile of GD12-15 rats is markedly 
different to GD17 rats, it does suggest that even with significant anatomical 
changes due to MAM, the functional effects of administration on freezing 
behaviour may be more difficult to highlight. The only main effect of MAM 
was observed at the post-CS time point of the pilot, but despite a trend towards 
increased freezing, this failed to achieve significance post-hoc. Previous 
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studies have identified specific, protocol-dependent effects of MAM treatment 
on contextual/cue conditioning (Gresack et al. 2010). A potential effect of 
MAM on cue-conditioning rather than contextual-conditioning may suggest an 
involvement of the amygdala, and whilst there is little published evidence on 
the specific effect of prenatal MAM treatment on the volume and organisation 
of the amygdala, in the rat GD17 is a key time point for neuronal development 
in regions including the amygdala (Bayer 1980). This would be consistent with 
neuronal development and/or organisation in this region being disrupted by 
MAM treatment at GD17, although this is mere speculation without 
statistically significant results to support the notion. Reduced cognitive 
flexibility, as seen previously with MAM treatment on GD17 (Gastambide et 
al. 2012) and GD15 (Leng et al. 2005), may also explain altered freezing 
following CS exposure. In this paradigm, a lack of flexibility may manifest as 
an inability to relearn that the CS is no-longer accompanied by an aversive 
footshock, and hence the rats continue to freeze for longer through the post-CS 
period than vehicle-treated controls. To assess cognitive flexibility, the Morris 
Water Maze paradigm was added to the behavioural battery (discussed below). 
However, the main study did not replicate the significance due to MAM in the 
pilot CER paradigm. A further lack of robustness for MAM-induced 
behavioural changes again weakens the basis for continued use in this dual-hit 
study. However, even if a significant increase in freezing due to MAM had 
been confirmed and replicated, this response is opposite to the effect of 
isolation rearing to reduce freezing. The effect of combining treatments would 
therefore cancel each other out, producing an inconclusive phenotype. 
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The Morris Water Maze test assessed visuo-spatial learning by requiring 
subjects to learn first the location of a hidden platform in a fixed position, and 
subsequently re-learn the location of the platform in differing positions on each 
trial requiring disregard of the previously learnt rule, and re-acquisition of a 
new rule in the same contextual setting. As expected, in the fixed location task 
rats progressively reduced their latency to reach the platform across the 15 
training trials, demonstrating spatial learning using the visual cues provided 
around the arena. Despite an indication that MAM rats may have demonstrated 
an increased latency to reach the platform, particularly in trials 8-12, this was 
shown to be non-significant, supported by a lack of significance in Probe 1. 
However, following a 60 hour extinction period, MAM-treated rats spent 
significantly less time in the correct maze quadrant in the second probe trial, 
showing their retention of the task was impaired. Altered acquisition of a water 
maze task is not a novel finding in prenatal MAM models, having been 
reported on following MAM treatment on GD11 (Fiore et al. 2002), GD14 
(Vorhees et al. 1984), and GD15 (Banfi et al. 1984), but only recently with 
GD17 (Snyder et al. 2013). Many prominent papers investigating MAM in the 
Morris Water Maze, however, have suggested the treatment is ineffective in 
impairing acquisition in the Morris Water Maze paradigm (Flagstad et al. 
2005; Leng et al. 2005). Results presented herein suggest that MAM-treated 
rats were able to learn the task after completing 15 learning trials. 
MAM-treated rats displayed impaired memory in Probe 2, 60h post-training, 
supporting previous work suggesting GD17 treatment impairs retention in the 
Morris Water Maze (Snyder et al. 2013) as well as other memory paradigms 
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(Gourevitch et al. 2004). There was no significant effect of isolation rearing on 
acquisition or retention of the task, in line with some previous work showing 
no deficit in performance (Schrijver et al. 2004), but not replicating previously 
observed improvements (Wongwitdecha and Marsden 1996a) or impairments 
(Hellemans et al. 2004; Lu et al. 2003) due to isolation. 
In the subsequent reversal learning phase, performance in the task did not 
significantly improve across trials, irrespective of treatment group. Therefore, 
this reversal learning protocol may be too simple to demonstrate any deficit 
produced by isolation rearing and/or MAM treatment. A wide array of 
previous data suggests both prenatal MAM including GD17 injection 
(Featherstone et al. 2007; Flagstad et al. 2005; Gastambide et al. 2012), and 
rearing in social isolation (Li et al. 2007; Quan et al. 2010; Schrijver et al. 
2004), causes deficits in reversal learning paradigms, including the Morris 
Water Maze, which reflects behavioural rigidity (Fone and Porkess 2008; 
Lodge and Grace 2009). Improvement in the performance of the control 
animals in this protocol by extending the number of trials may allow further 
evaluation of any deficits induced to better reflect the literature. 
As changes in reversal learning were not significant, the results of probe 3 are 
less informative. There was no significant effect of isolation or MAM on the 
WLPH VSHQW H[SORULQJ WKH ³SODWIRUP ULQJ´ EXW DV UDWV GLG QRW VLJQLILFDQWO\
improve their performance over the course of the 9 trials, this would be 
expected. Of use from this probe is the ability to investigate how perseverative 
the rats are to explore the previously correct region of the maze. There was no 
main effect due to either isolation or MAM, but there was a significant 
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interaction between the two treatments. Whilst GH-MAM and Iso-Con groups 
showed a slight increase in time spent exploring the previously correct 
TXDGUDQWDV\RXPLJKWH[SHFWLQUDWVXQDEOHWRUHYHUVHRU³XQOHDUQ´DSUHYLRXV
rule, rats in the Iso-MAM groups exhibited a slight decrease in time spent 
there. Whether this significance would persist with a fuller reversal learning 
protocol is unclear, however, as there was no significant effect of treatment on 
overall quadrant exploration in Probe 3 (data not shown). 
Whilst the MWM protocol used was relatively successful, future 
improvements were clearly required to give more relevant results. An 
extension of the reversal learning protocol to a full 15 trials, as in the initial 
acquisition phase, would improve the statistical outcome. 
 
In the prepulse inhibition of acoustic startle paradigm, results in the pilot and 
main studies differed. In the pilot study, a clear trend towards a significant 
decrease in PPI in the Iso-MAM group was noted at each of the three prepulse 
intensities, reaching post-hoc significance at prepulse intensity of 80dB. In the 
main study, a clear decrease in PPI due to isolation rearing was observed, with 
significance obtained post-hoc in at prepulse intensity of 76dB only. Previous 
work by numerous groups, including our own, has demonstrated impairments 
in prepulse inhibition in rats reared in social isolation (Cilia et al. 2001; Powell 
et al. 2002; Schubert et al. 2009), treated prenatally with MAM (Le Pen et al. 
2006; Moore et al. 2006; Talamini et al. 1998) and in other rodent models of 
psychiatric disorder (Brody et al. 2003a; Li et al. 2011b). Such deficits are 
thought to have translational relevance to deficits in sensorimotor processing 
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and the ability to filter non-essential sensory information, symptoms observed 
in several neuropsychiatric disorders including schizophrenia (Braff and Geyer 
1990). All of these deficits were observed in single-interference studies, yet a 
significant deficit due to MAM treatment alone was not observed in either 
study, with a main effect of isolation observed only the main cohort. Some 
previous reports have documented a lack of PPI deficit due to prenatal MAM 
treatment in rats (Jongen-Relo et al. 2004), but as this utilised earlier MAM 
administration the results cannot be directly compared to those herein.  When 
combined with isolation rearing, MAM treatment in the pilot study showed a 
PPI deficit, suggesting the potential for a synergistic effect of the two 
perturbations. As the aim of this project was to develop a model with increased 
robustness, such a synergistic effect observed in the combined treatment is an 
important finding, however the results were not replicated in the main study. 
One of the main motivations for developing a combined early-life 
PDQLSXODWLRQ PRGHO RI µVFKL]RSKUHQLD-OLNH¶ V\PSWRPV LV WKH YDULDELOLW\ DQG
lack of robustness of changes seen in a number of the most frequently used 
behavioural paradigms to assess change in performance in these models. PPI 
deficits are only reported in approximately 82% of isolation reared groups, 
falling to around 66% where shorter isolation periods have been utilised (Fone 
and Porkess 2008), but since this study further publications have also failed to 
observe a deficit in PPI following isolation rearing (Jones et al. 2011a; 
McIntosh et al. 2013). One small caveat to the isolation-induced PPI deficit 
seen here is the observation of a significant decrease in the initial startle 
amplitude of the isolation-reared rats compared to their group-housed 
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counterparts. Whilst this observation has also been reported previously in the 
absence of a PPI deficit (Jones et al. 2011a), meta-analyses concluded that 
isolation-induced PPI deficits were independent of startle reactivity (Cilia et al. 
2001), so should not confound the interpretation of the significant effect of 
isolation on PPI here. A lack of MAM effect alone in either study may again 
undermine this dual-hit model, despite the potential synergistic effect of 
combination treatment in the pilot study. This outcome was a major motivation 
in conducting the main isolation-MAM combination study, but a failure to 
replicate the pilot data is a further negative result. 
 
Consideration should be given to the fact that multiple behavioural tests were 
performed in the same animals in these studies, although there is little 
consensus over whether behavioural assessment may affect the outcome of 
subsequent tests. Some evidence suggests isolation-induced deficits may be 
lost due to previous testing (Domeney and Feldon 1998) or that the volume of 
rodent brain structures may be increased or decreased by repeated task training 
(Lerch et al. 2011), yet numerous publications, including those of our lab 
(McIntosh et al. 2013; Schubert et al. 2009), have shown schizophrenia-like 
deficits being produced in rodents undergoing numerous or repeated 
behavioural tests (Beninger et al. 2010; Moller et al. 2013; Nakatani-Pawlak et 
al. 2009). It is therefore unlikely that the repeated testing protocol used in this 
thesis is responsible for the lack of robust deficits observed. 
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MAM treatment significantly reduced the mean total brain weight, and reduced 
hippocampal volume by approximately 34% of control in the pilot study, and 
affected the wet weight of the hippocampus and striatum in rats from the main 
study (although this did not reach post-hoc significance). In contrast, isolation 
rearing had no similar effect on hippocampal volume or on total 
brain/hippocampal/striatal wet weight. The highly significant reduction in 
hippocampal volume due to GD17 has been seen consistently by many groups 
using a variety of measuring techniques, including magnetic resonance 
imaging (Chin et al. 2011), cross-sectional thickness (Moore et al. 2006) and 
area (Le Pen et al. 2006) measurement, and simple wet weight (Flagstad et al. 
2004), with the extent of the reductions observed comparable to those seen 
here. Similarly, other groups have noted decreased wet weight of the dorsal 
striatum (Featherstone et al. 2007) in GD17 treated rats, to which our 
observation lends support. A decrease in striatal weight may be of significant 
interest in this model, as it is hypothesised that behaviours and key functions 
including reversal learning (Ragozzino 2003; Ragozzino et al. 2002a; 
Ragozzino et al. 2002b) and attentional processing (Rogers et al. 2001) are 
dependent on neural circuits involving the striatum. In contrast, whilst it is 
known that some structural alterations are observed in the hippocampi of rats 
reared in social isolation including reduced levels of synaptophysin (Varty et 
al. 1999) and altered dendritic properties in  the pyramidal cells (Silva-Gomez 
et al. 2003), the effect of isolation rearing on overall hippocampal volume has 
produced both reductions (Fabricius et al. 2010) and a lack of significant 
changes (Schubert et al. 2009). Our results are in line with the findings of 
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Schubert et al, as no effects on volume or weight were observed in the 
hippocampus or striatum due to isolation rearing. Indeed, the results presented 
by Fabricius et al displayed changes in hippocampal volume following 15 
weeks of isolation rearing, much longer than the period of single housing 
employed here. Interestingly, despite large (34%) MAM-induced reductions in 
hippocampal volume/weight, very few behavioural deficits occurred after 
MAM alone compared to the GH-Con group across the behavioural paradigms 
investigated. Previous work giving prenatal MAM on earlier gestational days 
(GD9-15) produces a much more severe reduction in brain weight and reduced 
prefrontal cortical and striatal volume, with little or no accompanying deficits 
in PPI, conditioned emotional freezing, or visual and spatial learning and 
memory (Jongen-Relo et al. 2004; Leng et al. 2005). These results indicate 
largely conserved cognitive function despite hippocampal abnormality. 
Consistent with this observation, ablation of discrete hippocampal regions has 
little or no effect on novel object discrimination (Lee et al. 2005; Sannino et al. 
2012), or PPI (Bast and Feldon 2003; Pouzet et al. 1999), and cytotoxic lesions 
to the hippocampal poles (sparing the intermediate region) do not impair 
incremental learning in the Morris Water Maze (Bast et al. 2009). It is 
interesting to note that the highly significant decrease in total brain mass, 
accompanied by a limited profile of behavioural deficits, due to MAM 
treatment here most closely mirrors those observed previously with earlier 
prenatal treatments (Jongen-Relo et al. 2004; Leng et al. 2005). This may 
suggest a problem with the time of MAM administration used here, or may 
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indicate that in Lister-Hooded rats a different profile of deficits may be 
associated with particular time points of MAM treatment. 
 
In contrast to the morphological findings, monoamine levels in the 
hippocampus and frontal cortex were largely unaltered in the main study. 
ANOVA revealed that there was a significant alteration in 5-HIAA 
concentration in the hippocampus of MAM-treatment animals, but this was the 
only significant effect once anomalies were removed from the data.  No effect 
of isolation rearing was seen on any monoamine level in either region tested. 
Reported results have varied, but isolation rearing has been shown to increase 
basal PFC dopamine (Jones et al. 1992), yet decrease DA turnover in the 
mPFC together with a decrease in basal serotonin turnover in the NAc 
(Heidbreder et al. 2000). Furthermore, other studies have found no change in 
basal 5-HT, DA or glutamate in the NAc (Howes et al. 2000), and no change in 
5-HT in the PFC (Dalley et al. 2002) in isolation reared rats compared to 
control. This lack of consensus on monoamine changes in isolates makes 
results herein difficult to conclusively interpret. In MAM-treated rats, some 
studies have shown increased hippocampal 5-HIAA levels in GD15 MAM 
(15mg/kg and above) treated rats which also had increased 5-HT levels in the 
cerebral hemispheres (Tamaru et al. 1988). Several groups have reported that 
MAM significantly effects dopamine signalling in the hippocampus (Lodge 
and Grace 2007; 2008; Tamaru et al. 1988), but this was not replicated in the 
current study. 
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The enduring impression obtained from these neuroanatomical results is that 
despite marked deficits in hippocampal formations due to prenatal MAM 
treatment, they did not translate to behavioural impairments, limiting the utility 
of this dual-hit model. 
 
One of the biggest issues encountered in this study was identifying the time of 
conception, and hence accurately administering MAM on GD17. Whilst the 
mating period can be determined, the start of gestation can only be predicted 
by the discovery of the vaginal plug in the cage bedding, which although 
possible, can be difficult. Even in the event of the plug being found, this often 
occurred during morning inspection of the cages around 8am; as the cages 
were last checked the night before at approximately 6pm there is a 14 hour 
window in which gestation could have started. When attempting to accurately 
administer a drug on GD17, a 14 hour difference in injection time (3.4% of the 
gestational period to this point) could highly influence outcome. This is 
evident since injection of MAM on GD15 (36-48 hours earlier than GD17), 
has a drastically different effect on pup neurodevelopment, physiology and 
behaviour after birth (Balduini et al. 1991; Jongen-Relo et al. 2004; Leng et al. 
2005). In order to counteract this problem in the pilot study, pregnant dams 
were sourced externally rather than bred internally, as this came with the 
guarantee of identical and specific gestational day across all dams. However, 
this adds further issues to the protocol, as consistency of genetic background, 
mating procedure and early gestational housing cannot be confirmed. 
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Furthermore, transportation of animals in early gestation may have adverse 
effects on the pups through maternal stress, potentially confounding results. 
 
2.4.1 Conclusion 
Taken individually, both of the studies presented above show interesting 
results towards the aim of combining two neurodevelopmental models of 
schizophrenia as a dual-KLW WUHDWPHQW WR SURGXFH D PRGHO RI µVFKL]RSKUHQLD-
OLNH¶ V\PSWRPV +RZHYHU a striking a lack of consistent changes in any 
behavioural paradigm across the two studies, and no reproducible additive or 
synergistic effect of combined treatment, severely undermine the protocol and 
must lead to the hypothesis in this chapter being rejected. In the LMA, NOD 
and PPI paradigms there were no deficits caused by isolation or MAM that 
were consistent in both studies, with an isolation-induced reduction in freezing 
in the CER paradigm the only deficit seen in both cohorts. In contrast, 
neuroanatomical changes were consistently seen after MAM treatment only. 
These anatomical changes were not accompanied by consistent behavioural 
alterations, and so the conclusion must be that an isolation-MAM dual-hit 
treatment is not an improved model for µschizophrenia-like¶ symptoms, and so 
will not be continued in this thesis. As a well-established model within the 
group, isolation rearing was continued as the basis for future dual-hit models, 
but with an alternative pharmacological challenge added in the place of 
prenatal MAM treatment (Chapter 3).  
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Chapter 3 
 
Combined Rearing in Social Isolation 
and Perinatal Phencyclidine Treatment 
DVD0RGHORIµ6FKL]RSKUHQLD-/LNH¶
Symptoms in the Rat 
Chapter 3 ± Isolation and Perinatal 
PCP 
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3.1 Introduction 
 
Following the conclusion drawn from the previous chapter to discontinue use 
of the gestational 0$0 PRGHO DQ DOWHUQDWLYH µGXDO-KLW¶ VWUDWHJ\ ZDV
developed to produce a more complete and robust animal model than isolation 
rearing alone. As outlined previously (see Chapter 1.3.3), administration of the 
NMDA receptor antagonist phencyclidine (PCP) has been used to model 
behavioural changes which resemble symptoms seen in schizophrenia by many 
other groups. In this chapter, perinatal exposure to PCP was combined with 
isolation rearing as an early-life adverse intervention that might elicit changes 
similar to those that could occur in schizophrenia development in humans. This 
SURJUDPPHRIUHVHDUFKLQWHQGVWRDVVHVVWKHSUHGLFWLYHYDOLGLW\RIDQHZµGXDO-
KLW¶ SUHFOLQLFDO PRGHO XVLQJ H[LVWLQJ antipsychotic and potentially novel 
compounds to treat schizophrenia. Since PCP treatment is during the perinatal 
period it avoids possible drug-drug interactions that could complicate 
interpretation of results in possible future reversal studies.  
The specific protocol for PCP administration was modelled on a method 
previously published (Liu et al. 2010; Wang et al. 2001; Wang et al. 2008), 
utilising subcutaneous drug injection on PNDs 7, 9 and 11 at a dose of 
10mg/kg. The theory was that this NMDA receptor antagonist treatment could 
cause a decrease in cortical GABAergic interneuron density as seen previously 
(McKibben et al. 2010; Radonjic et al. 2013), as well as alterations in gene 
expressions (Liu et al. 2010) and receptor densities (du Bois et al. 2009) that 
have validity to the pathology of schizophrenia. PCP was chosen over other 
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NMDA receptor antagonists, such as MK-801 which has been used previously 
by other groups (Ashby et al. 2010), due to its more extensive effects on 
GABAergic interneuron populations. Whilst MK-801 treatment mirrors that of 
PCP in reducing the number of PV-positive interneurons in the hippocampus, 
unlike PCP it does not have the same effect in the prefrontal cortex (Braun et 
al. 2007), where GABAergic interneuron loss has been seen in different groups 
of schizophrenia patients (Beasley and Reynolds 1997; Beasley et al. 2002). 
 
3.1.1 Hypothesis 
Considering the wealth of previous findings detailing the cognitive deficits 
induced in adult rats following isolation rearing and perinatal PCP treatment, 
combination treatment was hypothesised to produce a phenotype that displayed 
impairments in all behavioural paradigms assessed. Furthermore, based on the 
indication from the previous chapter that two treatments may have the potential 
to cause more marked deficits when used in combination, it was also 
hypothesised that an additive or synergistic effect of dual-hit treatment would 
be observed in some behavioural tests. Confirmation of this hypothesis would 
indicate a preclinical model with improved validity to schizophrenia in man. 
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3.2 Materials and Methods 
3.2.1 Animals 
Eight litters of three-day old, male, non-cross fostered Lister Hooded rat pups 
(Study 1 n=43, Study 2 n=43) were obtained from Charles River UK (CRUK, 
Margate, UK) accompanied by their natural mothers. On PND 7, pups were 
treated with phencyclidine hydrochloride (Sigma-Aldrich, Irvine, Scotland, 
UK) dissolved in saline (10mg/kg s.c.) or vehicle control (1ml/kg) following 
the protocol outlined previously (Wang et al. 2001). In order to avoid maternal 
rejection of the pups, hands were thoroughly washed and were rubbed in 
bedding material prior to handling individual pups. Photographic records of the 
pups were kept to avoid repeated individual marking. Pups were checked 
hourly following injection and returned to the nest if separated from the dam. 
This process was repeated on PND 9 and 11, with pups receiving the same 
drug treatment on each occasion. Further details of the perinatal PCP treatment 
procedure are attached (see Appendix). Pups were subsequently weaned on 
PND23 and housed in groups of 3-4 (32x51cm polycarbonate cages with metal 
grid lids) or in social isolation (25x42cm cages) to produce four treatment 
groups, with food and housing conditions as described in the previous chapter; 
group-housed control-treated (GH-Con), group-housed PCP-treated (GH-
PCP), isolated control-treated (Iso-Con), and isolated PCP-treated (Iso-PCP) 
(Table 3.1). 
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A 
Table 3.1 Table to show the perinatal drug treatment and post-weaning 
housing condition of each pup in (A) the pilot study, and (B) the main 
study. Also shown, the behavioural tests undertaken by each litter  
B 
GH Saline GH PCP Iso Saline Iso PCP
1 6 1 2 1 2
2 7 1 2 2 2
3 5 2 1 0 2 All rats performed
4 3 0 0 2 1 LMA, NOD,
5 6 2 2 1 1 PPI, MWM, and
6 6 1 2 2 1 PCP-induced LMA
7 5 2 1 1 1
8 5 1 2 1 1
GH Saline GH PCP Iso Saline Iso PCP
1 6 2 1 1 2
2 6 1 2 2 1
3 5 2 1 1 1 All rats performed
4 5 1 2 1 1 LMA, NOD, PPI
5 5 2 1 1 1 CER, MWM, and
6 5 1 2 1 1 PCP-induced LMA
7 4* 2 1 0 0
8 5 0 0 2 3
*One pup found dead on PND 8
Behaviours
Behaviours
Litter Assignments
Litter Assignments
Litter No of Pups
Litter No of Pups
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Behavioural testing in the LMA, NOD, PPI and CER paradigms was identical 
to that detailed previously (see Chapter 2.2) and took place following the 
timeline showing in Figure 3.1. In the second cohort, half of each treatment 
group were assigned to the CER and half to the MWM behavioural tests to 
assess two different cognitive domains. Rats did not perform both tasks as they 
require considerable training, which could impact on subsequent behaviour if 
performed in the same animals. Modifications were made to the MWM 
protocol outlined below, and an additional acute response to PCP challenge 
paradigm was added to the battery. 
 
3.2.2 Morris Water Maze Modifications 
In modification of the previous MWM protocol (see Chapter 2.2.6), the 
reversal protocol was extended in this study to be the same length as the 
learning period ± a 15 trial, 5 day protocol, following the same pseudo-random 
ordering as previously, to increase the available data. Probe 3, as described 
previously, was then performed at the cessation of reversal learning. An 
identical fourth probe test was conducted in the second cohort 60 h after probe 
3, to objectively assess whether the rats had successfully re-acquired the new 
rule.   
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Figure 3.1 ± Time stick representations of the PCP administration and behavioural 
testing protocols used in study 1 and study 2.  Protocols were identical until PND 78, 
where in study 2 the CER protocol was reinstated to the behavioural battery. 
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3.2.3 Hyperactivity in Response to Acute PCP Treatment in an Open Field 
The acute response to PCP-treatment was examined to assess any long-term 
changes in NMDA receptor function in the same open field Perspex chambers 
used in the initial locomotor and novel object discrimination tests. Rats were 
assigned in a pseudo-random manner to a different one of the 12 chambers 
used previously to ensure some contextual novelty, and testing took place 28 
days after initial exposure to the context. Rats were placed in the chamber for 
1h habituation, during which ambulations were measured by infra-red beam 
breaks as described previously. Following habituation, all rats received a single 
injection of phencyclidine hydrochloride (3.2mg/kg i.p.) dissolved in saline 
and were immediately returned to the test arena for a further 1h and ambulation 
recorded. 
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3. 3 Results 
3.3.1 Effect of isolation rearing and perinatal PCP on locomotor activity 
Study 1: Rats were assessed for neophobia to a novel arena by measuring 
locomotor activity in a closed environment. In keeping with previous results, 
rats exhibited gradual habitation to the novel arena such that RM ANOVA 
showed a significant main effect of time [F(11,418)=69.977, p<0.001] but no 
significant main effect of housing [F(1,38)=0.051, p=0.822] nor a main effect of 
PCP treatment [F(1,38)=3.376, p=0.074]. There were no significant interactions 
between any of the three factors analysed by RM ANOVA (Figure 3.2). Two-
way ANOVA analysis of the total locomotor activity across the entire protocol 
supported these findings, with no significant main effects of housing or PCP 
treatment, and no interaction. One rat which exhibited exploratory activity 
twice that of any other (more than two standard deviations from the mean) was 
removed from data analysis. 
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Figure 3.2 ± Progressive decrease in locomotor activity during 60 min exposure 
to a novel arena.  (A) Repeated-measures ANOVA showed a significant main effect 
of time [F(11,418)=69.977, p<0.001] but no significant main effect of isolation rearing 
(Iso) or perinatal PCP treatment (PCP, 10mg/kg s.c. on PND 7, 9, 11), compared with 
group-housed (GH) and vehicle treated (Con) controls respectively, on horizontal 
locomotor response in 5 min epochs (horizontal beam breaks, mean ±SEM, n=6-8) for 
1h. (B) Total cumulative activity counts (mean ±SEM) over the 1h trial showed no 
main effect of isolation rearing or perinatal PCP treatment, and no interaction between 
factors. 
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Study 2: Rats in all four treatment groups exhibited a progressive decrease in 
motor activity over time, reflecting habituation to the arena (Figure 3.3), and 
RM ANOVA analysis confirmed a significant main effect of time 
[F(11,429)=109.676, p<0.001]. A significant main effect of rearing condition was 
also observed [F(1,38)=7.893, p=0.008], with post-hoc data indicating that 
particularly later in the 60 min protocol, rats in the Iso-Con group displayed 
significantly elevated activity compared to GH-Con controls. There was no 
main effect of perinatal PCP treatment and no interactions between the factors 
over the timecourse. Two-way ANOVA analysis of the cumulative locomotor 
activity confirmed a significant main effect of isolation rearing [F(1,38)=8.537, 
p=0.0058], and no main effect of PCP treatment nor an interaction between the 
two factors. Post-hoc tests following ANOVA showed that Iso-Con rats were 
significantly more active that GH-Con rats across the 1 h protocol (p<0.05). 
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Figure 3.3 ± Isolation rearing caused a significant elevation in locomotor activity. 
Significant effect of isolation rearing (Iso), but not perinatal PCP treatment (PCP), 
compared to group-housed (GH) and vehicle-treated (Con) controls respectively, on 
the locomotor response to a novel arena for a 1h test period by RM ANOVA. (A) 
Activity counts per 5 minute time bin (mean ±SEM, n=10-12) were significantly 
affected by time [F(11,429)=109.676, p<0.001, RM ANOVA] and isolation rearing 
[F(1,39)=7.893, p=0.008], but not perinatal PCP treatment (10mg/kg s.c. on PND 7, 9, 
11) and there was no interaction. **p<0.01 *p<0.05 isolation vs. PCP-matched group-
housed control, ##p<0.01 isolation+PCP treatment vs. GH-Con absolute control group 
by Bonferroni post-hoc following ANOVA. (B) Total cumulative activity counts over 
the 1h test period (mean±SEM) were significantly affected by isolation rearing 
[F(1,38)=8.537, p=0.0058] with no main effect of PCP treatment nor a between-
treatment interaction. *p<0.05 isolation vs. PCP-matched group-housed control by 
Bonferroni post-hoc analysis following ANOVA. 
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3.3.2 Effect of isolation rearing and perinatal PCP on novel object 
discrimination 
Study 1: To examine the effect of treatment on visual recognition memory, 
behaviour was examined in a two-trial novel object discrimination task. As 
expected, rats preferentially explored the novel over the familiar object such 
that two-way ANOVA of the second, choice trial showed a significant main 
effect of object [F(1,36)=32.14, p<0.001] (Figure 3.4). Subsequent post-hoc 
analysis indicated that only GH-Con and GH-PCP groups (p<0.001 and 
p<0.01, respectively), spent significantly more time exploring the novel object, 
whilst Iso-Con and Iso-PCP groups were unable to differentiate the novel 
object over familiar. Further analysis revealed no significant effect of housing 
or PCP treatment, nor any interaction between the two, on the derived D1 
discrimination ratio (two-way ANOVA, data not shown). There was no 
significant main effect of isolation rearing, prenatal MAM treatment, or of 
NOD trial on total object exploration (object 1 + object 2) by three way 
ANOVA (Figure 3.4B). 
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Figure 3.4 ± Isolation rearing-induced impairment in visual reference 
memory in the novel object discrimination task. Group-housed rats (GH) 
spent significantly more time exploring the novel object than familiar (A) (s, 
mean±SEM, n=10-12) compared to isolation-reared controls (Iso), irrespective 
of perinatal PCP (PCP, 10mg/kg s.c., on PND 7, 9, 11) or saline (Con) 
treatment, during the second choice trial of a two-trial novel object 
discrimination task  [Bonferroni post-hoc analysis following main effect of 
object by two-way ANOVA, F(1,36)=32.14, p<0.001] ***p<0.001, **p<0.01 vs. 
novel object by Bonferroni post hoc analysis following ANOVA. (B) No 
significant main effect of isolation rearing, prenatal MAM treatment, or of 
NOD trial on total object exploration (object 1 + object 2) by three way 
ANOVA. 
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Study 2: Overall, rats preferentially explored the novel object during the choice 
trial of the NOD task [F(1,37)=25.89, p<0.0001, ANOVA], which was 
particularly notable in GH-Con and GH-PCP rats, with post-hoc analysis 
confirming that only these groups (p<0.05 and p<0.001, respectively) and not 
the Iso-Con or Iso-PCP rats explored the novel significantly more than the 
familiar object (Figure 3.5A). A significant main effect of treatment was also 
seen [F(3,37)=3.514, p=0.0245]. In support of this, the derived D1 
discrimination ratio was significantly affected by housing by two-way 
ANOVA [F(1,38)=5.380, p=0.0258], but there was no effect of PCP treatment, 
no interaction between the two factors, and no post-hoc significance observed 
(Figure 3.5B). There was no significant main effect of isolation rearing, 
prenatal MAM treatment, or of NOD trial on total object exploration (object 1 
+ object 2) by three way ANOVA, despite a trend towards increased 
exploration in isolation reared rats in both trial 1 and trial 2 (Figure 3.5C). 
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Figure 3.5 ± Isolation rearing-induced impairment in visual reference memory in 
the novel object discrimination task. (A) Group-housed rats (GH) spent 
significantly more time exploring the novel object than familiar (s, mean±SEM, n=10-
11) compared to isolation-reared controls (Iso), irrespective of perinatal PCP (PCP, 
10mg/kg s.c., on PND 7, 9, 11) or saline (Con) treatment, during the second choice 
trial of a two-trial novel object discrimination task  [Bonferroni post-hoc analysis 
following main effect of object F(1,37)=25.89, p<0.0001 and treatment group 
F(3,37)=3.514, p=0.0245 by two-way ANOVA] ***p<0.001, **p<0.01 vs. novel object 
by Bonferroni post hoc analysis following ANOVA. (B) Two-way ANOVA 
confirmed a significant main effect of isolation rearing [F(1,38)=5.380, p=0.0258] on the 
derived discrimination ratio (mean±SEM, n=10-11), with no main effect of PCP 
treatment, and no between factor interaction. (C) No significant main effect of 
isolation rearing, prenatal MAM treatment, or of NOD trial on total object exploration 
(object 1 + object 2) by three way ANOVA.  
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3.3.3 Effect of isolation rearing and perinatal PCP on prepulse inhibition of 
acoustic startle 
Study 1: Behaviour was examined in a prepulse inhibition of acoustic startle 
test to evaluate changes in sensorimotor gating, thought to map preattentional 
processing cognitive domain in man (Young et al. 2009). As expected, 
exposure of rats to a sub-threshold acoustic pulse produced a significant 
attenuation of the acoustic startle response which increased with prepulse 
intensity (Figure 3.6). RM ANOVA of prepulse inhibition revealed a 
significant main effect of prepulse [F(2,78)=149.916, p<0.001] and of PCP 
treatment [F(1,39)=4.730, p=0.036] but no main effect of housing [F(1,39)=0.672, 
p=0.417] and no between-factor interactions. No post-hoc significance 
occurred. Observed effects were not due to an alteration in basal startle 
response or habituation of the groups to the 120dB startle tone, as two-way 
ANOVA analyses of both of these parameters revealed no significant main 
effect of housing or PCP treatment, and no interactions between the two. 
 
Study 2: Prepulse inhibition was increased at ascending prepulse levels but 
was decreased by isolation rearing and PCP treatment, supported by RM 
ANOVA [significant main effects of prepulse level F(2,78)=68.789, p<0.001, 
isolation rearing F(1,39)=4.372, p=0.043, and PCP F(1,39)=7.429, p=0.010]. Post-
hoc significance was observed between the GH-Con and Iso-PCP dual-hit 
treatment groups only at 76dB (p<0.05) and 84dB (p<0.05) prepulse levels 
(Figure 3.7).  Two-way ANOVA showed there were no effects of isolation 
rearing or PCP treatment on initial startle amplitude or habituation to the 
120dB tone, and no between-factor interaction (data not shown).  
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Figure 3.6 ± Prepulse inhibition of acoustic startle was significantly affected by 
perinatal PCP treatment. A significant effect of perinatal PCP treatment (PCP, 
10mg/kg s.c. on PND 7, 9, 11), but not isolation rearing (Iso), compared with group-
housed (GH) and vehicle treated (Con) controls, on the percentage prepulse inhibition 
to a 120dB startle eliciting tone (mean±SEM, n=10-12) [main effects of perinatal PCP 
F(1,78)=11.17, p=0.001, and prepulse level [F(2,78)=149.916, p<0.001] by RM ANOVA]. 
There was no between factor interaction, and no post-hoc significance observed. 
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Figure 3.7 ± Prepulse inhibition of the acoustic startle response was significantly 
reduced by combined isolation rearing and perinatal PCP treatment. Significant 
main effects of isolation rearing (Iso) and perinatal PCP treatment (PCP, 10mg/kg s.c. 
on PND 7, 9, 11), compared with group-housed (GH) and vehicle-treated (Con) 
controls, on the percentage prepulse inhibition of acoustic startle to a 120dB tone 
(mean±SEM, n=10-12). [main effects of prepulse level F(2,78)=68.789, p<0.001, 
isolation rearing F(1,39)=4.372, p=0.043, and perinatal PCP treatment F(1,39)=7.429, 
p=0.010 by RM ANOVA]. #p<0.05 isolation+PCP treatment vs. GH-Con absolute 
control by Bonferroni post-hoc analysis following ANOVA. 
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3.3.4 Effect of isolation rearing and perinatal PCP on the conditioned 
emotional response 
Study 2: To examine the impact of the early-life intervention on associative 
learning, contextual and conditioned emotional memory processes involving 
input from the hippocampus and amygdala were recorded in a conditioned 
emotional response paradigm (Woods et al. 2012). Freezing responses were 
reduced between the 24 and 48h time points, but were restored by presentation 
of the CS alone. Freezing responses were decreased in isolates at all time 
points, regardless of subsequent PCP treatment, such that two-way ANOVA 
revealed a significant main effect of isolation rearing at 24h [F(1,38)=23.52, 
p<0.0001] and 48h [F(1,38)=6.488, p=0.0150] post-conditioning, and following 
representation of the CS alone [F(1,37)=22.35, p<0.0001]. Bonferroni post-hoc 
analysis revealed that the Iso-Con and the Iso-PCP treatment groups froze 
significantly less than their group-housed counterparts (GH-Con and GH-PCP, 
respectively) at both the 24h post-conditioning time point (p<0.05 and 
p<0.001) and following presentation of the conditioned stimuli alone (p<0.01 
and p<0.05). The Iso-PCP combination group froze significantly less than the 
GH-Con absolute control group at all three time points (24h: p<0.001, 48h: 
p<0.05, Post-CS: p<0.001). Additionally, a main effect of perinatal PCP 
treatment was observed following CS presentation [F(1,37)=8.654, p=0.0056], 
but there were no post-hoc effects of perinatal PCP treatment alone. No 
isolation x PCP treatment interaction was observed. (Figure 3.8). 
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Figure 3.8 ± Significant reduction in freezing time in a conditioned emotional 
response paradigm by isolation reared (Iso) compared to group-housed (GH) rats, 
regardless of perinatal PCP treatment (PCP) or vehicle control (Con). Two-way 
ANOVA revealed a significant main effect of isolation rearing on freezing time 
(mean±SEM, n=10-12) at 24h [F(1,28)=23.52, p<0.0001] and 48h [F(1,38)=6.488, 
p=0.0150] post-conditioning of an aversive footshock (US) and a paired light-sound 
tone (CS), and following re-presentation of the CS alone (Post-CS) [F(1,37)=22.35, 
p<0.0001]. A significant main effect of perinatal PCP treatment (10mg/kg, s.c. on 
post-natal days 7, 9 and 11) was observed Post-CS only [F(1,37)=8.654, p=0.0056], 
with no isolation x PCP interaction observed at any time.  **p<0.01 *p<0.05 isolation 
vs. group-housing, ###p<0.001 #p<0.05 isolation+PCP vs. group-housed control-treated 
by Bonferroni post-hoc analysis following ANOVA. 
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3.3.5 Effect of isolation rearing and perinatal PCP on Morris water maze 
performance 
Study 1: Irrespective of treatment, all four groups of rats progressively 
decreased their latency to find the platform throughout the 15 trial acquisition 
phase, reflecting intact visuo-spatial learning. This was supported by RM 
ANOVA analysis, showing a highly significant main effect of trial 
[F(14,546)=27.132, p<0.001], indicating that all rats successfully learned the task 
at an equivalent rate. ANOVA also revealed that the effect of housing just 
failed to reach significance [F(1,39)=3.412, p=0.072], and there was no 
significant main effect of PCP treatment [F(1,39)=0.239, p=0.628] nor any 
interaction (Figure 3.9).  
 
Two-way ANOVA analysis of Probe 1, immediately following the completion 
of the learning phase in trial 15, revealed that the percentage of time spent 
H[SORULQJ WKH ³FRUUHFW´ TXDGUDQW GXULQJ WKH V WHVW ZDV QRW VLJQLILFDQWO\
affected by perinatal PCP treatment [F(1,39)=0.085, p=0.7715] or rearing in 
isolation [F(1,39)=3.144, p=0.084], and there was no interaction between the 
two, confirming that the degree of learning after 15 trials was the same in all 
treatment groups (Figure 3.10A). Similarly, the time spent in the correct 
quadrant during Probe 2 performed 60 h later was unaltered by perinatal PCP 
[F(1,39)=0.1533, p=0.6976] or isolation rearing [F(1,39)=2.292, p=0.1381] and 
once again there was no interaction (Figure 3.10B).  
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Figure 3.9 ± Acquisition of the Morris Water Maze task was not altered by 
isolation rearing or perinatal PCP treatment. There were no main effects  of 
isolation rearing (Iso) or perinatal PCP treatment (PCP, 10mg/kg s.c., on PND 7, 9, 
11), either alone or in combination, compared with group-housed (GH) and vehicle-
treated (Con) controls, on latency to find a hidden platform in the Morris Water Maze 
during a 15 trial learning period (s, mean±SEM, n=10-12). Significant main effect of 
trial [F(14,546)=27.132, p<0.001], but not of housing [F(1,585)=9.18, p=0.003], or PCP 
[F(1,39)=0.239, p=0.628] by RM ANOVA, reflecting a successful learning of the task 
by all rats. 
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Figure 3.10 ± Acquisition and retention of the Morris Water Maze task was not 
altered by isolation rearing or perinatal PCP treatment. There was no main effect 
of isolation rearing (Iso) or perinatal PCP treatment (PCP, 10mg/kg s.c., on PND 7, 9, 
11), either alone or in combination, compared with group-housed (GH) and vehicle-
WUHDWHG&RQFRQWUROVRQ WKHSHUFHQWDJHWLPHVSHQW LQ WKH³FRUUHFW´TXDGUDQW LQ$
Probe 1, and (B) Probe 2 (Mean Percentage ±SEM, n=10-12). In neither probe 1 nor 
probe 2 was a significant effect of housing or perinatal PCP treatment seen, nor was 
there an interaction between the two factors by two-way ANOVA. 
  
Chapter 3 Ȃ Isolation and Perinatal PCP 
- 129 - 
 
Unlike previously (see Chapter 2.3.5), RM ANOVA analysis showed a highly 
significant main effect of trial on latency to find the platform in the reversal 
phase of the protocol [F(14,546)=4.617, p<0.001], demonstrating that re-learning 
a new strategy as a result of a rule change occurred. There was no main effect 
of perinatal PCP treatment or isolation rearing on escape latency by RM 
ANOVA, with no observed interaction between any factors (Figure 3.11).  
No between-group differences were observed due to PCP [F(1,39)=2.337, 
p=0.1344] or housing [F(1,39)=0.3378, p=0.5644] on time spent in the Platform 
Ring during Probe 3 by two-way ANOVA, and there was no interaction. 
Similarly, two-way ANOVA analysis of the time spent in the previously 
correct quadrant revealed no significant main effect of housing [F(1,39)=0.76, 
p=0.3869], or  perinatal PCP treatment [F(1,39)=4.039, p=0.0514], and there was 
no interaction between the two [F(1,39)=0.4006, p=0.5304] (Figure 3.12).  
The mean latency to locate the platform consistently fell across the 3 trials 
within each test day for rats in the GH-Con group. Further analysis was 
performed to establish any difference in reversal learning strategy. The 
difference between the escape latency in trials 1 and 3 of each reversal learning 
day was calculated and compared between groups by three-way ANOVA. This 
analysis revealed significant main effects of isolation rearing [F(1,195)=6.71, 
p=0.010] and perinatal PCP treatment [F(1,195)=6.54, p=0.011], but no main 
effect of day, and no interaction between any parameters (Figure 3.13). 
Retrospective utilisation of this method on the main learning phase of the 
experiment revealed a significant main effect of day [F(4,195)=3.69, p=0.006], 
but no comparable main effect of housing or PCP treatment (data not shown). 
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Figure 3.11 ± Reversal learning in the Morris Water Maze task was unaffected 
by isolation rearing or perinatal PCP treatment. There was no main effect of 
isolation rearing (Iso) perinatal PCP treatment (PCP, 10mg/kg s.c., on PND 7, 9, 11), 
either alone or in combination, compared with group-housed (GH) and vehicle-treated 
(Con) controls, on latency to find a hidden platform in the Morris Water Maze 
following a 15 trial reversal learning period (s, mean±SEM, n=10-12). Repeated 
measures ANOVA revealed a significant main effect of trial only [F(14,585)=3.57, 
p<0.001], reflecting a significant improvement in acquisition of the task. 
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Figure 3.12 ± Acquisition of a new rule and extinction of a previously correct rule 
was unaffected by isolation rearing or perinatal PCP treatment in the Morris 
Water Maze protocol. There was no main effect of isolation rearing (Iso) and 
perinatal PCP treatment (PCP, 10mg/kg s.c., on PND 7, 9, 11), either alone or in 
combination, compared with group-housed (GH) and vehicle-treated (Con) controls, 
on the percentage time spent in (A) the Platform Ring area and (B) the previously 
³FRUUHFW´TXDGUDQWGXULQJSUREH0HDQ3HUFHQWDJH6(0 n=10-12). In neither A, 
nor B, was a significant effect of housing or perinatal PCP treatment seen, nor was 
there an interaction between the two. 
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Figure 3.13 ± A change in reversal learning strategy due to isolation rearing and 
perinatal PCP treatment in the Morris Water Maze protocol. Cumulative data 
UHSUHVHQWDWLRQ RI WKH ³ZLWKLQ-GD\´ LPSURYHPHQWV LQ HVFDSH ODWHQF\ V PHDQ±SEM, 
n=10-12)  during each reversal learning day of the Morris Water Maze protocol, 
comparing the effect of isolation rearing (Iso) and perinatal PCP treatment (PCP, 
10mg/kg s.c., on PND 7, 9, 11), alone and in combination, with group-housed (GH) 
and vehicle-treated (Con) controls. Three-way ANOVA analysis of the raw data 
revealed a significant effect of both isolation [F(1,195)=6.71, p=0.010] and perinatal 
PCP treatment [F(1,195)=6.54, p=0.011] on within-day improvements, but no effect of 
test day. p<0.05 perinatal PCP vs rearing-matched vehicle-treated control, ###p<0.001 
#p<0.05 isolation+PCP vs. GH-Con absolute control, Bonferroni post-hoc analysis 
following ANOVA. 
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Study 2: Initial observation demonstrated that the escape latencies in all groups 
progressively decreased to a comparable extent throughout the 15 trial learning 
period of this MWM experiment, showing successful task acquisition, 
supported by repeated measures ANOVA which showed a significant main 
effect of trial on escape latency [F(14,546)=15.511, p<0.001] (Figure 3.14). 
Similar to the previous cohort, there was no significant main effect of housing 
[F(1,39)=0.315, p=0.578], nor any significant main effect of perinatal PCP 
treatment [F(1,39)=3.266, p=0.078] and no interaction.  
 
In probe 1, PCP-treated animals performed no worse than saline treated rats; 
but ANOVA revealed a significant main effect of housing [F(1,38)=4.399, 
p=0.0427] and a significant interaction between isolation and PCP treatment 
[F(1,38)=5.527, p=0.024]. No post-hoc significance was observed (Figure 
3.15A). 
 
In contrast, in Probe 2 performed 60 h later, two-way ANOVA analysis 
revealed no significant effect of isolation rearing, or perinatal PCP treatment 
on time spent exploring the correct maze quadrant, nor was there an interaction 
between the two (Figure 3.15B). 
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Figure 3.14 ± Acquisition of the Morris Water Maze task was not altered by 
isolation rearing or perinatal PCP treatment. There were no main effects  of 
isolation rearing (Iso) or perinatal PCP treatment (PCP, 10mg/kg s.c., on PND 7, 9, 
11), both alone and in combination, compared with group-housed (GH) and vehicle-
treated (Con) controls, on latency to find a hidden platform in the Morris Water Maze 
during a 15 trial learning period (s, mean±SEM, n=10-11). Significant main effect of 
trial only [F(14,546)=15.511, p<0.001] with no effect of isolation rearing or PCP 
treatment by repeated measures ANOVA. 
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Figure 3.15 ± Comparison of the effect of isolation rearing (Iso) and perinatal PCP 
treatment (PCP, 10mg/kg s.c., on PND 7, 9, 11), both alone and in combination, 
compared with group-housed (GH) and vehicle-treated (Con) controls, on the 
percentage tLPHVSHQWLQWKH³FRUUHFW´TXDGUDQWLQ$3UREHDQG%3UREH0HDQ
Percentage ±SEM, n=10-12). (A) Two-way ANOVA analysis revealed a significant 
main effect of housing [F(1,38)=4.399, p=0.0427] and a significant interaction between 
isolation and PCP treatment [F(1,38)=5.527, p=0.024], but no effect of PCP treatment 
alone in Probe 1, and no post-hoc significance was observed. (B) No main effect of 
isolation rearing or perinatal PCP treatment, nor a between factor interaction, was 
observed during Probe 2. 
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As in Study 1, RM ANOVA analysis of the reversal learning protocol revealed 
a significant main effect of trial [F(14,546)=3.871, p<0.001], indicating 
acquisition of the new rule. However, RM ANOVA also revealed significant 
main effects of housing [F(1,39)=5.774, p=0.021] and PCP treatment 
[F(1,39)=5.234, p=0.028], but no interaction was seen between any factor 
(Figure 3.16).  
 
Two-way ANOVA analysis of performance in Probe 3 revealed a significant 
HIIHFW RI 3&3 WUHDWPHQW LQ H[SORUDWLRQ RI WKH ³SODWIRUP ULQJ´ DUHD
[F(1,38)=4.299, p=0.045], but no post-hoc significance, no significant main 
effect of isolation rearing, and no interaction between the two factors was 
observed (Figure 3.17B). Further ANOVA analysis showed that neither PCP 
treatment nor isolation rearing significantly affected the amount of time spent 
exploring the previously correct quadrant during Probe 3, and there was no 
interaction (Figure 3.17A). 
 
Similarly in Probe 4, no effect of isolation rearing or PCP treatment was 
observed on the exploration of the previously correct quadrant (Figure 3.17D). 
It was also revealed that there were no significant effects of isolation or PCP, 
nor was there an interaction between the two, on exploration of the platform 
ring in Probe 4 (Figure 3.17C). 
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Figure 3.16 ± Reversal learning in the Morris Water Maze protocol was 
significantly altered by isolation rearing and perinatal PCP treatment. 
Comparison of the effect of isolation rearing (Iso) and perinatal PCP treatment (PCP, 
10mg/kg s.c., on PND 7, 9, 11), both alone and in combination, compared with group-
housed (GH) and vehicle-treated (Con) controls, on latency to find a hidden platform 
in the Morris Water Maze following a 15 trial reversal learning period (s, mean±SEM, 
n=10-12). RM ANOVA revealed significant main effects of trial [F(14,546)=3.871, 
p<0.001], housing [F(1,39)=5.774, p=0.021], and PCP treatment [F(1,39)=5.234, 
p=0.028], but no interaction between any factor. p<0.05 PCP treatment vs. rearing-
matched vehicle-treated control by Bonferroni post-hoc analysis following ANOVA. 
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Figure 3.17 - Comparison of the effect of isolation rearing (Iso) and perinatal PCP 
treatment (PCP, 10mg/kg s.c., on PND 7, 9, 11), both alone and in combination, 
compared with group-housed (GH) and vehicle-treated (Con) controls, on the 
SHUFHQWDJH WLPH VSHQW LQ $ WKH SUHYLRXVO\ ³FRUUHFW´ TXDGUDQW 0HDQ 3HUFHQWDJH
±SEM, n=10-11)  and (B) the Platform Ring area (s, mean±SEM) during Probe 3, and 
the same arenas during Probe 4 (C and D, respectively). Note a significant effect of 
perinatal PCP treatment on exploration of the Platform Ring area during Probe 3 
[F(1,38)=4.299, p=0.045] by two-way ANOVA (B), unaccompanied by post-hoc 
significance. No significant effect of isolation rearing or perinatal PCP treatment, or 
an interaction between the two, was seen in any other parameter.   
  
Chapter 3 Ȃ Isolation and Perinatal PCP 
- 139 - 
 
As in the previous study, within-day improvement in learning for each rat was 
calculated for both the acquisition and reversal periods of the protocol. Three-
way ANOVA revealed a significant main effect of day during the learning 
phase of the protocol [F(4,190)=4.07, p=0.003] but no significant main effect of 
isolation rearing or perinatal PCP treatment on within-day improvement (data 
not shown). Furthermore, during the reversal learning portion of the protocol, 
none of the three factors assessed by three-way ANOVA (day, isolation, PCP) 
revealed a significant effect on within-day improvement in escape latency 
(Figure 3.18). 
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Figure 3.18 - &XPXODWLYH GDWD UHSUHVHQWDWLRQ RI WKH ³ZLWKLQ-GD\´ LPSURYHPHQWV LQ
escape latency during each reversal learning day of the Morris Water Maze protocol.  
There was no main effect of isolation rearing (Iso) or perinatal PCP treatment (PCP, 
10mg/kg s.c., on PND 7, 9, 11), alone or in combination, compared with group-
housed (GH) and vehicle-WUHDWHG &RQ FRQWUROV RQ ³ZLWKLQ-GD\´ LPSURYHPHQWV LQ
escape latency (s, mean±SEM, n=10-11) by ANOVA. 
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3.3.6 Effect of isolation rearing and perinatal PCP on locomotor response to 
acute PCP treatment 
Study 1: To assess whether treatment caused hypersensitivity to acute NMDA 
receptor antagonist treatment, rats were tested in a locomotor response 
paradigm including an acute PCP challenge. As predicted, acute injection of 
PCP to all rats caused a spike in locomotor activity which decreased over time. 
RM ANOVA analysis of the 1 h period following injection revealed that this 
change in locomotion was significant [F(11,429)=35.834, p<0.001], and there 
was also a significant change due to early-life PCP treatment [F(1,39)=4.306, 
p=0.045], which reached post-hoc significance in one 5 min epoch (p<0.05). 
There was no main effect of housing [F(1,39)=1.146, p=0.291], but a significant 
interaction between time and perinatal PCP treatment was revealed 
[F(11,429)=2.353, p=0.008] (Figure 3.19). 
 
Study 2: RM ANOVA of activity for the 1h period following acute PCP 
administration revealed a significant main effect of time [F(11,429)=7.854, 
p<0.001], but no main effect of housing or PCP treatment. However a 
significant time x PCP interaction was observed [F(11,429)=2.174, p=0.015], and 
post-hoc analysis revealed a significant increase in locomotion in the Iso-PCP 
dual-hit group compared to GH-Con controls in the 5 mins immediately 
following PCP injection (p<0.05). RM ANOVA of just the first 10 min 
following PCP injection revealed that the significant main effects of time and 
time x PCP interaction were maintained, with an additional effect of perinatal 
PCP treatment also observed [F(1,39)=9.376, p=0.004] (Figure 3.20).  
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Figure 3.19 ± Perinatal treatment with phencyclidine causes locomotor 
sensitisation to acute treatment in adult rats. A significant main effect of perinatal 
PCP treatment (PCP, 10mg/kg s.c., on PND 7, 9, 11) on locomotor response in 5 min 
epochs (horizontal beam breaks, mean±SEM, n=10-12,) over 1h to an acute injection 
of PCP (3.2mg/kg, i.p.), compared to animals treated perinatally with vehicle control 
(Con), regardless of subsequent rearing in isolation (Iso) or social groups (GH) 
[F(1,39)=4.306, p=0.045] by RM ANOVA. There was also a significant main effect of 
time [F(11,429)=35.834, p<0.001] and a significant time x PCP interaction 
[F(11,429)=2.353, p=0.008]. Note three data points at -15 to -5 mins, showing baseline 
locomotor activity prior to acute PCP injection. p<0.05 perinatal PCP treatment vs. 
rearing-matched vehicle-treated control by Bonferroni post-hoc analysis following 
ANOVA. 
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Figure 3.20 - Comparison of the effect of isolation rearing (Iso) and perinatal PCP 
treatment (PCP, 10mg/kg s.c., on PND 7, 9, 11), both alone and in combination, with 
group-housed (GH) and vehicle-treated (Con) controls, on the locomotor response to 
acute PCP injection (3.2mg/kg, i.p.) in an enclosed arena crossed with infra-red beam 
for a 1h trial. Repeated measures ANOVA revealed a significant main effects of time 
only [F(11,429)=7.854, p<0.001],  but perinatal PCP treatment was shown to have a 
significant main effect during the first 10 minutes only [F(1,39)=9.376, p=0.004]. Note 
three data points at -15 to -5 mins, showing baseline locomotor activity prior to acute 
PCP injection. #p<0.05 isolation+PCP vs. GH-Con absolute control group by 
Bonferroni post-hoc analysis following ANOVA. 
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3.4 Discussion 
 
Based on these results, perinatal PCP administration in combination with 
isolation rearing could be suggested to be a XVHIXO µGXDO-KLW¶ WUHDWPHQW IRU
producing a WUDQVODWLRQDO PRGHO RI µVFKL]RSKUHQLD-OLNH¶ V\PSWRPV. The 
behavioural responses of rats in study 1 and 2 were again variable, but 
statistically significant effects were observed due to isolation rearing and/or 
perinatal PCP treatment in all of the paradigms assessed, so further 
investigation is warranted.  
  
In the locomotor activity assessment, whilst no change was observed in study 1 
as in the previous chapter, hyperlocomotion was seen in isolation-reared 
animals in study 2, irrespective of perinatal PCP treatment. It was expected 
that isolation rearing would induce an increase in locomotor activity in line 
with the majority of published work (detailed previously, see Chapter 1.3.1), 
but the lack of isolation-induced hyperlocomotion in the first cohort again 
highlights that these deficits are not 100% reproducible and an additive effect 
of dual-hit treatment is highly desirable. Acute PCP treatment has been 
consistently shown to cause increases in locomotor activity, however the effect 
of early-life treatment of rats with NMDA receptor antagonists has yielded 
varied results. Administration of PCP (10mg/kg, s.c.) to rat pups on PND 2-15 
caused elevated locomotor activity on PND 30 in one study (Zhang et al. 
2012b), but when Sprague-Dawley rats were treated on PND 7, 9 and 11, no 
baseline change in activity was seen on PND 42 compared to saline treated 
Chapter 3 Ȃ Isolation and Perinatal PCP 
- 145 - 
 
counterparts (Boctor and Ferguson 2010); nor was increased activity seen 
following perinatal treatment with another NMDA receptor antagonist, 
ketamine (20mg/kg) (Boctor and Ferguson 2010). Subchronic treatment with 
MK-801 (0.5mg/kg, twice daily from PND52-70) did not induce baseline 
locomotor activity increases in a novel arena in rats, either alone or in 
combination with social isolation (Ashby et al. 2010). Neonatal MK-801 
treatment (on PND 7, 9 and 11 at 0.2mg/kg) also did not affect locomotor 
activity in adulthood, but did produce hyperlocomotion when combined with 
isolation rearing (Lim et al. 2012). Thus, a lack of effect of perinatal PCP alone 
on locomotor activity is as expected, but an additive effect in combination with 
isolation rearing would have supported the recent findings of Lim et al.  
 
Conversely, perinatal PCP treatment caused significant increases in locomotor 
response to acute PCP treatment in both of the cohorts tested herein. Acute 
challenge with PCP was specifically added to the current study due to the 
wealth of literature demonstrating sensitisation to the locomotor response after 
prior exposure to an NMDA receptor antagonist. Many studies have shown 
that pre-treatment with PCP, and other NMDA receptor antagonists, causes 
increased sensitivity to subsequent acute treatment of amphetamine (Ashby et 
al. 2010; Beninger et al. 2010) and PCP (Boctor and Ferguson 2010) in rats, as 
well as acute PCP treatment in mice (Nakatani-Pawlak et al. 2009). Results 
herein support the phenomenon of sensitisation to PCP, demonstrating a 
significant increase in the acute PCP locomotor response in rats exposed 
perinatally to PCP in both cohorts.  Although the mechanistic basis of 
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sensitisation is unclear, importantly for the validity of the proposed new 
combination model, sensitization is regarded as a key index of psychosis, and 
movement and thought disorders, present in the human condition of 
schizophrenia (Robbins 1990), suggesting that the mechanisms responsible for 
sensitisation are preserved across species. Additionally, these results are the 
first to demonstrate that the sensitisation effect of perinatal NMDA receptor 
antagonists lasts 12 weeks post-treatment in rats. A consideration of the time 
point of behavioural testing post-PCP treatment is essential, as many previous 
studies have shown a transient nature of the deficits induced by NMDA 
receptor antagonism. Long-term effects of an early-life challenge are a vital 
component adding strength to the validity of any animal model, particularly 
considered in conjunction with the developmental aetiology theory of 
schizophrenia in humans. Therefore the results obtained in this study showing 
alterations in behaviour due to PCP on PND 98 are highly relevant.  
Whilst acute PCP-induced hyperlocomotion is an interesting and relevant 
behaviour to assess in these dual-hit animals, it has little continuing utility 
beyond a proof of concept. Whilst exacerbation of symptoms in schizophrenia 
patients exposed to NMDA receptor antagonists is a well-established 
phenomenon, the need for acute drug treatment to induce the behavioural 
phenotype makes the paradigm less desirable for the assessment of 
antipsychotic compounds in the future. Drug-drug interactions may confound 
any results observed, and are less representative of the desired clinical outcome 
of antipsychotic drugs (to reverse baseline behavioural deficits, not drug-
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induced deficits), and so this paradigm was not continued beyond this study 
now that the concept of PCP sensitisation has been proven. 
 
Of far greater utility, hence its addition to the battery of tests in study 2 of this 
chapter, is the conditioned emotional response paradigm. As discussed 
previously, this paradigm uniquely includes an emotional substrate, which is 
combined with classical Pavlovian conditioning to assess cognitive 
performance relevant to both contextual and conditioned emotional cognition 
and memory. Both isolation rearing and perinatal PCP treatment had highly 
significant effects on these forms of learning and memory. Decreased freezing 
was observed in the Iso-PCP dual-hit treatment group at all three time points of 
the protocol. Whilst all four of the treatment groups demonstrated a decay in 
freezing response from the 24 to 48 hour time points as would be expected 
from extinction, as well as a marked elevation in freezing upon re-presentation 
with the conditioned stimuli, it is notable that at each of the three time points 
analysed the freezing response was greatest in the GH-Con group, with GH-
PCP, Iso-Con and Iso-PCP groups all demonstrating decreased freezing to 
some extent. Based on work conducted over the past 15 years, a significant 
effect due to PCP treatment can be well justified. The neural circuits that 
underlie Pavlovian fear conditioning have come under great scrutiny and have 
been mapped (Maren 2001). In brief, conditioning relies strongly on activation 
of the hippocampus and the amygdala, and the molecular basis of this learning 
lies within activation of extracellular signalling-regulated kinases (ERKs) 
through NMDA receptors in the aforementioned regions (Athos et al. 2002; 
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Atkins et al. 1998; Coelho et al. 2013; Schafe et al. 2000). Hence, aberrant 
function of these receptors through treatment with NMDA receptor antagonists 
will alter the expected fear conditioning response (Bolton et al. 2012; Enomoto 
et al. 2005). Interestingly, although no significant interaction between housing 
and PCP treatment was seen, rats in the Iso-PCP group consistently froze less 
than those in either the GH-PCP or Iso-Con groups. From these results it is not 
possible to conclude that there was an additive effect of the two treatments, but 
the highly significant decrease in freezing between GH-Con and Iso-PCP 
animals could be utilised in future studies to aid the assessment of 
antipsychotic drugs. One major caveat of this, however, is the translational 
relevance of the CER paradigm to schizophrenia specifically. As behavioural 
tasks that rely on emotional processing and Pavlovian conditioning were not 
included in the MATRICs battery (Marder and Fenton 2004; Young et al. 
2009), the significance of positive results in the CER paradigm is much lower 
than if they were achieved in the PPI paradigm, for instance. 
 
Similar to the acute PCP locomotion test, in both cohorts prepulse inhibition of 
acoustic startle was significantly impaired by perinatal PCP treatment, without 
any accompanying changes in initial startle intensity or habituation to the 
120dB tone alone. The results here support previous work that PPI 
impairments in NMDA receptor antagonist-treated animals, following not only 
PND 7, 9, 11 PCP administration (Anastasio and Johnson 2008a; Wang et al. 
2001), but also after escalating and constant/sub-chronic treatment with PCP 
and MK-801 (Li et al. 2011b), and acute ketamine administration (Sabbagh et 
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al. 2012). Both the GH-PCP and Iso-Con groups herein exhibited marginally 
decreased PPI at all three analysed prepulse intensities in both cohorts which 
did not reach significance, whereas the Iso-PCP group had a significantly 
lower PPI response than GH-Con controls at two prepulse levels, i.e. a greater 
LPSDLUPHQWSHUKDSV VXJJHVWLQJDQDGGLWLYHHIIHFWRI WKH µGXDO-KLW¶ WUHDWPHQW
The robustness of PPI in preclinical models of schizophrenia-like symptoms, 
particularly isolation reared deficits, has been somewhat called into question 
with a growing body of negative results (Cilia et al. 2001; Fone and Porkess 
2008; McIntosh et al. 2013), so the fact that a significant effect of isolation 
rearing was only observed in the second of the two cohorts is not entirely 
surprising. However, that perinatal PCP treatment induced a deficit in both 
study 1 and 2, both in the presence (study 2) and absence (study 1) of a 
significant effect of isolation rearing, lends significant strength to this dual-hit 
model. The recent dual-hit model using isolation rearing and neonatal MK-801 
combined also identified a significant effect of combining treatments on PPI 
deficits (Lim et al. 2012), supporting the results observed here. Although no 
interaction was seen between the isolation and perinatal PCP treatments in 
either study, suggesting no synergistic effects occurred, combining these two 
treatments ensured that a significant effect of treatment was seen in both 
cohorts with post-hoc significance in the Iso-PCP group in one.  
 
In contrast to the PPI paradigm, results of the novel object discrimination task 
showed a highly significant impairment due to isolation rearing in both 
cohorts, in the absence of any effect due to perinatal PCP. As discussed in the 
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previous chapter, isolation rearing robustly and consistently produces deficits 
in novel object discrimination tasks similar to the one utilised in this study 
(Fone and Porkess 2008; McLean et al. 2010a), and so these results were as 
anticipated. Perhaps less expected, however, is the lack of any deficit induced 
by perinatal PCP treatment. Although the literature on the long-term effects of 
perinatal PCP treatment on visual learning and memory is sparse, evidence 
suggests that some PCP treatment protocols produce deficits in behaviour in 
non-spatial learning paradigm equivalent to the NOD paradigm used in mice 
(Hashimoto et al. 2005), as well as in visual reference memory in variations of 
a Morris Water Maze protocol (Andersen and Pouzet 2004; Sircar 2003). Most 
importantly, a recent paper utilising perinatal PCP treatment in Wistar rats, 
albeit at a dose higher than that used here (20mg/kg), did show PCP-induced 
deficits in novel object discrimination in adulthood (Redrobe et al. 2012). 
Whilst a lack of perinatal PCP-induced deficits in NOD does not support the 
aim of this study to produce additive effects of combined treatments (as has 
been seen in protocols using isolation rearing and neonatal MK-801 in 
combination (Lim et al. 2012)), the strong impairment in performance 
produced by isolation rearing here would prevent any additive effects being 
observed. Despite the reproducibility of the isolation-induced deficits in NOD, 
the translational relevance of the task must be considered. The task, recently 
extensively reviewed (Lyon et al. 2012), has many merits but also some 
drawbacks (see Chapter 1.2.3). The apparent lack of predictive validity the 
novel object discrimination task possesses is a major caveat. Whilst it has been 
shown to have some predictive validity (in so far as atypical antipsychotics 
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have greater efficacy in novel object tasks than their typical counterparts ± 
similar to the effects in humans (Keefe 2007)), compounds including 
galantamine (Noda et al. 2010) and donepezil (Kunitachi et al. 2009)  have 
produced strong reversals of NOD deficits, whilst producing little benefit on 
visual reference memory function in clinical trials (Buchanan et al. 2008; 
Keefe et al. 2008). This disparity between preclinical and clinical data is an 
important consideration when interpreting drug reversal of NOD deficits 
produced by dual-hit models of schizophrenia.  
 
Whilst learning and memory in the NOD paradigm was shown to be impaired 
by isolation rearing, results of the Morris Water Maze protocols showed that 
visual and spatial reference memory were less affected. Indeed, neither cohort 
demonstrated any deficits in the MWM protocol due to isolation rearing. 
Previously, deficits in MWM learning protocols due to isolation rearing have 
been noted (Hellemans et al. 2004; Lu et al. 2003), whereas others have 
demonstrated an improvement in both spatial learning and reversal in isolation-
reared rats compared to social controls, potentially through cholinergic 
mechanisms (Wongwitdecha and Marsden 1996a). Indeed, the results 
presented in the previous chapter showed no significant effects due to isolation 
rearing at any stage of the MWM protocol, so the outcome of these studies is 
not surprising and may suggest that isolation rearing is not a successful method 
for inducing deficits in spatial learning. 
As stated previously, deficits in visual reference memory in variations of a 
Morris Water Maze protocol have been shown due to perinatal PCP treatment 
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(Andersen and Pouzet 2004; Sircar 2003), and to some limited extent these 
results were replicated in the second cohort presented here. Although neither 
cohort demonstrated impairments in spatial learning due to perinatal PCP 
treatment, cohort 2 did suggest impaired reversal learning, with a significant 
PDLQHIIHFWRISHULQDWDO3&3RQVZLPWLPHLQWKH³SODWIRUPULQJ´DUHDLQ3UREH
3, but this failed to reach post-hoc significance. This is a fairly limited 
observation, however, considering the wealth of data that this paradigm 
produces, and that it was only evident in one of the two cohorts tested suggests 
it lacks the robustness for serious consideration as a deficit that may be 
targeted by putative antipsychotic compounds in future experiments. 
The most striking observation from the MWM protocols in this study was from 
the reversal stage of the first cohort, where despite no apparent deficit due to 
either treatment during acquisition, an alteration in re-learning profile was 
identified. Analysis of the within-day improvements in escape latency revealed 
significant main effects of housing and PCP treatment, with post-hoc tests 
indicating lower within day improvements in GH-PCP and Iso-PCP rats, 
suggesting impaired working memory processes. As there were no deficits 
seen in Probe 3 of this protocol, however, a compensatory learning mechanism 
must have been utilised to improve escape latencies as the experiment 
progressed, masking the within-day learning deficit from having a significant 
observable effect on reversal learning as a whole. However, the changes in 
reversal learning profile seen in study 1 were not repeated in study 2, meaning 
that there was no correlation between the significant results seen between the 
two cohorts, another serious caveat to using this protocol in future studies. 
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3.4.1 Conclusion 
7KLV QHZ µGXDO-KLW¶ PRGHO FRPELQHV HDUO\-life developmental adversity 
through isolation rearing, with perinatal glutamatergic dysfunction by 
administering phencyclidine at a high dose, both separate risk factors for 
schizophrenia development. These studies show that combined perturbations 
produce a range of behavioural deficits with translational salience to the human 
condition of schizophrenia, although the robustness of the impairments does 
not completely meet the aims of the study. Furthermore, the behavioural 
effects of isolation rearing alone are not as robust as expected, even with the 
known limitations of this model (Fone and Porkess 2008), highlighting the 
possible need for a successful combination model of schizophrenia. 
However, in all six of the behavioural paradigms examined, significant deficits 
were observed due to isolation rearing and/or PCP treatment in at least one 
cohort, and potential additive effects of the two treatments have been observed 
in PPI in the second cohort. These results provided enough support to continue 
evaluation the Iso-PCP model to examine reversal of the deficits with 
antipsychotic and novel therapeutic agents.  
Chapter 4 Ȃ Risperidone Challenge 
- 154 - 
 
 
Chapter 4 ± Risperidone Challenge 
 
 
Chapter 4 
 
Evaluating the Effect of Risperidone in 
the Iso-PCP Dual-Hit Model of 
µ6FKL]RSKUHQLD-/LNH¶6\PSWRPVLQWKH
Rat   
Chapter 4 Ȃ Risperidone Challenge 
- 155 - 
 
4.1 Introduction 
 
Risperidone is an atypical antipsychotic compound with high affinity and 
antagonist activity at 5-HT2A serotonin and D2/3 dopamine receptors (Shahid et 
al. 2009). Like many antipsychotic drugs it is relatively successful in the 
treatment of the positive symptoms of the disorder, however some evidence 
suggests efficacy in cognitive domains also (Bilder et al. 2002; Houthoofd et 
al. 2008). Preclinically, risperidone at relevant doses (0.1-1.0mg/kg) can 
produce marked improvement in a variety of behavioural paradigms with 
considerable face validity to the human condition, including in models and 
paradigms directly relevant to this study. Of particular note, the effect of 
risperidone in isolation-reared animals has been well-characterised, including 
ameliorating deficits in PPI (Cilia et al. 2001) and recognition memory 
(McIntosh et al. 2013), and reducing hyperlocomotion (Fabricius et al. 2011). 
Further work has also shown risperidone may be effective in ameliorating 
PCP-induced reversal learning deficits (McLean et al. 2010b), or preventing 
the induction of PPI and object recognition deficits and hyperlocomotion by 
PCP treatment (Anastasio and Johnson 2008a; McKibben et al. 2010). In rats 
treated perinatally with PCP (on PND 2, 6, 9, 12), chronic risperidone is also 
able to restore reduced glutathione levels and reverse alterations in antioxidant 
enzyme levels in a variety of brain structures including the hippocampus and 
cortex (Stojkovic et al. 2012). However, no previous studies have examined 
the effects of risperidone in a dual-hit model of schizophrenia-like symptoms.  
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4.1.1 Hypothesis 
Based on previous evidence it was hypothesised that risperidone would be 
effective in reversing behavioural deficits induced by dual-hit isolation rearing-
perinatal PCP treatment KHUHXSRQGHQRWHG³,3´ in rats at clinically relevant 
doses. However, as the dual-hit phenotype may have wider-ranging and 
differing deficits which have not previously been exposed to pharmacological 
challenge, the outcomes will be novel.  
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4.2 Materials and Methods 
4.2.1 Animals 
Three-day old, male, Lister-Hooded rat pups (n=48 from 8 litters in Study 1, 
n=50 from 5 litters in Study 2) were obtained from Charles River UK (CRUK, 
Margate, UK) accompanied by their natural dams, and underwent an early-life 
treatment protocol as described previously (see Chapter 3.2.1). In a change to 
earlier protocols, all animals treated perinatally with vehicle were subsequently 
housed in groups of 3/4 (GV, n=21 in Study 1, n=20 in Study 2), whereas all 
animals that received perinatal PCP were housed in isolation (IP, n=27 in 
Study 1, n=30 in Study 2). Rats were reared for forty days post-weaning in 
previously described ambient conditions (see Chapter 2.2.1). 
 
4.2.2 Drug Administration 
Risperidone (Sigma-Aldrich, Irvine, Scotland, UK) was dissolved in minimal 
amounts of 1 M HCl, brought to volume with 0.154 M saline and adjusted to 
pH 7 using 0.1 M NaOH. Rats were subdivided into risperidone treatment 
groups, with IP-reared rats receiving either vehicle control, low dose 
risperidone (Study 1: 0.2mg/kg, Study 2: 0.1mg/kg) or high dose risperidone 
(Study 1: 0.5mg/kg, Study 2: 0.2mg/kg), and group-housed, perinatal saline-
treated (GV) animals receiving either vehicle control or high dose risperidone 
only, creating five treatment groups as below. 
S1: GV-V (n=11), GV-R0.5 (n=10), IP-V (n=9), IP-R0.2 (n=9), IP-R0.5 (n=9).  
S2: GV-V (n=10), GV-R0.2 (n=10), IP-V (n=10), IP-R0.1 (n=10), IP-R0.2 
(n=10) (Table 4.1). 
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  Table 4.1 Table to show the perinatal drug treatment, post-weaning housing 
condition, and acute risperidone treatment of each pup in (A) study 1, and (B) 
study 2. Also shown, the behavioural tests undertaken by each litter. 
 
A
GV-V GV-R0.5 IP-V IP-R0.2 IP-R0.5
1 6 2 1 1 1 1
2 7 1 2 1 1 2
3 7 2 1 1 2 1 All animals performed
4 5 1 2 1 0 1 LMA, NOD,
5 5 2 1 1 1 0 PPI, CER
6 5 1 2 0 1 1 and MWM tests
7 5 2 1 1 0 1
8 4 0 0 1 2 1
9 4 0 0 2 1 1
B
GV-V GV-R0.2 IP-V IP-R0.1 IP-R0.2
1 10 2 2 2 2 2
2 10 2 2 2 2 2 All animals performed
3 10 2 2 2 2 2 LMA, NOD,
4 10 2 2 2 2 2 PPI and CER tests
5 10 2 2 2 2 2
Litter Assignments
Litter Assignments
BehavioursPup NumbersLitter
Litter Pup Numbers Behaviours
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Risperidone doses were selected based on literature showing efficacy in 
previous schizophrenia models whilst undertaking behavioural analysis, but 
without demonstrating significant sedative effects (Anastasio and Johnson 
2008a; McIntosh et al. 2013; McKibben et al. 2010; McLean et al. 2010b). 
Furthermore, acute risperidone treatment at 0.5mg/kg has been shown to 
achieve clinically relevant levels of D2 receptor occupancy in rats (65-80%) 
(Kapur et al. 2003). All treatments were administered by intraperitoneal 
injection (1 ml/kg), 30 min before the initiation of each behavioural test, 
except in the Morris Water Maze paradigm, when treatment was administered 
30 min before the first trial of each training day.  
 
4.2.3 Behavioural Testing and Statistical Analysis 
Behavioural testing took place following protocols described previously, with 
no alterations from the previous use (see Chapter 2.2 and 3.2), following the 
timeline shown in Figure 4.1. The method of statistical analyses for this study 
was also as previously, with all unbalanced data analysed using SPSS 
software. 
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Figure 4.1 - Timestick representation of the protocols used in study 1 and 2 
examining the effect of risperidone treatment (0.1, 0.2 and 0.5mg/kg, i.p.) on 
behaviour in the Iso-PCP dual-hit model of schizophrenia-like symptoms in rats. 
Protocol timings of study 1 and 2 were identical until the completion of the CER 
paradigm on PND78. In study 1, rats were then continued into the MWM protocol 
before completion of the experiment on PND99, whereas in study 2 the experiment 
was completed following the CER protocol with the final endpoint occurring on PND 
82.  
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4.3 Results 
4.3.1 Effect of risperidone on IP-rearing induced changes in locomotor activity 
Study 1: A progressive decrease in locomotion was seen during the 60 min 
protocol, reflecting habituation to the arena as seen previously. RM ANOVA 
revealed a highly significant main effect of time [F(11,462)=46.830, p<0.001] 
supporting this observation, with a marked reduction in activity in rats treated 
with risperidone, regardless of rearing condition. This was supported by a main 
effect of risperidone treatment by RM ANOVA [F(2,41)=30.995, p<0.001] and 
subsequent post-hoc analysis revealed highly significant locomotor reductions 
in GV-R0.5 and IP-R0.5 groups (p<0.05) compared to respective vehicle-
treated controls over the initial 40 minutes of the protocol. ANOVA also 
identified a significant IP-rearing x risperidone interaction [F(1,42)=4.089, 
p=0.049], but a significant main effect of IP-rearing was seen across the first 
20 min of the protocol only [F(1,42)=4.558, p=0.039] (Figure 4.2A). 
Two-way ANOVA of the total locomotor counts over the 1 h protocol 
supported the findings of RM ANOVA, with a significant main effect of 
risperidone [F(2,41)=30.995, p<0.001] and an IP-rearing x risperidone 
interaction [F(1,42)=4.089, p=0.049] (Figure 4.2B). Bonferroni post-hoc analysis 
notably revealed significant differences between the GV-V and GV-R0.5 
groups (p<0.001), and between the IP-V and IP-R0.5R groups (p<0.01). 
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Figure 4.2 ± Reduction in locomotor activity due to acute risperidone treatment 
in a 60 min LMA protocol. (A) Horizontal beam breaks (mean±SEM, n=9-11) 
decreased over a 60 min LMA protocol, demonstrating habituation, and were 
significantly reduced by acute risperidone treatment 30 min before testing (0.2mg/kg 
(R0.2) and 0.5mg/kg i.p. (R0.5)) compared with acute vehicle control (V) in IP-reared 
(IP) and group-housed, vehicle-treated (GV) rats. Main effects of time 
[F(11,462)=46.830, p<0.001] and risperidone [F(2,41)=30.995, p<0.001], plus IP-rearing x 
risperidone interaction [F(1,42)=4.089, p=0.049] by RM ANOVA. ***p<0.001 
**p<0.01 *p<0.05 risperidone vs vehicle control, p<0.05 IP-rearing vs. GV-control, 
###p<0.001 ##p<0.01 #p<0.05 IP-rearing+risperidone vs. GV-V absolute control by 
Bonferroni post-hoc following ANOVA.  
(B) Total cumulative horizontal beam breaks (mean±SEM, n=9-11) were significantly 
reduced by risperidone treatment [F(2,41)=30.995, p<0.001] with an IP-rearing x 
risperidone interaction observed [F(1,42)=4.089, p=0.049]. ***p<0.001 **p<0.01 
risperidone vs. rearing-matched vehicle-treated control, ##p<0.01 IP-
rearing+risperidone vs. GV-V absolute control by Bonferroni post-hoc following 
ANOVA. 
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Study 2: As previously, locomotor activity progressively decreased across the 
1 h protocol reflecting habituation, such that RM ANOVA revealed a highly 
significant main effect of  time [F(11,473)=86.840, p<0.001]. A decrease in 
horizontal beam breaks was again noted due to risperidone treatment, 
supported by ANOVA [F(2,43)=15.492, p<0.001] and post-hoc significance 
showing that both GV and IP rats treated with high dose, 0.2mg/kg risperidone 
recorded significantly fewer beam breaks than their respective saline-treated 
counterparts at numerous points throughout the protocol, most notably during 
the first 10 minutes of activity. A significant effect of IP-rearing was also 
observed [F(1,43)=6.375, p=0.015], as was a significant time x risperidone 
interaction [F(22,451)=2.066, p=0.003], but no post-hoc effects (Figure 
4.3AFigure ).  
Two-way ANOVA of total cumulative locomotor activity confirmed the 
significant main effects of risperidone treatment [F(2,43)=15.492, p<0.001] and 
IP-rearing [F(1,43)=6.375, p=0.015], as well as the IP-rearing x risperidone 
interaction [F(22,451)=2.066, p=0.003] (Figure 4.3B). Bonferroni post-hoc 
analysis identified between group differences between GV-V and GV-R0.2 
(p<0.05) and the IP-V and IP-R0.2 (p<0.05) groups. Two rats were excluded 
from analysis due to faults with the apparatus leading to incorrect data 
acquisition.   
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Figure 4.3 - Reduction in locomotor activity due to acute risperidone treatment 
in a 60 min LMA protocol.  A reduction in horizontal beam breaks (mean±SEM, 
n=9-10) due to acute 0.2mg/kg i.p. risperidone (R0.2), but not 0.1mg/kg (R0.1), 
regardless of previous dual-hit isolation rearing-perinatal PCP (IP) treatment or group-
housed perinatal vehicle (GV) treatment, over the 60 min time course of an LMA 
protocol, (A) supported by RM ANOVA [F(2,41)=15.492, p<0.001]. Also noted were a 
significant main effects of time [F(11,462)=86.840, p<0.001], and IP-rearing 
[F(1,42)=6.375, p=0.015], with a significant IP-rearing x risperidone interaction 
[F(22,451)=2.066, p=0.003] (RM ANOVA). ***p<0.001 **p<0.01 *p<0.05  risperidone 
treatment vs. rearing-matched vehicle control by Bonferroni post-hoc analysis 
following ANOVA.  
(B) Total cumulative horizontal beam breaks (mean±SEM, n=9-11) over 60 min 
confirmed a significant main effect of IP-rearing [F(1,43)=6.375, p=0.015], and a 
reduction by risperidone treatment [F(2,43)=15.492, p<0.001], with an IP-rearing x 
risperidone interaction observed  [F(22,451)=2.066, p=0.003]. *p<0.05 risperidone 
treatment vs. rearing-matched vehicle-treated controls, by Bonferroni post-hoc 
analysis following ANOVA.  
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4.3.2 Effect of risperidone on IP-rearing induced changes in NOD 
Study 1: As expected, rats in the GV-V group displayed in tact visual reference 
memory by exploring the novel over the familiar object in the second, choice 
trial of the NOD protocol. IP-V rats explored the two objects for similar 
amounts of time, reflecting impairment in this field of cognition. Bonferroni 
post-hoc analysis following a significant main effect of object [F(1,37)=16.95, 
p<0.001, two-way ANOVA], and an interaction between object and treatment 
[F(4,37)=2.700, p=0.0453], revealed a highly significant difference in 
exploration in GV-V rats (p<0.001), but not IP-V. Risperidone did not reverse 
the deficit, as no significant difference between exploration of the novel and 
familiar objects was noted in the IP-R0.2 or IP-R0.5 groups (p>0.05 for both). 
A reduction in discrimination was noted in GV animals treated with 0.5mg/kg 
risperidone (GV-R0.5), such that no significant difference between novel and 
familiar object exploration was observed (p>0.05) (Figure 4.4A). The 
discrimination ratio supported a change in exploration due to IP-rearing. A 
significant main effect of rearing condition was seen by two-way ANOVA 
[F(1,37)=5.113, p=0.030] (no post-hoc significance), with no effect of 
risperidone, and no between-factor interactions (Figure 4.4B).  A significant 
main effect of risperidone was seen on total exploration [F(2,43)=5.561, 
p=0.007], with no main effect of rearing, trial, and no between factor 
interaction. Bonferroni analysis revealed that GV and IP-reared rats receiving 
0.5mg/kg risperidone spent significantly less time exploring during Trial 1 
than vehicle counterparts (p<0.01 and p<0.05, respectively) (Figure 4.4C). The 
scores of six rats had to be excluded for failing to complete the task. 
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Figure 4.4 ± A significant impairment in novel object discrimination 
caused by IP-rearing was not reversed by risperidone (A) Group-housed, 
perinatal saline treated animals that received vehicle prior to NOD (GV-V) 
spent significantly longer exploring the novel than familiar object during the 
second choice trial of the NOD protocol by Bonferroni post-hoc following 
ANOVA (s, mean±SEM, n=9-11)   [treatment x object interaction, 
F(4,37)=2.700, p=0.0453]; this was not observed in group-housed, perinatal 
saline treated animals receiving 0.5mg/kg risperidone (GV-R0.5), isolation-
perinatal PCP reared animals given saline (IP-V), 0.2mg/kg risperidone (IP-
R0.2) or 0.5mg/kg risperidone (IP-R0.5) ***p<0.001 Novel vs. Familiar by 
Bonferroni post-hoc test following ANOVA. (B) D1 discrimination ratio of 
object exploration during the choice trial was significantly affected by IP-
rearing [F(1,37)=5.113, p=0.030, two-way ANOVA], with no significant effect 
of risperidone. (C) High dose risperidone significantly decreased total object 
exploration during the familiarisation trial [F(2,43)=5.561, p=0.007] with no 
effect of rearing condition ##p<0.01, #p<0.05 Risperidone vs. rearing-matched 
vehicle control 
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Study 2: Whilst animals in the GV-V group displayed in tact visual reference 
memory, clearly exploring the novel object more than familiar during the 
second, choice trial of the NOD paradigm, this was not the case for any of the 
other four groups, suggesting that IP-rearing impaired performance, and that 
0.2mg/kg risperidone had a negative effect in GV-reared rats. Following two-
way ANOVA (significant main effects of object [F(1,43)=25.93, p<0.001] and  
treatment group [F(4,43)=2.636, p=0.0469], but no object x treatment group 
interaction [F(4,43)=2.578, p=0.0508] (Figure 4.5A), Bonferroni post-hoc 
analysis of novel vs. familiar objects showed that there was a highly significant 
difference in exploration in the GV-V group alone (p<0.001). In contrast, 
analysis of the D1 discrimination ratio revealed no significant effect of IP-
rearing, risperidone treatment, nor an interaction between the two factors by 
two-way ANOVA, suggesting no impairment due to either IP-rearing or 
risperidone treatment (Figure 4.5B). Analysis of the total exploration time 
revealed significant main effects of trial [F(1,43)=4.646, p=0.037], and 
risperidone treatment [F(2,43)=7.401, p=0.002], but not of rearing condition and 
no interactions, by three way RM ANOVA. Post-hoc analysis revealed that a 
decrease in object exploration occurred in the familiarisation trial due to 
0.2mg/kg risperidone treatment in GV-reared animals only (Figure 4.5C). 
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Figure 4.5 - Impairment in novel object discrimination caused by IP-rearing was 
not reversed by risperidone treatment at 0.2 or 0.1mg/kg. (A)  GV-reared rats that 
received vehicle (GV-V) spent significantly longer exploring the novel than familiar 
object (s, mean±SEM, n=9-11) during the second, choice trial of the protocol by 
Bonferroni post-hoc following ANOVA, (significant main effect of object 
[F(1,43)=25.93, p<0.001], and of treatment group [F(4,43)=2.636, p=0.0469], but no 
interaction, ANOVA). GV-reared animals receiving 0.5mg/kg risperidone (GV-R0.5), 
or IP- reared animals receiving saline (IP-V), 0.2mg/kg risperidone i.p. (IP-R0.2) or 
0.5mg/kg risperidone i.p. (IP-R0.5) did not discriminate. ***p<0.001 Novel vs. 
Familiar by Bonferroni post-hoc following ANOVA. (B) The D1 discrimination ratio 
of object exploration during the second choice trial was not significantly affected by 
IP-rearing or risperidone treatment by two-way ANOVA, nor was there an interaction 
observed. (C) 0.2mg/kg risperidone caused a significant decrease in object exploration 
in GV-reared animals only, following significant overall main effects of risperidone 
treatment [F(1,43)=4.646, p=0.037] and trial [F(2,43)=7.401, p=0.002] by ANOVA. 
#p<0.05 Risperidone vs. rearing-matched vehicle control 
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 4.3.3 Effect of risperidone on IP-rearing induced changes in prepulse 
inhibition of acoustic startle 
Study 1: The startle response to the 120dB tone was attenuated by addition of a 
sub-threshold prepulse as previously in all treatment groups, with increasing 
prepulse intensity causing greater reductions in the startle amplitude, supported 
by a highly significant effect of prepulse by RM ANOVA [F(2,84)=95.562, 
p<0.001]. Although a significant main effect due to IP rearing [F(1,42)=4.656, 
p=0.037] and a significant IP-rearing x risperidone interaction [F(1,42)=50.53, 
p=0.030] were observed, this was due solely to elevation of PPI in GV-R0.5 
rats only, confirmed by Bonferroni post-hoc tests showing a significant 
increase in PPI of this group compared to GV-V controls at 76dB (p<0.01) and 
80dB (p<0.05) prepulse intensities. Furthermore, there was no main effect of 
risperidone [F(2,41)=2.916, p=0.065] (Figure 4.6). There was no main effect of 
IP-rearing or risperidone treatment on either initial startle response amplitude 
or habituation to the 120dB tone across the protocol, nor was there an 
interaction between the two subject factors by two-way ANOVA (data not 
shown).  
 
  
Chapter 4 Ȃ Risperidone Challenge 
- 170 - 
 
7 6 8 0 8 4
0
2 0
4 0
6 0
8 0 G V  -  V
G V  -  R 0 .5
IP  -  V
IP  -  R 0 .2
IP  -  R 0 .5
P re p u ls e  In te n s ity  (d B )
%
 
P
re
p
u
ls
e
 
In
h
ib
it
io
n
*
*
*

 
Figure 4.6 ± Attenuation of the acoustic startle response to 120dB tone by sub-
threshold prepulses was altered by IP-rearing in combination with acute 
risperidone treatment. Prepulse inhibition (mean percentage ±SEM, n=9-11) 
significantly increased with elevations in prepulse intensity [F(2,86)=95.562, p<0.001, 
RM ANOVA]. Group-housed, perinatal vehicle treated animals receiving 0.5mg/kg 
i.p. risperidone (GV-R0.5) had significantly higher PPI responses than their acute 
vehicle treated counterparts (GV-V) following a significant IP-rearing main effect 
[F(1,43)=4.656, p=0.037] and a rearing x risperidone interaction [F(1,43)=50.53, 
p=0.030], but no main effect of risperidone treatment alone. IP-reared rats receiving 
acute vehicle (IP-V), 0.2mg/kg i.p. risperidone (IP-R0.2) or 0.5mg/kg i.p. risperidone 
(IP-R0.5) performed comparably to control (GV-V) at all prepulse levels. **p<0.01 
*p<0.05 risperidone treatment vs. rearing-matched vehicle control, p<0.05 IP-rearing 
vs. risperidone treatment-matched GV control by Bonferroni post-hoc test following 
ANOVA.  
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Study 2: As previously, attenuation of the startle response by presentation of 
increasing prepulse intensities was observed, supported by RM ANOVA with 
a highly significant main effect of prepulse intensity [F(2,90)=125.129, 
p<0.001]. Despite a trend towards reduction in prepulse inhibition, ANOVA 
revealed no effect of IP-rearing [F(1,45)=0.512, p=0.478], but an observable 
increase in percentage PPI due to risperidone was supported by a significant 
main effect by RM ANOVA [F(2,45)=5.089, p=0.010] with Bonferroni post-hoc 
analysis confirming 0.2mg/kg risperidone caused a significant increase in PPI 
in IP-reared rats at the 76dB and 80dB prepulse levels. There were no 
interactions between any of the factors analysed (Figure 4.7). Two-way 
ANOVA analysis revealed no significant effects of IP-rearing or risperidone 
treatment on initial startle amplitude or habituation, with no interaction 
between the factors (data not shown). 
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Figure 4.7 ± Elevated prepulse inhibition of the acoustic startle response by 
risperidone pretreatment. Prepulse inhibition (mean percentage ±SEM, n=9-10) 
significantly increased with rising prepulse intensity [F(2,90)=125.129, p<0.001]. PPI 
was significantly elevated by acute 0.2mg/kg i.p. risperidone treatment 30 min prior to 
testing to isolation-reared, perinatal PCP-treated rats (IP-R0.2), but less so at 
0.1mg/kg to IP-reared rats (IP-R0.1) and 0.2mg/kg to GV-reared rats (GV-R0.2), 
compared to their acute vehicle-treated, rearing matched counterparts (IP-V and GV-
V, respectively). There was no effect of IP-rearing, nor an IP-rearing x risperidone 
interaction by RM ANOVA. **p<0.01 *p<0.05 risperidone treatment vs. rearing-
matched vehicle treated control by Bonferroni post-hoc test following ANOVA. 
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4.3.4 Effect of risperidone on IP-rearing induced changes in conditioned 
emotional response 
Study 1: Animals which had received 0.5mg/kg risperidone did not display 
normal exploratory behaviour when placed in the CER chamber and appeared 
sedated. A general decrease in exploratory activity caused the latency to cross 
the chamber partition to dramatically increase, supported by two-way ANOVA 
which revealed a very highly significant effect of risperidone treatment 
[F(2,41)=17.165, p<0.001], but no effect of IP-rearing and no interaction 
between the two factors (Figure 4.8A). Bonferroni post-hoc analysis showed 
that the route of this significance was specifically 0.5mg/kg risperidone 
treatment, which had a significantly increased entry latency compared to both 
saline and 0.2mg/kg risperidone treated animals (p<0.001).  
With subsequent chamber exposures, rats in all treatment groups froze with 
decreasing duration, reflecting extinction of contextual conditioning. Upon re-
presentation of the conditioned stimulus, freezing response was increased in all 
treatment groups, demonstrating successful acquisition of the cue-conditioning 
behaviour. During all testing phases, GV-V animals froze to a greater extent 
than all IP-rearing groups, replicating the IP-induced deficit seen previously 
(see Chapter 3.3.4). Two-way ANOVA supported this observation with highly 
significant effects of IP-rearing at 24h [F(1,42)=4.748, p=0.035] and 48h post-
conditioning [F(1,42)=10.683, p=0.002], and following re-presentation of the CS 
[F(1,42)=14.798, p<0.0001] (Figure 4.8B). Furthermore, freezing was decreased 
in group-housed animals that received 0.5mg/kg risperidone, reflected by a 
significant main effect of drug treatment at 24h [F(2,42)=4.101, p=0.024] and 
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48h post-conditioning [F(2,42)=4.504, p=0.017]. Significance was not reached 
following re-presentation of the CS alone, but a significant IP-rearing x 
risperidone interaction was observed at all three time points (24h: 
[F(1,42)=11.903, p=0.00], 48h: [F(1,42)=6.409, p=0.015], Post-CS: [F(1,42)=6.830, 
p=0.012]). Bonferroni post-hoc analysis confirmed the decreases in freezing in 
GV-R0.5 and all IP-reared rats (regardless of risperidone treatment), with 
significance seen between GV-V and all four other groups at 24 and 48h post-
training (p<0.01), and between GV-V and all IP-reared rats following re-
presentation of the CS at the end of the protocol (p<0.05, p<0.01, p<0.001).  
  .  
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Figure 4.8 ± see overleaf  
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Figure 4.8 ± An IP-rearing induced reduction in freezing response to contextual 
and conditioned fear in a conditioned emotional response protocol was not 
reversed by risperidone treatment. (A) The entry latency (s, mean±SEM, n=9-11) 
to the CER chamber was significantly increased due to 0.5mg/kg risperidone, 
regardless of rearing condition (significant main effect of risperidone [F(2,41)=17.165, 
p<0.001], two-way ANOVA). ***p<0.001 *p<0.05 risperidone vs. rearing-matched 
vehicle control, #p<0.05 IP-rearing+risperidone vs. GV-V absolute control by 
Bonferroni post-hoc test following ANOVA. 
(B) Freezing response (s, mean±SEM, n=9-11) was reduced by combined isolation 
rearing and perinatal PCP treatment (IP) compared to vehicle-treated group-housed 
animals (GV) at 24h [F(1,42)=4.748, p=0.035] and 48h [F(1,42)=10.683, p=0.002] post-
conditioning of an aversive footshock (US) and a paired light-sound tone (CS), and 
following re-presentation of the CS alone [F(1,42)=14.798, p<0.0001] by two-way 
ANOVA. 0.2mg/kg (R0.2) and 0.5mg/kg i.p. risperidone (R0.5) 30 minutes before 
conditioning also altered freezing at 24h [F(2,42)=4.101, p=0.024] and 48h post-
conditioning [F(2,42)=4.504, p=0.017] by ANOVA. An IP-rearing x risperidone 
interaction was also seen in all trials analysed (24h: [F(1,42)=11.903, p=0.00], 48h: 
[F(1,42)=6.409, p=0.015], Post-CS: [F(1,42)=6.830, p=0.012]). ***p<0.001 
**p<0.01risperidone vs. vehicle control, p p<0.01 IP-reared vs. GV-
controls, ###p<0.001 ##p<0.01 #p<0.05 IP-rearing+risperidone vs. absolute control GV-
V by Bonferroni post-hoc following ANOVA. 
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Study 2: With lower doses of risperidone, the level of sedation observed in the 
first study was not repeated. No between group differences were observed in 
latency to enter the CER chamber, supported by non-significant effects of IP 
rearing and risperidone treatment by two-way ANOVA (Figure 4.9A). As 
previously, decreased freezing was observed at 48h compared to 24h post-
training, with the response restored upon re-presentation of the CS, reflecting 
extinction of contextual conditioning and retention of cue-based conditioning. 
Freezing was markedly reduced by IP-rearing such that two-way ANOVA 
revealed significance at 24h [F(1,45)=30.089, p<0.001], 48h post-conditioning 
[F(1,45)=21.052, p<0.001] and following presentation of the CS alone 
[F(1,44)=9.047, p=0.004]. Bonferroni post-hoc analysis showed that IP-V rats 
froze significantly less than GV-V rats at all the time points analysed (24h 
p<0.01, 48h: p<0.001, Post-CS: p<0.001) (Figure 4.9B). Despite minor 
increases in freezing response following risperidone treatment, this was non-
significant by two-way ANOVA during all trials. However, ANOVA revealed 
a significant IP-rearing x risperidone interaction following presentation of the 
CS alone [F(1,45)=9.187, p=0.004], reflecting an IP-induced reduction in 
freezing that was partially restored by risperidone treatment, confirmed by a 
lack of post-hoc significance between GV-V and IP-R0.2 groups at the Post-
CS time point.  
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Figure 4.9 ± see overleaf  
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Figure 4.9 - An IP-rearing-induced reduction in freezing response to contextual 
and conditioned fear in a conditioned emotional response protocol is partially 
reversed by acute risperidone treatment. (A) The entry latency (s, mean±SEM, 
n=10) to the CER chamber prior to acquisition was not significantly affected by 
risperidone treatment or rearing condition, and there was no interaction.  
(B) Freezing response (s, mean±SEM, n=10) was reduced by isolation rearing and 
perinatal PCP treatment (IP) compared to vehicle-treated group-housed animals (GV) 
at 24h [F(1,45)=30.089, p<0.001, two-way ANOVA] and 48h post-conditioning 
[F(1,45)=21.052, p<0.001] of an aversive footshock (US) and a paired light-sound tone 
(CS), and following re-presentation of the CS alone [F(1,44)=9.047, p=0.004]. There 
was no significant main effect of acute risperidone treatment at 0.1mg/kg i.p. (R0.1) 
or 0.2mg/kg i.p. (R0.2) 30 mins before conditioning compared to vehicle control (V) 
on freezing during any trial, however an IP-rearing x risperidone interaction was 
observed Post-CS [F(1,45)=9.187, p=0.004], indicative of a partial reversal of the IP-
induced deficit. p p<0.01 IP-reared vs. GV-controls, ##p<0.01 #p<0.05 
IP-rearing+risperidone vs. GV-V absolute control by Bonferroni post-hoc following 
ANOVA. 
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4.3.5 Effect of risperidone on IP-rearing induced changes in Morris water 
maze performance 
Study 1: For protocol viability, the IP-R0.2 group were excluded from the 
Morris Water Maze experiment.  As in previous paradigms, 0.5mg/kg 
risperidone caused sedation, leading to markedly decreased swimming activity 
for much or all of the 90 second trials throughout the acquisition phase. RM 
ANOVA supported this observation, with a highly significant increase on 
latency to platform due to risperidone [F(1,34)=55.869, p<0.001], and complete 
impairment of task acquisition. Vehicle-treated rats in both rearing groups did 
complete the task, improving with time, reflected by a significant main effect 
of trial [F(14,476)=8.395, p<0.001]. A rearing x risperidone interaction was also 
observed [F(1,34)=5.316, p=0.027], but there was no main effect of rearing alone  
[F(1,34)=1.158, p=0.289], confounded by the impairment due to risperidone 
(Figure 4.10). Bonferroni post-hoc analysis supported the deficits produced by 
risperidone treatment, particularly notable during trials 9 to 15 (effect of 
risperidone p<0.001 in trials 9-14, p<0.01 in trial 15, GV-V vs. GV-R0.5). 
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Figure 4.10 ± Impaired acquisition of a Morris water maze task by pretreatment 
with risperidone. Latency to locate a hidden platform in a fixed location (s, mean 
±SEM, n=9-11) in the Morris Water Maze paradigm was significantly increased by 
daily risperidone treatment (0.5mg/kg i.p. 30 min prior to training) in group-housed, 
perinatal saline-treated (GV-R0.5) and isolation-reared, perinatal PCP-treated (IP-
R0.5) rats compared to respective acute vehicle controls (GV-V and IP-V). RM 
ANOVA of the 15 trial acquisition period revealed highly significant main effects of 
trial [F(14,476)=8.395, p<0.001] and risperidone  [F(1,34)=55.869, p<0.001], plus an IP 
rearing x risperidone interaction  [F(1,34)=5.316, p=0.027], but no main effect of IP-
rearing alone  [F(1,34)=1.158, p=0.289]. ***p<0.001, **p<0.01, *p<0.05 risperidone 
treatment vs. rearing-matched acute vehicle treatment, ###p<0.001, ##p<0.01 #p<0.05 
IP-rearing+risperidone treatment vs. GV-V absolute controls by Bonferroni post-hoc 
following ANOVA. 
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Following training, rats were tested in two unbiased probe trials to assess 
acquisition and retention levels. Probe 1 demonstrated that risperidone-treated 
animals spent significantly less time in the correct quadrant, reflecting an 
inability to learn the task [two-way ANOVA, F(1,35)=22.82, p<0.001]. There 
was also a rearing x risperidone interaction [F(1,35)=10.75, p=0.0024], but no 
main effect due to rearing, despite a clear trend towards decreased performance 
in the IP-V group compared to GV-V (Figure 4.11A). Bonferroni post-hoc 
analysis supported the previous finding that risperidone treatment impaired 
performance, with both GV-R0.5 (p<0.001) and IP-R0.5 (p<0.01) groups 
spending significantly less time in the correct quadrant than GV-V rats. 
Furthermore, IP-V rats spent a significantly decreased time in the correct 
quadrant compared to GV-V rats, suggesting IP-induced impairment in 
acquisition masked by risperidone effects in ANOVA (p<0.05). 
Probe 2 demonstrated a similar rearing x risperidone interaction to Probe 1 
[F(1,35)=5.882, p=0.0206], but there was no significant main effect of IP-rearing 
or risperidone by two-way ANOVA. Performance of all rats fell reflecting 
extinction of the task (Figure 4.11B). Bonferroni post-hoc analysis revealed 
that GV-R0.5 rats still explored the correct quadrant significantly less than 
their vehicle treated GV-V counterparts (p<0.05). 
 
Risperidone treated animals were removed from the experiment following 
completion of Probe 2, as their inability to learn the initial task would 
confound any reversal learning protocol findings.  
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Figure 4.11 ± Rats treated with risperidone (0.5mg/kg i.p.) during acquisition were 
significantly impaired in the MWM task, spending less time exploring the correct 
quadrant (mean percentage of time ±SEM, n=9-11) in (A) Probe 1 by two-way 
ANOVA [F(1,35)=22.82, p<0.001]. A rearing x risperidone interaction was observed 
[F(1,35)=10.75, p=0.0024], but no significant main effect of IP-rearing. Main 
significance was lost during Probe 2 (B), but a rearing x risperidone interaction was 
again observed [F(1,35)=5.882, p=0.0206].  ***p<0.001 *p<0.05 risperidone treatment 
vs. rearing-PDWFKHG DFXWH YHKLFOH FRQWURO  p<0.05 IP-rearing vs. risperidone-
matched GV-control, ##p<0.01 IP-rearing+risperidone vs. GV-V absolute control by 
Bonferroni post-hoc test following ANOVA. 
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The experiment was continued with just GV-V and IP-V rats in an attempt to 
confirm a deficit in reversal learning due to IP-rearing combination treatment. 
A trend towards increased latency to locate the platform in IP-V rats suggested 
a potential impairment in reversal learning performance, but RM ANOVA 
revealed that there was no main effect of IP-rearing (Figure 4.12). A 
significant main effect of trial was seen [F(14,252)=2.4178, p=0.0034], as was a 
significant IP-rearing x trial interaction [F(14,252)=1.797, p=0.0394], suggesting 
some trial-dependant impairment in reversal performance may have occurred, 
but this was not confirmed by post-hoc analysis. Probe 3 and Probe 4 revealed 
QR VLJQLILFDQW GLIIHUHQFHV LQ WKH WLPH VSHQW H[SORULQJ WKH ³SODWIRUP ULQJ´
(Figure 2.2) or previously correct quadrant area between the GV-V and IP-V 
rats by t-test (Figure 4.13), further suggesting a lack of robust impairment by 
the combined IP-rearing.  
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Figure 4.12 ± No significant main effect of combined isolation rearing-perinatal PCP 
treatment (IP-V) compared to group-housed, saline treated controls (GV-V) on 
platform escape latency (s, mean±SEM, n=9-11) in a 15 trial reversal learning phase 
of a MWM protocol. A significant main effect of trial [F(14,252)=2.4178, p=0.0034], 
and a significant IP-rearing x trial interaction [F(14,252)=1.797, p=0.0394] were 
observed by RM ANOVA, with no post-hoc significance. 
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Figure 4.13 ± No significant effects of combined isolation rearing-perinatal PCP 
treatment (IP-V) compared to group-housed, vehicle treated rats (GV-V) on time 
spent exploring the Platform Ring zone (s, mean±SEM) in Probe 3 (A) and Probe 4 
(C), or on time spent exploULQJ WKH SUHYLRXVO\ ³FRUUHFW´ TXDGUDQW  WLPH
mean±SEM, n=9-11) in Probe 3 (B) and Probe 4 (D) of the Morris Water Maze 
protocol. 
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4.4 Discussion 
 
It is clear from the high dose risperidone study that 0.5mg/kg induced sedation, 
most notably in LMA, CER and MWM protocols which require active 
movement. Although sedative effects have not been seen at this dose when 
used previously in rats (Anastasio and Johnson 2008a; Fabricius et al. 2011; 
McLean et al. 2010b), including in recent work in our lab (McIntosh et al. 
2013), behaviour was clearly compromised. In the LMA paradigm, risperidone 
produced very marked reduction in locomotor activity from the outset of the 1 
h protocol that persisted throughout. In the CER paradigm, rats in the 
0.5mg/kg group took up to 300 s to cross the box partition (only three rats 
receiving this dose took below 60 s), whilst no single rat that received vehicle 
control or low dose risperidone took more than 60 s. Although placing rats in 
the cool water of the MWM was anticipated to be mildly aversive and induce 
active swimming, rats placed in the maze following treatment exhibited little 
or no swimming activity and instead floated in the maze for much or all of the 
90 s trial. Because of this sedation, risperidone-treated rats were severely 
impaired in acquisition of the MWM task, highlighted by their poor 
performance in Probe 1. Having failed to acquire the task successfully in the 
first place, rats in the 0.5mg/kg risperidone treatment groups (both GV and IP) 
were discontinued in the protocol, as any learning response would have been 
confounded by poor previous acquisition and continued sedation. Instead, GV-
V and IP-V rats continued in the reversal learning phase to attempt 
confirmation of a significant IP-rearing-induced deficit. In line with earlier 
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findings, the IP-reared rats were not shown to be significantly impaired in 
reversal learning compared to controls either in latency to find the platform or 
maze exploration in Probe 3 and 4, suggesting no impairment in cognitive 
flexibility. The lack of consistent deficits observed in dual-hit animals 
throughout three cohorts indicates that this paradigm lacks the robustness 
required to be used as part of the test battery, and so it was discontinued. 
The risperidone-induced sedation, which occurred regardless of rearing 
condition in study 1, also caused impairment in the NOD paradigm, where 
GV-R0.5 rats performed less well than vehicle treated controls (GV-V).  
One paradigm where the GV-R0.5 rats performed comparably or better than 
controls was in the PPI protocol, where at each prepulse analysed, the 
percentage PPI exhibited by these rat was higher than those in the GV-V 
group. This is most likely also explained by the sedative effect of risperidone, 
reflecting a reduced physical response to the startling tones rather than an 
increased inhibition of the startle due to prepulse presentation.  
 
One key observation from study 1 was that 0.2mg/kg produced little sedation. 
Based on these results, the second risperidone reversal study used this dose as 
³KLJK´ULVSHULGRQHZLWKPJNJXVHGDVWKHORZGRVH Although these doses 
have been commonly used in previous preclinical investigations, acute 
risperidone below 0.5-1mg/kg in rats has been shown to achieve a lower level 
of D2 receptor occupancy than is seen with clinically relevant doses of the drug 
in patients (Kapur et al. 2003). However, with strong 5-HT2A (Shahid et al. 
2009) and recently identified voltage-gated sodium channel activity (Brauner 
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et al. 2014), occupancy of the D2 receptor is unlikely to be the only factor 
governing the efficacy of risperidone in rodents or in man. In this second 
study, risperidone was shown to cause a significant reduction in locomotor 
activity in both GV and IP rats. This effect of risperidone reversing basal 
hyperlocomotion has been previously noted in isolation-reared rats, with 
different groups utilising doses from 0.08mg/kg to 0.5mg/kg to produce 
decreased locomotion in both isolates and controls (Fabricius et al. 2011; 
McIntosh et al. 2013). Furthermore, a single dose of 0.25mg/kg risperidone 
given as a pre-treatment before perinatal PCP administration has been shown 
to prevent the development of basal hyperlocomotion (Anastasio and Johnson 
2008a). The results presented here support these published findings. As 
described previously (see Chapter 1.2.1), the locomotor activity paradigm is 
considered to have validity to the positive symptoms of schizophrenia in 
humans through aberrant dopamine activity, a symptom domain known to be 
well controlled by current antipsychotics including risperidone (Houthoofd et 
al. 2008). As elevated locomotor activity in isolates has recently been shown to 
be reversed by D2 and D3 dopamine receptor selective antagonists (Watson et 
al. 2012b), the activity of risperidone at these receptors likely underlies the 
decrease in locomotor activity observed here. This result lends weight to the 
use of the IP dual-hit protocol for modelling schizophrenia-like symptoms.  
 
A similar reversal effect due to acute risperidone was observed in the PPI 
paradigm. Despite an inconsistent deficit due to IP-rearing, rats in the IP-R0.2 
group were shown to have elevated prepulse inhibition compared to other IP-
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reared animals, responding to a level comparable to GV-V and GV-R0.5 rats, 
and reflected by a statistically significant effect of risperidone in this paradigm. 
This effect was seen in the absence of any effect of risperidone on initial startle 
intensity or habituation to the 120dB startle-eliciting tone. These results also 
support the literature demonstrating that reversal of PPI deficits by 
antipsychotic drugs including risperidone is possible in preclinical models of 
schizophrenia, including subchronic PCP administration (Anastasio and 
Johnson 2008a; Li et al. 2011a), isolation rearing (Varty and Higgins 1995), 
hippocampal lesioning (Adams and van den Buuse 2011), and the 
administration of the NMDA receptor antagonist MK-801 (Varty and Higgins 
1995). Much like locomotor activity, PPI is known to be affected by 
mesolimbic dopamine activity, and blockade of D2 and D3 dopamine receptors 
with the non-selective antagonist raclopride can reverse isolation-induced 
deficits (Geyer et al. 1993). With similarities between the receptor 
pharmacology of these two behaviours it is perhaps unsurprising that the 
beneficial outcome of risperidone treatment was seen in both. However, there 
was little effect of the 0.1mg/kg dose of risperidone in this paradigm, 
indicating that this dose may be below the therapeutic window. Considering 
the marked sedation that was previously observed with a dose of 0.5mg/kg 
risperidone, it could be suggested that Lister-Hooded rats may have heightened 
responsiveness to this drug over the Sprague-Dawley rats commonly used 
previously (Adams and van den Buuse 2011; Li et al. 2011a).  
Whilst sensory gating in schizophrenia patients is consistently deficient 
compared to healthy controls, these deficits appear to be largely insensitive to 
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treatment with first- and second-generation antipsychotic drugs, notably 
including risperidone (Hong et al. 2009; Sanchez-Morla et al. 2009; Zhang et 
al. 2012a). Effective reversal of PPI deficits in this study may indicate that the 
problem of false-positive outcomes of antipsychotic drugs in PCP-based 
preclinical models persist in the IP-rearing dual-hit model, providing lower 
predictive validity to the human condition.  
 
Risperidone treatment was less successful in reversing IP-induced deficits in 
the other two behaviours examined. In the novel object discrimination 
paradigm, risperidone treatment at both high and low doses did not reverse the 
IP-induced deficit in visual learning and memory. Evidence from the literature 
suggests that reversal of visual learning and memory impairments is a 
reasonably well characterised effect of risperidone in preclinical models of 
schizophrenia at a range of doses (Grayson et al. 2007; Jenkins et al. 2010a; 
McIntosh et al. 2013), although some prior work suggests risperidone is 
ineffective at preventing chronic PCP-induced recognition memory deficits in 
rats (McKibben et al. 2010). It has been noted that blockade of prefrontal D3 
dopamine receptors can reverse delay-induced deficits in NOD, whereas D2 
receptor antagonism impairs performance (Watson et al. 2012b). Given that 
risperidone is not selective between D2/3 receptors, this may explain the lack of 
effect observed here. Clinically, risperidone has also produced mixed results in 
improving visual learning and memory in schizophrenic patients, with groups 
reporting both positive improvements (Harvey et al. 2005; Riedel et al. 2007) 
and lack of change (Purdon et al. 2000) due to the drug. The results presented 
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herein suggest that IP-induced novel object discrimination deficits are not 
susceptible to risperidone treatment at the doses used. Based on the level of 
sedation caused by the 0.5mg/kg dose in Study 1 it is unlikely that higher 
doses would yield more beneficial effects in these rats. Indeed, higher doses 
would yield elevated D2 receptor occupancy, and based on evidence in man 
using aripiprazole, higher D2 receptor occupancy may cause increased 
impairments in working memory, rather than improvement (Kim et al. 2013). 
Although IP-induced deficits in the conditioned emotional response were not 
significantly reversed by risperidone overall, it could be speculated that a trend 
towards some increase in freezing time was observed. Previous work in our 
laboratory also found a trend towards improvement in this paradigm which 
failed to reach significance following 0.2mg/kg and 0.5mg/kg risperidone 
treatment to isolation-reared rats, supportive of findings presented here 
(McIntosh et al. 2013). However, another group suggested risperidone was 
unable to reverse deficits in contextual or cued fear-conditioning in rats with 
excitotoxin-induced hippocampal neuropathy, an alternative model of 
schizophrenia (Martin et al. 2005), suggesting the ability of risperidone to 
reverse such emotional memory-based deficits is dependent on the preclinical 
model being utilised. Clinically, deficits in emotional learning and 
conditioning are well characterised in schizophrenic patients (Herbener 2009; 
Rushe et al. 1999), but current evidence suggesting whether risperidone or 
other atypical anti-psychotic drugs are beneficial in treating these symptoms is 
mixed (Behere et al. 2009; Kucharska-Pietura et al. 2012; Woodward et al. 
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2005). Here, it can be suggested that the deficit induced by IP-rearing cannot 
be reversed by risperidone treatment.  
 
4.4.1 Conclusion 
The results presented herein are difficult to interpret due to a continuing lack of 
reliability in the deficits of the IP-dual hit model. Broadly, this study does not 
lend much support to suggest risperidone as an effective treatment of the 
cognitive symptoms of schizophrenia. Whilst study 1 demonstrated the 
sedative effect of risperidone, significant behavioural deficits due to IP-rearing 
were observed in the NOD and CER paradigms only. Further inconsistent 
results in the MWM supported the cessation of this test in future cohorts. 
Improved performance of IP-reared rats following 0.2mg/kg risperidone was 
seen in LMA and PPI protocols, but no effect was seen on NOD or CER, 
suggesting a lack of effect of risperidone on cognition in this model. The IP 
dual-hit model is clearly amenable to pharmacological challenge, providing 
some support to its use. But with the effect of risperidone on cognition here not 
entirely in line with its effect in patients, it is hard to make inferences about the 
model¶s predictive validity for cognition in schizophrenia. However, as this 
clinical need is largely still unmet, D³SRVLWLYHFRQWURO´WRIXOO\DVVHVV validity 
is unavailable.  
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Chapter 5 ± Lamotrigine Challenge 
 
Chapter 5 
 
Evaluating the Effect of Lamotrigine in 
the Iso-PCP Dual-Hit Model of 
µ6FKL]RSKUHQLD-/LNH¶6\PSWRPVLQWKH
Rat 
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5.1 Introduction 
 
The anticonvulsant drug lamotrigine is prescribed clinically for the treatment 
of epilepsy and bipolar disorder. The primary pharmacological target is 
thought to be blockade of voltage-gated sodium channels (Nav1.2), preventing 
depolarization of neurones and reduction of synaptic release of excitatory 
amino acids including glutamate and  aspartate (Leach et al. 1991). However, 
lamotrigine also has weaker inhibitory effects at the 5-HT3, 5-HT1A and 
nicotinic acetylcholine receptors among others (Bourin et al. 2005; 
GlaxoSmithKline 2007; Zheng et al. 2010). Although it is not approved for the 
treatment of schizophrenia, a number of clinical studies have noted that 
lamotrigine may have efficacy in treating some of the symptoms, particularly 
in patients who are resistant to the clozapine treatment (Goff 2009; Tiihonen et 
al. 2009). Notably, lamotrigine and related voltage-gated sodium channel 
blockers have been shown to have beneficial effects on, or block the induction 
RI FRJQLWLYH GHILFLWV LQ URGHQW PRGHOV RI µVFKL]RSKUHQLD-OLNH¶ V\PSWRPV
including visual and spatial learning (Celikyurt et al. 2012), reversal learning 
(Large et al. 2011) and prepulse inhibition of acoustic startle (Brody et al. 
2003a; Nakato et al. 2010). The exact mechanisms of these effects are 
uncertain, however in line with the proposed contribution of altered function of 
glutamate signalling in the aetiology of schizophrenia it is plausible that 
lamotrigine could exert beneficial effects to negative and cognitive symptoms 
by attenuating cortical glutamate release. Furthermore, with the recent 
discovery that risperidone has activity at voltage-gated sodium channels also, 
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there is some suggestion that this pharmacology may underlie some of the 
beneficial effects of currently available antipsychotics (Brauner et al. 2014). 
Hence, evaluation of a more established sodium channel blocked in this model 
holds some value. 
To date there have been few preclinical studies evaluating the effect of 
lamotrigine in rodent models of schizophrenia. However, as a compound 
which has already been shown to have preclinical efficacy in a number of the 
paradigms in which the IP model has been assessed, it was selected as good 
candidate for further examining the predictive validity of the model. 
Furthermore, lamotrigine lacks the dopaminergic activity held by risperidone 
and other clinically available antipsychotic agents. Examining whether the 
behavioural deficits induced by the IP dual hit model would be more 
susceptible to reversal through alternative mechanisms was considered a strong 
rationale for selecting lamotrigine for this study.  
 
5.1.1 Hypothesis 
Based on the preclinical results from the literature, it was hypothesised that 
lamotrigine would cause a dose-dependent reversal of the behavioural deficits 
induced by the IP-rearing dual-hit model of schizophrenia in the rat. In 
particular, the paradigms involving visual learning and memory (NOD) and 
sensorimotor gating (PPI) would be most susceptible to drug challenge, as 
these have been shown previously to be reversed by lamotrigine treatment.  
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5.2 Materials and Methods 
5.2.1 Animals 
Three day old, male, Lister Hooded rat pups (n=12 from 2 litters in the pilot 
test, n=38 from 5 litters in the full behavioural battery study) were obtained 
from Charles River UK (CRUK, Margate, UK) accompanied by their natural 
dams and underwent an identical early-life treatment protocol to that described 
previously (see Chapter 3.2.1). In the dose-response pilot study, all animals 
were treated perinatally with PCP and subsequently housed in isolation, giving 
IP-V (n=12). In the full behavioural battery study (FBBS), animals treated 
perinatally with vehicle were subsequently housed in groups of 3/4 (GV, 
n=15), whereas all animals that received phencyclidine were housed in 
isolation (IP, n=23). Rats were reared for 40 days post-weaning in previously 
described ambient conditions (see Chapter 2.2.1). 
 
5.2.2 Drug Administration 
Lamotrigine (Sigma-Aldrich, Irvine, Scotland, UK) is insoluble in H2O or 
physiological saline (0.154 M) without reducing the pH to acidity unsuitable 
for systemic administration. Lamotrigine was therefore suspended in 50% w/v 
methyl cellulose, aided by the addition of a few drops 1M HCl before adjusting 
to pH 7 with 0.1M NaOH. Rats in the pilot study were placed on a within-
subject protocol, receiving methyl cellulose vehicle control (2ml/kg), low dose 
lamotrigine (10mg/kg) or high dose lamotrigine (20mg/kg) once each on three 
occasions in a pseudorandom order. FBBS rats were subdivided into 
lamotrigine or control treatment groups, giving IP-reared animals receiving 
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either vehicle control (2ml/kg, IP-V, n=8), low dose lamotrigine (10mg/kg, IP-
L10, n=8) or high dose lamotrigine (15mg/kg, IP-L15, n=7), and group-
housed, perinatal saline-treated (GV) animals receiving either vehicle control 
(GV-V, n=8) or high dose lamotrigine only (15mg/kg, GV-L10, n=7). All 
treatments were administered by intraperitoneal injection (2 ml/kg), 60 min 
before the initiation of each behavioural test, based on the literature.  
 
5.2.3 Behavioural Testing and Statistical Analysis 
During the pilot study, rats were tested in the NOD protocol on three 
occasions. Rats were initially exposed to the test chamber for 60 mins exactly 
24 hours before NOD testing was due to commence, and the NOD protocol 
was then performed as outlined previously (see Chapter 2.2.3). This was 
repeated with each rat assigned to a different test chamber and receiving a 
different pretreatment (vehicle control, L10 or L20) on two further occasions, 
such that each rat had been tested in the NOD protocol having received each 
drug treatment once, allowing within-subject statistical comparisons. 
 
During the full study, behavioural testing took place following the LMA, 
NOD, PPI and CER protocols described previously (see Chapter 2.2), and 
following the timeline identified in Figure 5.1 
  
Chapter 5 Ȃ Lamotrigine Challenge 
- 199 - 
 
 
 
  
Table 5.1 Table to show the perinatal drug treatment, post-weaning housing 
condition and acute lamotrigine treatment of each pup in the main study. 
Also shown, the behavioural tests undertaken by each litter  
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Figure 5.1 ± Protocol Timeline used in the full behavioural test battery study 
examining the effect of lamotrigine treatment (10 and 15mg/kg, i.p.) on behaviour in 
the IP dual-hit model of schizophrenia-like symptoms in rats. 
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In an addition to the statistical analysis used previously, the D1 discrimination 
ratio derived from the NOD paradigm was also analysed by one sample t-test 
in the pilot study, comparing the D1 of each individual treatment group with a 
³FKDQFH´VFRUHRI' :KLOVWWKLVOHVVVWULQJHQWDQDO\VLVGRHVQRWFRPSDUH
between treatment groups, it does identify whether animals receiving a 
particular treatment have explored the two objects in a pattern that is 
significantly different to what would be expected by chance, and so some 
inference can be drawn about the efficacy of treatment.  
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5.3 Results 
5.3.1 Pilot Study - Effect of lamotrigine on performance in novel object 
discrimination 
As expected, vehicle-treated IP animals did not explore the novel more than 
the familiar object during the second choice trial, whereas those treated with 
lamotrigine did. However, two-way ANOVA of the NOD choice trial showed 
a significant main effect of object [F(1,30)=37.93, p<0.0001] and a significant 
object x treatment interaction [F(2,30)=3.404, p=0.0465] but no significant main 
effect of treatment alone [F(2,30)=0.3023, p=0.7413]. Despite this, Bonferroni 
post-hoc analysis confirmed a highly significant difference in object 
exploration in both the L10 (p<0.001) and L20 (p<0.001) treatment groups 
which was absent in the vehicle control group (Figure 5.2A).  
A trend towards dose-dependent improvement in discrimination due to 
lamotrigine was seen, but RM ANOVA analysis (one-way) failed to show a 
significant main effect of lamotrigine on D1 ratio [F(2,18)=2.885, p=0.0819]. 
However, one sample t-test comparing each D1 ratio to chance (D1=0.5) 
demonstrated a significant effect of L10 and L20 (p<0.05 for both), not seen in 
vehicle-treated rats (Figure 5.2B). 
Data from two rats was excluded from the analysis; one rat failed to complete 
the task in two of the three sessions and another had an unexpected adverse 
reaction to drug treatment. Although no adverse symptoms were noted in any 
other rats, a lower high dose of lamotrigine (15mg/kg) was used for the full 
behavioural battery study.  
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Figure 5.2 ± An IP-rearing induced impairment in NOD performance was 
reversed by lamotrigine treatment at 10 and 20mg/kg. (A) Rats receiving vehicle 
(Veh) did not spend significantly longer exploring the novel than familiar object (s, 
mean±SEM, n=11) during the second choice trial of the NOD protocol by Bonferroni 
post-hoc following ANOVA, whilst those treated with lamotrigine at 10mg/kg (L10) 
or 20mg/kg (L20) did [treatment x object interaction, F(2,30)=3.404, p=0.0465]. 
***p<0.001 Novel vs. Familiar by Bonferroni post-hoc test following ANOVA. 
(B) The D1 discrimination ratio (mean±SEM, n=11) during the second choice trial 
was not significantly increased by lamotrigine [F(2,18)=2.885, p=0.0819, RM 
ANOVA]. L10 and L20 treated rats had a D1 ratio of significantly higher than chance, 
Veh did not. #p<0.05 vs. ' ³FKDQFH´E\RQHVDPSOHt-test.  
Chapter 5 Ȃ Lamotrigine Challenge 
- 204 - 
 
5.3.2 Full Behavioural Battery Study - Effect of lamotrigine on IP-induced 
changes in locomotor activity 
As expected, when placed in a novel arena, horizontal activity gradually 
decreased in all treatment groups during the LMA protocol, reflecting 
habituation to the mildly aversive arena, supported by a significant main effect 
of time by RM ANOVA [F(11,352)=93.408, p<0.001]. Furthermore, lamotrigine 
pretreated rats showed decreased locomotion, reflected by a significant main 
effect of drug treatment [F(2,31)=4.020, p=0.027] over the entire 60 min test 
period (RM ANOVA), although there was no main effect of rearing, and no 
rearing x lamotrigine interaction (Figure 5.3A). Post-hoc significance occurred 
during the 25-30 min epoch, where IP-L10 and IP-L15 rats were significantly 
less active than their IP-V control (p<0.01 for both), but no post-hoc 
significance by lamotrigine was observed in group-housed treated animals. 
 In contrast, two-way ANOVA analysis of total activity during the first 30 min 
(where activity differences were most marked) revealed a significant IP-rearing 
x drug interaction [F(1,32)=6.719, p=0.014], but no main effect of either rearing 
condition or drug treatment alone (Figure 5.3B). This suggests that an increase 
in locomotor activity due to IP-rearing during in the first 30 min was reversed 
by lamotrigine, most notably at the highest dose, supported by Bonferroni 
post-hoc analysis revealing increase in locomotion in IP-V rats compared to 
control GV-V (p<0.05) and a significant reduction by 15mg/kg lamotrigine 
treatment (IP-L15) compared to IP-V (p<0.05). 
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Figure 5.3 ± Lamotrigine attenuated IP-rearing induced hyperlocomotion in a 
novel arena, without reducing horizontal activity in controls. (A) Locomotor beam 
breaks (mean±SEM, n=7-8) significantly decreased over 60 min, reflecting 
habituation to a novel arena [F(11,352)=93.408, p<0.001, RM ANOVA]. Lamotrigine 
treatment at 10mg/kg i.p. (L10) and 15mg/kg i.p. (L15) 1 h before testing to IP-reared 
(IP) and control (GV) rats caused a significant alteration in activity compared to acute 
vehicle treatment (V, 2ml/kg) [F(2,31)=4.020, p=0.027, RM ANOVA]. Although no 
main effect of IP-rearing occurred, there was a rearing x lamotrigine interaction 
during the first 30 minutes of the protocol [F(1,32)=4.720, p=0.037], suggesting reversal 
of IP-induced hyperlocomotion by lamotrigine. **p<0.01 lamotrigine vs. rearing-
matched group-housed control by Bonferroni post-hoc following ANOVA.   
(B) Total locomotor counts during first 30min showed an elevation in locomotor 
activity in IP-rearing which was significantly attenuated by lamotrigine (15mg/kg), 
without any accompanying decrease in locomotion in GV-reared animals treated with 
the same dose [F(4,33)=2.530, p=0.046, ANOVA]. p<0.05 IP-rearing vs. lamotrigine-
matched group-housed control, *p<0.05 lamotrigine vs. rearing-matched group-
housed control by Bonferroni post hoc-test following ANOVA.  
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5.3.3 Effect of lamotrigine on IP-induced novel object discrimination deficits 
Rats reared in social groups after perinatal vehicle injection were able to 
discriminate between objects during the second choice trial of NOD, such that 
they spent more time exploring the novel vs. familiar object (Figure 5.4A). 
Two-way ANOVA showed a main effect of object [F(1,32)=64.72, p<0.0001], a 
significant object x treatment interaction [F(4,29)=4.620, p=0.0045] but no main 
effect of drug [F(4,29)=2.064, p=0.1081]. Bonferroni post-hoc showed GV-V 
and GV-L15 groups spent significantly longer exploring the novel over 
familiar object (p<0.001), while IP rats given vehicle (IP-V) or high dose 
lamotrigine (IP-L15) did not. In contrast, IP rats given lamotrigine at 10mg/kg 
(IP-L10) spent longer exploring the novel object (p<0.001).  Thus low dose 
lamotrigine reversed an IP-rearing induced NOD impairment. Furthermore, 
two-way ANOVA analysis of the D1 ratio showed significant main effects of 
rearing [F(1,31)=25.731, p<0.001] and drug treatment [F(2,30)=9.795, p<0.001], 
but no interaction between the two [F(1,31)=0.844, p=0.365]. Bonferroni post-
hoc confirmed the findings, showing that D1 was significantly lower in IP-V 
than GV-V (p<0.01), and 10mg/kg lamotrigine (IP-L10) had a significantly 
higher D1 than IP-V rats (p<0.01, Figure 5.4B). Data from one animal was 
excluded from the analysis as it failed to perform the task, according to 
outlined criteria (see Chapter 2.2.3). A significant main effect of trial was 
observed on total object exploration [F(1,33)=11.734, p=0.002], with a decrease 
in exploration shown by post-hoc analysis in IP animals treated with 15mg/kg 
lamotrigine (p<0.01). There was no overall main effect of rearing condition or 
lamotrigine treatment, with no between-factor interactions (Figure 5.4C). 
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Figure 5.4 ± A significant impairment in NOD discrimination due to IP-rearing is 
reversed by lamotrigine treatment at 10mg/kg. (A) GV-reared rats, regardless of 
acute treatment with 15mg/kg lamotrigine (GV-L15) or vehicle (GV-V), significantly 
discriminated between objects, exploring the novel over familiar (s, mean±SEM, n=7-
8) by Bonferroni post-hoc during the second choice trial of the NOD protocol 
[significant object x treatment interaction by two-way ANOVA, F(4,29)=4.620, 
p=0.0045]. IP-reared rats did not discriminate between objects when treated with 
vehicle (IP-V) or 15mg/kg lamotrigine (IP-L15). IP-reared rats receiving 10mg/kg 
lamotrigine (IP-L10) were able to discriminate between the two objects. ***p<0.001 
Novel vs. Familiar by Bonferroni post-hoc test following ANOVA. (B) The D1 
discrimination ratio (mean±SEM, n=7-8) was significantly affected by IP-rearing 
[F(1,31)=25.731, p<0.001] and lamotrigine [F(2,30)=9.795, p<0.001], with a significant 
impairment in IP-V rats reversed by 10mg/kg lamotrigine treatment **p<0.01 
lamotrigine vs. rearing-matched vehicle-treated control, p<0.01 IP-rearing vs. 
lamotrigine-matched group-housed vehicle-treated control by Bonferroni post-hoc (C) 
A significant decrease in object exploration in trial 2 compared to trial 1 was 
confirmed by three way ANOVA [F(1,33)=11.734, p=0.002] ##p<0.01 Trial 2 vs. Trial 1 
by post-hoc analysis following ANOVA  
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5.3.4 Effect of lamotrigine on IP-induced attenuation of prepulse inhibition of 
acoustic startle 
As expected, inhibition of the acoustic startle progressively increased with 
increasing prepulse intensity in all five treatment groups. However, this was 
lower in IP-V rats at all prepulse intensities than in any other group such that 
RM ANOVA showed a significant main effect of prepulse [F(2,64)=105.060, 
p<0.001] and rearing condition [F(1,32)=4.447, p=0.043]. The effect of IP-
rearing reached post-hoc significance at the 76dB prepulse level only (GV-V 
vs. IP-V, p<0.05). Despite a trend towards elevated PPI in the IP-L10 group 
compared to the IP-V, most notably at the 84dB prepulse intensity, the IP-
induced impairment was not significantly reversed by lamotrigine 
[F(2,33)=0.284, p=0.754], and there was no rearing x lamotrigine interaction by 
RM ANOVA [F(1,32)=0.437, p=0.513] (Figure 5.5).  
Two-way ANOVA analysis of the initial startle amplitude and habituation to 
the 120dB tone alone revealed no significant effect of either rearing condition 
or lamotrigine, nor any interaction between the two on either factor, 
confirming that the observed effects were not confounded by a non-specific 
effect on the startle response (data not shown). 
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Figure 5.5 - A significant attenuation of the acoustic startle response by IP-
rearing was not reversed by lamotrigine treatment. (A) IP-reared rats (IP) 
demonstrated a significant impairment in PPI response (mean±SEM, n=7-8) compared 
to group-housed, vehicle-treated controls (GV) following acute vehicle treatment (V) 
[F(1,32)=4.447, p=0.043, RM ANOVA]. Impairment was not significantly reversed by 
lamotrigine treatment at either 10 (L10) or 15mg/kg (L15), and there were no 
between-factor interactions p<0.05 IP-rearing vs. lamotrigine-matched group-housed 
control by Bonferroni post-hoc following ANOVA. 
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5.3.5 Effect of lamotrigine on IP-induced deficits in a conditioned emotional 
response 
In order to assess any effect of lamotrigine on conditioned emotional learning, 
freezing responses were examined in a conditioning chamber. All rats froze as 
expected when returned to the chamber following conditioning, confirming 
that associative learning had occurred. Despite a trend towards decreased 
freezing in IP-V rats compared to GV-V, as has been seen previously, no 
significant decrease in freezing was observed due to IP-rearing by two-way 
ANOVA at 24h [F(1,32)=3.066, p=0.090] or 48h post-conditioning 
[F(1,32)=1.891, p=0.179], nor after re-presentation of the condition stimulus 
alone [F(1,32)=1.173, p=0.287], and furthermore there was also no main effect 
due to lamotrigine at any time point, nor any IP-rearing x lamotrigine 
interaction observed (Figure 5.6). 
Two-way ANOVA analysis of the latency to enter the CER chamber revealed 
no significant effect of rearing condition or lamotrigine, but there was a 
significant IP x lamotrigine interaction [F(1,32)=4.629, p=0.039]. However, 
removal of a clear outlier in the IP-L15 group (more than 2 standard deviations 
from the mean of all groups) negated this interaction (data not shown).   
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Figure 5.6 - A reduction in freezing response to contextual and conditioned fear 
in a CER protocol due to IP-rearing just failed to reach significance, and was not 
elevated by lamotrigine treatment.  Freezing times (s, mean±SEM, n=7-8)  were 
reduced at all time points by combined isolation rearing and perinatal PCP treatment 
(IP) compared to vehicle-treated group-housed animals (GV), but this failed to reach 
significance at any time point by two-way ANOVA. No significant increases in 
freezing were observed due to acute lamotrigine treatment at 10mg/kg i.p. (L10) or 
15mg/kg i.p. (L15) 1h before conditioning compared to vehicle (V) at any time point, 
nor was an IP-rearing x lamotrigine interaction observed. 
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5.4 Discussion 
 
As observed previously (see Chapter 3), the combination of isolation rearing 
and perinatal PCP treatment produced deficits in LMA, NOD and PPI 
performance, although the previously robust CER deficit was not replicated. 
Further issues with the reliability of this model make the effect of lamotrigine 
in the paradigms examined difficult to interpret. Whilst lamotrigine appeared 
to reverse a deficit in visual learning and memory in the NOD task and 
attenuated novelty-induced neophobia in the LMA protocol, it did not 
significantly restore the reduction in sensorimotor gating seen in PPI, nor did it 
increase freezing behaviour in the fear motivated associative learning 
paradigm. The results will now be considered in detail. 
From the pilot dose-response NOD study, the potential for lamotrigine to exert 
a beneficial cognitive effect was evident. By using a within-subject evaluation 
of 10 and 20mg/kg lamotrigine, both doses were found to reinstate a preference 
for the novel object in the second choice trial. This suggested an improvement 
in IP-induced impairment in NOD, as has been previously reported by 
cognitive enhancing and antipsychotic drugs in isolation-reared rats by our 
group using this well-established method (Jones et al. 2011a; McIntosh et al. 
2013; Watson et al. 2012a; Watson et al. 2012b), and in PCP-based models 
previously by others (Grayson et al. 2007; Hashimoto et al. 2005; McKibben et 
al. 2010; Nagai et al. 2009). Similarly in the FBBS study, lamotrigine reversed 
the neurodevelopmental deficit in NOD at 10mg/kg only. A lack of object 
discrimination following 15mg/kg lamotrigine may have been due to a 
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significant overall decrease in object exploration in trial 2. The preclinical 
evidence for a visual learning and memory effect of lamotrigine is very 
limited. Aside from the Morris Water Maze which also includes a significant 
spatial substrate (Celikyurt et al. 2012), no previous studies have reported an 
improvement in visual learning and memory after systemic lamotrigine as 
observed here. Furthermore, other groups focusing on the effects of 
antiepileptic drugs in the same or different class as lamotrigine showed that the 
drug did not cause a significant change in working memory performance 
(Shannon and Love 2004) or attention in a five-choice serial reaction time task 
in rats (Shannon and Love 2005), and in fact caused a significant impairment 
in learning as measured by a repeated acquisition of response sequences task 
(Shannon and Love 2007). However, there is conflicting evidence suggesting 
that reversal learning may be enhanced by lamotrigine (Large et al. 2011), as 
well as phenytoin and valproate, which like lamotrigine work through 
modulation of sodium ion channels (Idris et al. 2009). There are even fewer 
publications examining the effect of lamotrigine on cognition in the clinic, but 
currently there is little evidence to suggest any beneficial effect in limited 
patient groups (Eun et al. 2012; Ijff and Aldenkamp 2013; Vayisoglu et al. 
2013). These studies combined suggest that the finding of a benefit of 
lamotrigine here in a specifically visual memory task is highly novel, and may 
reflect the problem of false-positive effects of compounds in PCP-based rodent 
models of schizophrenia (Chapter 1.3.3) and in novel object recognition-based 
tasks (Lyon et al. 2012). 
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Somewhat more evidence exists clinically in the reversal of positive symptoms 
of schizophrenia. Studies, including a large meta-analysis (Goff 2009; 
Tiihonen et al. 2009), have indicated the potential benefit of lamotrigine to 
treat psychosis and schizoaffective disorder (Erfurth et al. 1998), particularly 
in clozapine-resistant patients. It is important to balance these previously 
published results, however, with other studies that have found little or no 
supportive evidence for the use of lamotrigine in schizophrenia when 
reviewing the available literature (Reid et al. 2013; Sommer et al. 2012). In 
this study, lamotrigine significantly reduced the locomotor response elicited by 
placement in a novel arena selectively in IP rats but not in GH littermates. 
Importantly, this selectivity of action suggests that the suppression of 
hyperactivity seen was not due to sedation as observed with risperidone. 
Several previous studies have examined the effects of acute and perinatal 
lamotrigine on locomotor activity in adult rodents in various paradigms 
(Bourin et al. 2005; Forcelli et al. 2012; Kaur and Starr 1996; Quarta and 
Large 2010), but of particular interest, one study noted the effect of 
lamotrigine on acute PCP-induced hyperlocomotion in rats in combination 
with clozapine, which has direct relevance to its potential use in the clinic as an 
adjunct therapy alongside an antipsychotic (Williams et al. 2006). They noted 
that although lamotrigine enhanced acute PCP-induced hyperlocomotion when 
administered without clozapine, combined administration caused a highly 
significant decrease in locomotion in acute PCP treated rats, even below that of 
vehicle treated controls. This is consistent with some clinical data showing the 
potential benefit of combined clozapine and lamotrigine treatment (Tiihonen et 
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al. 2009). Mechanistically, lamotrigine has been shown to reduce excitability 
in striatal neurons in vitro (Calabresi et al. 1999) by preventing the release of 
neurotransmitters through pre-synaptic blockade of voltage-gated sodium 
channels (Leach et al. 1991). This activity could prevent the excessive levels of 
striatal dopamine release that have been correlated with hyperlocomotion in 
rodents (Paulson and Robinson 1995) and psychoses in schizophrenia patients 
(Abi-Dargham et al. 1998; Abi-Dargham et al. 2000; Laruelle et al. 1996), but 
without supporting evidence this is purely speculative.  
 
Unlike each of the previous cohorts in this thesis, IP rats did not freeze 
significantly less than their control counterparts in the CER paradigm, 
indicating that the desired impairment in contextual and cue conditioned fear 
memory was not induced. This was despite the mean freezing time for each IP 
group (V, L10 and L15) being lower than both GV groups (V, L15) at each of 
the three examined time points. The lack of a significant IP-induced 
impairment makes it difficult to interpret the effect of lamotrigine in this 
paradigm, but there was no notable increase in freezing time in the IP-L15 
group. Interestingly, some limited clinical evidence does suggest lamotrigine 
may affect conditioned emotional responses in humans (Haldane et al. 2008; 
Jogia et al. 2008). Despite a lack of significant behavioural effect, lamotrigine 
in these studies reduced elevated activity levels in the temporal regions around 
the left hippocampus/parahippocampus in patients with bipolar disorder. 
Furthermore, lamotrigine produced increased neural responses in regions of the 
prefrontal cortex involved in the regulation of emotion through innervation of 
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limbic regions, including the amygdala-hippocampus complex. The authors 
suggested that through these effects lamotrigine could potentially exert a 
µQRUPDOLVLQJ¶ HIIHFW RQ PRRG DQG HPRWLRQDO SURFHssing, which may be 
translatable from bipolar disorder to schizophrenia. Results presented herein 
fail to support or oppose those previously published, due to the unreliability of 
the model. 
 
Positive effects of lamotrigine have been observed previously in preclinical 
PPI studies, with an impairment in PPI in mGluR1 knock-out mice reversed by 
27mg/kg lamotrigine (Brody et al. 2003a). Another group demonstrated that 
30mg/kg i.p. blocked the induction of PPI deficits by repeated 
methamphetamine (2.5mg/kg s.c.), and reversed methamphetamine-induced 
PPI deficits when given acutely (Nakato et al. 2010). Recent evidence also 
shows that unlike other antiepileptic drugs, lamotrigine does not induce 
sensorimotor gating deficits when administered on PNDs 7-13 to rats 
(20mg/kg i.p.) (Forcelli et al. 2012). The current results however do not 
replicate these reports since the IP-deficit in PPI was not elevated by 
lamotrigine. Nonetheless, not all groups have demonstrated an effect of 
lamotrigine on PPI. One group noted that oral administration was unable to 
reverse ketamine-induced PPI deficits (Cilia et al. 2007), and another showed 
it was unable to reverse either mGluR5 KO (Brody et al. 2004), or 
amphetamine induced deficits (Brody et al. 2003b), more closely resembling 
this data which shows no effect of lamotrigine on PPI in this dual-hit model. 
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5.4.1 Conclusion 
The administration of lamotrigine to IP rats at 10 and 15mg/kg is somewhat 
effective at reversing specific behavioural deficits in IP-dual hit rats, and this 
may have some relevance to schizophrenia. However, the most notable effect 
of lamotrigine in this study was to reverse an NOD impairment known to be 
susceptible to false-positive reversals. Furthermore, lamotrigine has previously 
been shown to be ineffective at improving cognition in domains similar to 
those examined in NOD. Together, this suggests that rather than lamotrigine 
having therapeutic potential in treating the cognitive deficits of schizophrenia, 
in fact the IP dual-hit model is susceptible to producing false-positive drug 
reversals, again undermining the predictive validity of this model. In 
paradigms where a significant effect of lamotrigine was not seen (PPI and 
CER), questions still remain about the reproducibility of the IP model, making 
firm conclusions DERXWWKHGUXJ¶VHIILFDF\LQWKHVHGRPDLQVGLIILFXOW 
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6.1 Aims 
 
The treatment of schizophrenia in the clinic is hindered by inadequate 
PHGLFDWLRQ :KLOVW ³SRVLWLYH´ V\PSWRPV RI WKH disorder are relatively well 
XQGHUVWRRGDQGWUHDWHGZLWKDYDLODEOHPHGLFDWLRQVV\PSWRPVLQWKH³QHJDWLYH´
DQG ³FRJQLWLYH´ GRPDLQV DUH QRW ,PSURYHG SUHFOLQLFDO PRGHOV RI
schizophrenia would aid research into its aetiology and lead to better therapies 
for antipsychotic-resistant patients. 
Although current preclinical models of schizophrenia each have individual 
strengths, all also have weaknesses in procedure or validity. The main aim of 
WKLVWKHVLVZDVWRSURGXFHHYDOXDWHDQGYDOLGDWHDQRYHO³GXDO-KLW´model of 
schizophrenia-like symptoms in the rat. Combining pre-existing preclinical 
models was intended to produce a phenotype that encompassed the relative 
strengths of each model whilst eliminating the weaknesses. The hypothesis 
was that such a combination model would be highly replicable and 
demonstrate increased robustness of behavioural and neurobiological changes 
salient to schizophrenia. Through this improved model, disease understanding 
and the evaluation of novel therapies could be improved. 
 
6.2 Findings & Implications 
 
Isolation rearing was selected as the foundation for this thesis, based on it 
being well-characterised and validated within the group. As expected, isolation 
rearing produced somewhat consistent changes in behaviour throughout the 
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experiments conducted, however it also demonstrated a lack of robustness, 
with individual deficits in LMA and PPI for example not occurring in every 
cohort. These findings demonstrated one of the major motivations behind 
developing a dual-hit model. Two challenges were selected for addition to the 
isolation rearing model, prenatal MAM and perinatal PCP treatment. 
The addition of prenatal MAM on GD17 to the isolation rearing model 
(Chapter 2) was fraught with difficulties. Accurate identification of gestational 
day is vital to ensure correct administration of MAM, but the standard method 
for confirming conception, locating a vaginal plug in bedding material, is 
easily missed and inaccurate. Whilst this procedural challenge can be 
overcome by careful, continuous observation, the phenotype produced by the 
dual-hit treatment was largely inconsistent (Table 6.1). Despite isolation 
rearing-induced deficits in novel object discrimination, conditioned emotional 
response and prepulse inhibition paradigms, with a possible additional effect of 
isolation + MAM observed in one cohort, MAM was only successful in 
producing decreased retention of a visuo-spatial learning task in the Morris 
Water Maze. This shortage of effects was despite marked and replicated 
hippocampal and striatal pathology due to MAM treatment alone, suggesting 
that drug degradation or incorrect administration was not to blame.  
Lister-Hooded rats were selected for this study based on their strong record of 
isolation rearing deficits, however with no literature published on the effect of 
prenatal MAM in this strain, it was concluded that different strain-sensitivity to 
MAM may be responsible for the behavioural results seen. Although the 
³LVRODWLRQV\QGURPH´ZDVQRWIXOO\LQGXFHGQRORFRPRWRUK\SHUDFWLYLW\ZDV 
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Table 6.1 ± Table showing the behavioural and neurobiological outcomes of combined isolation rearing-prenatal MAM treatment and 
isolation rearing-perinatal PCP treatment, as well as subsequent acute treatment with risperidone and lamotrigine 
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observed in either cohort), the addition of MAM did not assist in ensuring a 
full profile of behavioural deficits occurred. On this basis the protocol failed to 
meet the aims of this thesis, and was discontinued. 
In some ways the range and robustness of behavioural deficits induced by 
addition of perinatal PCP treatment to the isolation rearing procedure was 
increased, but not to such an extent to fully meet the aims of this thesis (Table 
6.1). Hyperlocomotion in a novel arena was observed in only three of five 
cohorts due to isolation rearing, whilst PPI was only significantly impaired 
following dual-hit treatment in two cohorts.  The variability in responses 
between cohorts was greater than expected, and it was hypothesised that 
combination treatment would eliminate this variability. Previous analyses have 
shown that the isolation rearing procedure does not produce a complete profile 
of behavioural deficits in all cohorts, even within the same group following an 
identical, repeated protocol (Fone and Porkess 2008). Despite stringent 
measures being put in place to ensure the isolation procedure was as identical 
as possible between cohorts here, there is a possibility that routine handling 
during cage changes may have negated the full induction of the isolation 
syndrome (Gentsch et al. 1988; Krebs-Thomson et al. 2001), or that the noise 
levels in the holding rooms may have been inconsistent, preventing identical 
auditory contact between isolates in individual cohorts. One suggested 
improvement to the isolation procedure could be to house the animals in 
LQGLYLGXDOO\ YHQWLODWHGFDJHVRU ³,9&V´ This system of housing, where each 
cage is connected to a continually changing air supply, would not only 
continue to prevent social contact between isolates, but would also limit 
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olfactory contact, and potentially auditory, depending on the background noise 
created by the ventilation system. These additional sensory isolations may, as 
has been seen previously with more austere housing (Greco et al. 1989; Holson 
et al. 1991), produce a more severe phenotype or one that is more robust than 
observed here.  The addition of perinatal PCP to the protocol was not effective 
at eliminating the between-cohort differences in behaviour in these paradigms, 
and as such did not meet the thesis aim. Robust novel object discrimination 
and conditioned emotional response deficits were, however, seen due to 
isolation rearing with possible additional effects of adding perinatal PCP, but 
the magnitude of isolation rearing-induced deficits in these paradigms may 
have prevented additive effects of dual-hit treatment due to ceiling effects.  
The translational relevance of the model to schizophrenia is also limited due to 
the fact that two of the least reliable paradigms assessed, locomotor activity 
and prepulse inhibition of acoustic startle, are seen as being some of the most 
relevant in modelling schizophrenia preclinically by the MATRICS initiative 
(Young et al. 2009). By contrast, the novel object discrimination task has the 
potential for false-positive compound reversals, and is less translatable to the 
human condition of schizophrenia (Lyon et al. 2012). Furthermore, the 
conditioned emotional response was not included in the MATRICS initiative, 
suggesting relevance to schizophrenia is limited, despite requiring brain 
regions potentially key in disease pathology (Maren 2001; Young et al. 2009). 
Despite these limitations, the susceptibility of the IP-rearing model to 
pharmacological challenge was assessed with acute treatment of risperidone 
(Chapter 4) and lamotrigine (Chapter 5) immediately prior to behavioural 
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testing. Whilst 0.5mg/kg risperidone had a clear sedative effect, lower doses 
restored PPI responses and increased freezing behaviour in the CER paradigm 
in IP-reared rats specifically, as well as reducing locomotor activity across all 
treatment groups. Conversely, lamotrigine restored normal performance in the 
novel object discrimination paradigm and attenuated IP-induced 
hyperlocomotion, while having no beneficial effects in PPI or CER paradigms 
(Table 6.1). However, evidence for the efficacy of these drugs in treating 
particularly cognitive deficits in schizophrenia patients is mixed, with a 
number of recent studies suggesting that lamotrigine may have little future use 
in the disease (see Chapter 5.4). The ability for lamotrigine to reverse novel 
object deficits may therefore be indicative of the false positive drug reversal 
effects that are known to exist with NOD and paradigms and PCP-based 
models of schizophrenia alike. It is somewhat difficult to fully interpret the 
results showing that risperidone is able to restore PPI responses and increase 
CER freezing at low doses based on the unreliable nature of the IP deficits.  
Compared to other, previously published dual-hit approaches, the isolation-
PCP protocol has a number of relative strengths, although these may not have 
been strongly supported in this thesis. Isolation rearing has previously been 
combined with other NMDA receptor antagonists, most notably MK-801, with 
highly variable results (Ashby et al. 2010; Gilabert-Juan et al. 2013; Hawken et 
al. 2013; Hickey et al. 2012; Lim et al. 2012). As well as differing results due 
to isolation rearing alone, as has been seen here, most papers failed to note 
marked additive effects of the two hits combined. Lim et al were able to 
demonstrate that NMDA receptor antagonism in the early post-natal period 
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could produce PPI and NOD deficits in isolation reared animals that were more 
robust than where saline was administered instead. This paper is the closest 
published work to that presented in this thesis, as no other groups have yet 
attempted the isolation-PCP combination approach, and somewhat supports the 
decision to use perinatal PCP to augment the isolation rearing protocol.  
Other strong lines of study using dual-hit protocols have focused on models 
utilising genetic and/or maternal immune activation to induce schizophrenia-
like deficits (Abazyan et al. 2010; Deslauriers et al. 2013; Giovanoli et al. 
2013; Lipina et al. 2013; Vuillermot et al. 2012), with some combining these 
challenges with developmental models such as isolation rearing (Ishihama et 
al. 2010; Jiang et al. 2013; Niwa et al. 2013). As discussed previously (Chapter 
1.3), perturbations that hold a strong genetic link to schizophrenia or are 
associated with maternal infection have a high level of construct validity to 
schizophrenia (Sullivan 2005). This validity gains additional strength when 
combined with a developmental disruption model such as isolation rearing 
with a post-pubertal onset of phenotype. Hence, these models may have 
stronger validity than the Iso-PCP model presented here. However, no genetic 
x isolation dual-hit models have demonstrated cognitive deficits to date, and 
there is no published data on the effect of combining maternal immune 
activation with isolation rearing. Here, the isolation-PCP model displays a 
relative strength, with cognitive deficits observed reproducibly in the NOD 
paradigm. Despite this, and the face validity of NMDA receptor antagonism 
and glutamate hypofunction as a model of schizophrenia, the findings of this 
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thesis suggest that other dual-hit approaches are likely to yield more 
productive results than the Iso-PCP model presented herein. 
 
6.3 Future Studies 
 
The key long-term aim of this thesis was to produce a model that would enable 
better understanding of the aetiology of schizophrenia, as well as aid in the 
discovery of novel therapies. The proposed future studies below work towards 
these two goals by looking to improve the Iso-PCP model and better 
understand the neurobiology behind the behavioural deficits induced by both 
model hits.  
It is clear that further work is required to make the Iso-PCP model a viable tool 
for use in future schizophrenia research. One approach could be to improve the 
constituent parts of the model individually, such that a combination of the two 
will automatically be strengthened. As mentioned above, more austere housing 
conditions could be used to induce a more severe isolation syndrome, and has 
been previously used to induce elevated basal corticosterone (Greco et al. 
1989; Holson et al. 1991). The use of individually ventilated cages that limit 
the auditory and olfactory contact between isolates, could be compared to the 
housing conditions utilised here to evaluate whether enduring increases in 
corticosterone are coupled with more severe, robust or reproducible changes in 
behavioural relevant to schizophrenia. Additionally, routine handling to change 
cage bedding material could be reduced further to ensure isolates have as little 
physical contact as possible. 
Chapter 6 - General Discussion 
- 227 - 
 
The administration of PCP perinatally could also be potentially improved. 
Other groups have utilised PCP administration on days 2, 6, 9 and 12 to induce 
oxidative stress in the frontal cortex and hippocampus through reduced 
expression and activity of antioxidant enzymes such as superoxide dismutase 
(Radonjic et al. 2010). Mounting evidence suggests that mitochondrial 
dysfunction leading to redox dysregulation may be a primary mechanism for 
neuronal damage in schizophrenia (Ballesteros et al. 2013; Do et al. 2009; 
Gubert et al. 2013; Wang et al. 2009), and markers of  this pathology has also 
been observed following isolation rearing (Moller et al. 2011; Moller et al. 
2013). Hence, using this alternative and early-starting PCP treatment regime 
may represent an improvement over the one utilised here, and could feasibly 
combine with isolation rearing in later life to produce marked dysregulation of 
antioxidant activity and hence neuropathology. Furthermore, improved 
cognitive performance has been seen with clozapine+NAC treatment in 
isolates (Moller et al. 2013), showing that a model based on oxidative stress 
may be susceptible to co-treatment with an anti-oxidant and antipsychotic. 
To assess the impact of the isolation-PCP dual-hit treatment on neurobiology, 
ex vivo tissue could be examined for levels of parvalbumin-positive 
GABAergic interneurons by immunohistochemistry or microarray analysis. 
Aberrant PV-positive GABAergic interneuron function is now believed to be 
heavily implicated in schizophrenia (Chapter 1.1.2), with both isolation-reared 
and PCP-treated rats previously shown to have decreased levels of 
parvalbumin in the hippocampus and frontal cortex (Harte et al. 2007; Kaalund 
et al. 2013; McKibben et al. 2010; Wang et al. 2008). Preliminary data not 
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presented here has suggests that the Pvalb gene for parvalbumin may be down-
regulated in the hippocampi of Iso-PCP treated rats, as well as the GAD1 gene 
encoding glutamate decarboxylase, responsible for the majority of neuronal 
GABA production. Confirmation of this down-regulation would add 
substantial weight to the face validity of the Iso-PCP model. Additionally, 
some evidence suggests that impaired antioxidant defence mechanisms are 
responsible for PV-positive interneuron pathology in isolation-reared animals 
(Jiang et al. 2013). Hence, further work to analyse the mechanisms by which 
parvalbumin-positive interneurons are lost in Iso-PCP rats could also 
contribute knowledge to the oxidative stress theory of the schizophrenia 
pathology. 
 
6.4 Conclusions 
 
This thesis sought to produce and characterise a new dual-hit model of 
schizophrenia-like symptoms, however the results obtained do not support the 
aim of creating a robust and reproducible model with significant benefits over 
the individual hits alone. 
An initial protocol combining rearing in social isolation with prenatal MAM 
treatment did not produce robust behavioural deficits, despite marked 
neuropathology in relevant subcortical structures. The addition of perinatal 
PCP treatment to the isolation rearing model resulted in somewhat improved 
behavioural changes relevant to the positive and cognitive symptom domains 
of schizophrenia, although the reliability of the model is questioned due to 
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inconsistencies in the deficits observed. Furthermore, the behaviours in which 
robust deficits were seen, such as NOD and CER, are less translationally 
relevant to schizophrenia than other used and seen to be less reliable, such as 
LMA and PPI. Challenge with risperidone and lamotrigine was able to reverse 
some of the behavioural deficits observed in dual-hit animals, but the 
variability in behavioural data and the potential for false-positive reversal 
emerging from the NOD paradigm make interpretation of these results 
difficult. Overall, the model presented here shows some interesting traits but 
requires greater refinement before it will be a useful tool for on-going 
schizophrenia research.  
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Perinatal PCP administration procedure 
 
Great care was taken to prepare for perinatal PCP treatment, as the very early 
time point of the interference could lead to issues of maternal rejection. Pilot 
studies carried out within our lab (data not published) demonstrated that the 
administration of 10mg/kg PCP at this early stage of development produced 
visible effects on the pups, causing writhing, arching of the back, and 
stereotypic limb movement. PCP-treated pups commonly become separated 
from the nest. It is somewhat unclear whether the uncontrolled movement of 
PCP-treated pups causes them to make their way out of the nest, or whether 
dams choose to remove them from the nest due to their excessive movement 
(personal observation suggests the former). This departure from safety has a 
very direct impact on the pups, as they lose access to feeding from their mother 
and are exposed to the ambient temperature, which whilst comfortable for pups 
above approximately 13 days old (a point by which a significant amount of 
hair growth has occurred), is too low for the survival of younger pups.  The 
first specific protocol consideration was to ensure that the pups obtained from 
Charles River UK for the study were from natural (non-cross-fostered) litters, 
limited to n10, with an experienced dam. This natural and manageably-sized 
litter ensured the greatest chance of maternal protection. The natural instinct of 
the dam is to protect her pups, and as was seen in this study, will briefly leave 
the nest to recover separated pups from the surrounding cage. This instinct 
may be reduced in a number of circumstances, and we hypothesised that non-
natural pups introduced to the litter to make up numbers, or an inexperienced 
Appendix 
- 232 - 
 
dam, may not produce the strength of maternal instinct required. Further to 
this, the experimenter administering PCP (or saline) was required to 
thoroughly wash their hands between litters, as well as rubbing them in a small 
amount of home cage bedding material in between the handling of each pup. 
Both measures were intended to avoid transferring scents between each litter, 
or introducing external scents to pups, either of which may cause rejection of 
the pups or infanticide. This approach was successful in this study, as whilst 
pups were commonly noted to be out of the nest during hourly checks, in many 
cases closer inspection triggered the dam to recover the separated pups. Where 
pups were left exposed without recovery by the dam, the pups were manually 
returned to the nest by the experimenter. By following these self-imposed 
guidelines, only one pup in seven cohorts treated with perinatal PCP was lost 
prior to weaning. 
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